<SEC-DOCUMENT>0001104659-24-056462.txt : 20240502
<SEC-HEADER>0001104659-24-056462.hdr.sgml : 20240502
<ACCEPTANCE-DATETIME>20240502165706
ACCESSION NUMBER:		0001104659-24-056462
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20240502
DATE AS OF CHANGE:		20240502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279077
		FILM NUMBER:		24909417

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tm2413199d1_s3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on May&nbsp;2, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No.&nbsp;333-</B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-3&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>THERIVA BIOLOGICS,&nbsp;INC.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><B>Nevada</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><B>2834</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><B>13-3808303</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of<BR>
    incorporation or organization)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Primary Standard Industrial <BR>
    Classification Code Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer<BR>
    Identification No.)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite&nbsp;270&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, Maryland 20850&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(301) 417-4364&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone number,
including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Steven A Shallcross&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer and Chief Financial
Officer<BR>
9605 Medical Center Drive, Suite&nbsp;270&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, Maryland 20850&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(301) 417-4364&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leslie Marlow,&nbsp;Esq.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Patrick J. Egan,&nbsp;Esq.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Melissa Palat Murawsky,&nbsp;Esq.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Blank Rome LLP&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1271 Avenue of the Americas&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10020&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (212) 885-5000&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Facsimile: (212) 885-5001</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate date of commencement of proposed
sale to the public:</B> From time to time after the effective date of this registration statement, as determined by market conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the only securities being registered on this
Form&nbsp;are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on
this Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or interest reinvestment plans, check the following box. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is filed to register additional
securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a post-effective amendment
filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a registration statement
pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule&nbsp;462(e)&nbsp;under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form&nbsp;is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes
of securities pursuant to Rule&nbsp;413(b)&nbsp;under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%">Large accelerated filer</TD>
    <TD STYLE="width: 38%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 32%">Accelerated filer</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Non-accelerated filer</TD>
    <TD><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD>Smaller reporting company</TD>
    <TD><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Emerging growth company</TD>
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that
specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the
Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This registration statement
is a replacement registration statement being filed pursuant to Rule&nbsp;415(a)(6)&nbsp;under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), with respect to securities that remain unsold under the Registration Statement on Form&nbsp;S-3 (File
No.&nbsp;333-255726), originally filed on May&nbsp;3, 2021, and declared effective on May&nbsp;11, 2021 (the &ldquo;Prior Registration
Statement&rdquo;). Pursuant to Rule&nbsp;415(a)(5)(ii)&nbsp;under the Securities Act, by filing this registration statement on Form&nbsp;S-3
(the &ldquo;Registration Statement&rdquo;), the Company may issue and sell securities covered by the Prior Registration Statement until
the earlier of (i)&nbsp;the effective date of this Registration Statement and (ii)&nbsp;November&nbsp;7, 2024, which is&nbsp;180 days
after the third-year anniversary of the effective date of the Prior Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This registration statement of&nbsp;<FONT STYLE="background-color: white">Theriva
Biologics,&nbsp;Inc</FONT>. contains two prospectuses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                            base prospectus, which covers the offering, issuance and sale by us of common stock, preferred
                                            stock, warrants, and units identified above from time to time in one or more offerings, which
                                            together shall have an aggregate initial offering price not to exceed $200,000,000; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an
                                            &ldquo;at the market offering&rdquo; prospectus covering the offer, issuance and sale by
                                            us of up to a maximum aggregate offering price of up to $1,235,303 of our common stock that
                                            may be issued and sold from time to time under the <FONT STYLE="background-color: white">Amended
                                            and Restated At Market Issuance Sales Agreement, dated February&nbsp;9, 2021, as amended
                                            by Amendment No.&nbsp;1 thereto, dated May&nbsp;3, 2021, and Amendment No. 2 thereto, dated
                                            </font><FONT STYLE="background-color: white">May 2, 2024 (the &ldquo;Sales
Agreement&rdquo;), with A.G.P./Alliance Global Partners</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The base prospectus immediately follows this explanatory
note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in one or more prospectus supplements
to the base prospectus. The Sales Agreement prospectus immediately follows the base prospectus. The $1,235,303 of common stock that may
be offered, issued and sold under the sales agreement prospectus is included in the $200,000,000 of securities that may be offered, issued
and sold by us under the base prospectus. Upon termination of the sales agreement, any portion of the $1,235,303 included in the sales
agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base
prospectus, and if no shares are sold under the sales agreement, the full $1,235,303 of securities may be sold in other offerings pursuant
to the base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>The information contained in this
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy
these securities in any jurisdiction where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>Subject to Completion, Dated May&nbsp;2,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$200,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;<IMG SRC="tm2413199d1_s3img001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THERIVA BIOLOGICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred Stock&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Debt Securities&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may, from time to time, offer and sell up
to $200,000,000 of any combination of our common stock, par value $0.001 (the &ldquo;common stock&rdquo;), preferred stock, par value
$0.001 (the &ldquo;preferred stock&rdquo;), debt securities, warrants or units described in this prospectus, either individually or in
combination with other securities, at prices and on terms described in one or more supplements to this prospectus. We may also offer
common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock,
preferred stock, or debt securities upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus provides you with a general description
of the securities that we may offer. Each time we offer and sell securities, we will <FONT STYLE="background-color: white">provide a
supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities.
</FONT>We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus
supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should
carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents
incorporated by reference, before buying any of the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities may be sold by us to or through underwriters
or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale,
you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus and in the applicable prospectus supplement.
<FONT STYLE="background-color: white">If any underwriters, dealers or agents are involved in the sale of any of the securities, their
names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be
calculable from the information set forth, in the applicable prospectus supplement. </FONT>The price to the public of such securities
and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. <FONT STYLE="background-color: white">No
securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of
the offering of such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the NYSE American
LLC under the symbol &ldquo;TOVX.&rdquo; On April&nbsp;29, 2024, the last reported sale price of our common stock on the NYSE American
LLC was $0.42 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if
any, on any securities market or other exchange of the specific security covered by such prospectus supplement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, the aggregate
market value of our outstanding common stock held by non-affiliates is approximately $10,508,889, which is calculated based on 17,026,717
shares of our outstanding common stock held by non-affiliates and a price of $0.6172 per share, the closing price of our common stock
on March&nbsp;20, 2024, which is the highest closing sale price of our common stock on the NYSE American LLC within the prior 60 days
of this prospectus. During the prior twelve calendar month period that ends on and includes the date hereof, we have offered and sold
$2,267,660 of shares of our common stock pursuant to General Instruction I.B.6 to Form&nbsp;S-3.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; beginning
on page&nbsp;5 of this prospectus and contained in the applicable prospectus supplement and in any free writing prospectuses we have
authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by
reference into this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_001"><FONT STYLE="color: blue">About this Prospectus</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_001">ii</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#b_002"><FONT STYLE="color: blue">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_002">1</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_003"><FONT STYLE="color: blue">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_003">5</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#b_004"><FONT STYLE="color: blue">Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_004">6</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_005"><FONT STYLE="color: blue">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_005">7</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#b_006"><FONT STYLE="color: blue">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_006">8</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_007"><FONT STYLE="color: blue">Description of Debt Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_007">13</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#b_008"><FONT STYLE="color: blue">Description of Warrants</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_008">19</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_009"><FONT STYLE="color: blue">Description of Units</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_009">21</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#b_016"><FONT STYLE="color: blue">Legal Ownership of Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_016">22</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_011"><FONT STYLE="color: blue">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_011">25</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#b_012"><FONT STYLE="color: blue">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_012">27</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_013"><FONT STYLE="color: blue">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_013">27</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#b_014"><FONT STYLE="color: blue">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_014">27</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#b_015"><FONT STYLE="color: blue">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_015">27</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
on Form&nbsp;S-3 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration
process. Under this shelf registration statement, we may sell from time to time in one or more offerings up to a total dollar amount
of $200,000,000 of shares of common stock, preferred stock, various series of debt securities and/or warrants to purchase any of such
securities, either individually or as units in combination with other securities as described in this prospectus. Each time we sell any
type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information
about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain
material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize
to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have
incorporated by reference into this prospectus. To the extent that any statement that we make in a prospectus supplement is inconsistent
with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in
a prospectus supplement. You should carefully read both this prospectus and the applicable prospectus supplement and any related free
writing prospectus, together with the additional information described under &ldquo;Where You Can Find More Information,&rdquo; before
buying any of the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS PROSPECTUS MAY&nbsp;NOT BE USED TO CONSUMMATE
A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we, nor any agent, underwriter or dealer
has authorized any person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to
which we have referred you. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus,
any applicable supplement to this prospectus or any related free writing prospectus does not constitute an offer to sell or the solicitation
of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus, any applicable
supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy
securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not assume that the information contained
in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to
the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent
to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related
free writing prospectus is delivered, or securities are sold, on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains summaries of certain
provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is
a part, and you may obtain copies of those documents as described below under the section entitled &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated herein or as the
context otherwise requires, references in this prospectus to &ldquo;Theriva,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo; and similar references refer to Theriva Biologics,&nbsp;Inc., an entity incorporated under the laws of the State of
Nevada, and where appropriate our consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the information incorporated
herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and
trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing
prospectus are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary highlights information
contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may be important
to purchasers of our securities. Prospective purchasers of our securities should carefully read the entire prospectus, the applicable
prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the
heading &ldquo;Risk Factors&rdquo; contained in this prospectus, the applicable prospectus supplement and any related free writing prospectus,
and under similar headings in the other documents that are incorporated by reference into this prospectus. Prospective purchasers of
our securities should also carefully read the information incorporated by reference into this prospectus, including our financial statements,
and the exhibits to the registration statement of which this prospectus is a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are a diversified
clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result
of the acquisition (the &ldquo;Acquisition&rdquo;)in March&nbsp;2022 of Theriva Biologics, S.L. (&ldquo;VCN&rdquo;, formerly named VCN
Biosciences, S.L.), we began transitioning our strategic focus to oncology, which is now our primary focus, through the development of
VCN&rsquo;s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve
access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient&rsquo;s
immune system. Our lead product candidate, VCN-01, a clinical stage oncolytic human adenovirus that is modified to express an enzyme,
PH20 hyaluronidase, is currently being administered in a Phase 2 clinical study for the treatment of pancreatic cancer, a Phase 1 clinical
study for the treatment of retinalblastoma, a Phase 1 clinical study for the treatment of &nbsp;head and neck squamous cell carcinoma
and a Phase 1 clinical study for the treatment of solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Prior to the Acquisition,
our focus was on developing therapeutics designed to treat gastrointestinal (GI) diseases which included our clinical development candidates:
(1)&nbsp;SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV)&nbsp;beta-lactam antibiotics within
the GI tract to prevent microbiome damage, thereby preventing overgrowth and infection by pathogenic organisms such&nbsp;<I>Clostridioides
difficile</I>&nbsp;infection (CDI) and vancomycin resistant Enterococci (VRE), and reducing the incidence and severity of acute graft-versus-host-disease
(aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2)&nbsp;SYN-020, a recombinant oral formulation of the enzyme
intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. As part
of our strategic transformation into an oncology focused company, we are exploring value creation options for our SYN-004 and SYN-020
assets, including out-licensing or partnering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Our Current Product Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2413199d1_s3img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>*Based on management&rsquo;s current
beliefs and expectations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>allo-HCT</B> allogeneic hematopoietic cell transplant. <B>CPI</B>
immune checkpoint inhibitor. <B>HNSCC</B> head and neck squamous cell carcinoma. <B>IV</B> intravenous. <B>IVit</B> intravitreal. <B>ODD
</B>Orphan Drug Designation. For other abbreviations see the text.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><SUP>1</SUP>Additional
products with preclinical proof-of-concept include SYN-006 (carbapenemase) to prevent aGVHD and infection by carbapenem resistant enterobacteriaceae
and SYN-007 (ribaxamase) DR to prevent antibiotic associated diarrhea with oral &beta;-lactam antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><SUP>2</SUP>Depending
on funding/partnership. SYN-004 may enter an FDA-agreed Phase 3 clinical trial for the treatment of CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><SUP>3</SUP>We have
an option-license agreement with Massachusetts General Hospital to develop SYN-020 in several potential indications related to inflammation
and gut barrier dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT>We
have an option agreement with Sant Joan de D&eacute;u-Barcelona Children&rsquo;s Hospital to license their intellectual property rights
related to the use of VCN-01 in combination with topoisomerase I inhibitor chemotherapies for the treatment of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our predecessor, Sheffield
Pharmaceuticals,&nbsp;Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics,&nbsp;Inc., a publicly-traded
Delaware corporation formed in 2001. After the reverse merger, we changed our name to Pipex Pharmaceuticals,&nbsp;Inc., and in October&nbsp;2008
we changed our name to Adeona Pharmaceuticals,&nbsp;Inc. On October&nbsp;15, 2009, we engaged in a merger with a wholly owned subsidiary
for the purpose of reincorporating in the State of Nevada. On February&nbsp;15, 2012, we changed our name to Synthetic Biologics,&nbsp;Inc.
On August&nbsp;10, 2018, we effected a one for thirty-five reverse stock split of our authorized, issued and outstanding common stock.
On July&nbsp;15, 2022, we effected a one for ten reverse stock split of our authorized, issued and outstanding common stock. On October&nbsp;12,
2022, we changed our name to Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
9605 Medical Center Drive, Suite&nbsp;270, Rockville, Maryland 20850, and our telephone number is (301) 417-4367. Our website address
is <I>www.therivabio.com</I>. <FONT STYLE="background-color: white">Information contained on our website is intended for informational
purposes only and is not incorporated by reference into this prospectus, and it should not be considered to be part of this prospectus
or the </FONT>registration statement of which this prospectus forms a part. The SEC maintains an internet site that contains reports,
proxy and information statements, and other information regarding issuers like us that file documents electronically with the SEC. The
address of the SEC website is <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a &ldquo;smaller reporting company&rdquo;
as defined in the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). As a result, we may take advantage of
certain reduced disclosure obligations available to smaller reporting companies, including the exemption from compliance with the auditor
attestation requirements pursuant to the Sarbanes-Oxley Act of 2022, reduced disclosure about our executive compensation arrangements
and the requirements to provide only two years of audited financial statements in our annual reports and registration statements. We
will continue to be a &ldquo;smaller reporting company&rdquo; as long as (1)&nbsp;we have a public float (i.e., the market value of our
common stock held by non-affiliates) less than $250 million calculated as of the last business day of our most recently completed second
fiscal quarter, or (2)&nbsp;our annual revenues are less than $100 million for our previous fiscal year and we have either no public
float or a public float of less than $700 million as of the end of that fiscal year&rsquo;s second fiscal quarter. Decreased disclosures
in our SEC filings due to our status as a &ldquo;smaller reporting company&rdquo; may make it harder for investors to analyze our results
of operations and financial prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Associated with our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to numerous risks, as
described under the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement and in any free writing prospectuses
we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated
by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Securities We May&nbsp;Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may offer shares of our common stock, preferred
stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or as units in combination
with other securities, with a total value of up to $200,000,000 from time to time under this prospectus at prices and on terms to be
determined at the time of any offering. This prospectus provides you with a general description of the securities we may offer. Each
time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific
amounts, prices and other important terms of the securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">designation or classification;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">aggregate principal amount or aggregate offering price;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">maturity;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">original issue discount;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">rates and times of payment of interest or dividends;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">redemption, conversion, exercise, exchange or sinking fund terms;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">ranking;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">restrictive covenants;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">voting or other rights;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">conversion or exchange prices or rates and, if applicable, any provisions for changes to or adjustments
    in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">a discussion of material United States federal income tax considerations, if any.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus
or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security
that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this
prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the securities directly to investors
or to or through agents, underwriters or dealers. We, and our agents, underwriters or dealers reserve the right to accept or reject all
or part of any proposed purchase of securities. If we do offer securities to or through agents, underwriters or dealers, we will include
in the applicable prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the names of those agents, underwriters, or dealers;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">applicable fees, discounts and commissions to be paid to them;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">details regarding over-allotment options, if any; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the net proceeds to us.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the securities
we may offer with this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue shares of our common stock from
time to time. Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders,
including the election of directors. Under our articles of incorporation, as amended (the &ldquo;Articles of Incorporation&rdquo;) and
second amended and restated bylaws (the &ldquo;Bylaws&rdquo;), our stockholders do not have cumulative voting rights. Subject to preferences
that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends,
if any, as may be declared from time to time by the board of directors out of legally available funds. In the event of our liquidation,
dissolution or winding up, holders of common stock are entitled to share ratably in the net assets legally available for distribution
to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted
to the holders of any then-outstanding shares of preferred stock. Holders of shares of our common stock do not have preemptive, subscription,
redemption, or conversion rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences
and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of
any series of preferred stock that we may designate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue shares of our preferred stock from
time to time, in one or more series. Our board of directors will determine the designations, voting powers, preferences and rights of
the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights,
preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting
any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for
other securities. Conversion may be mandatory or at the holder&rsquo;s option and would be at prescribed conversion rates. If we sell
any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series
of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to
that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference
from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred
stock that we are offering before the issuance of the related series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you to read the applicable prospectus
supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being
offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Debt Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities
will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in
right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness.
Convertible debt securities will be convertible into or exchangeable for our common stock or other securities. Conversion may be mandatory
or at your option and would be at prescribed conversion rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any debt securities issued under this prospectus
will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other
eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however,
to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to
the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form
of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures
and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration
statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue warrants for the purchase of common
stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or as units in combination with
common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this
prospectus, we have summarized certain general features of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you, however, to read the applicable
prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of warrants
being offered, as well as any warrant agreements and warrant certificates that contain the terms of the warrants. We will file as exhibits
to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the
SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular
series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any warrants issued under this prospectus may
be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant agreement that we enter into with a warrant
agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular
series of warrants being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue units consisting of any combination
of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates
that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or
trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating
to a particular series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus, we have summarized certain
general features of the units under &ldquo;Description of Units.&rdquo; We urge you, however, to read the applicable prospectus supplement
(and any related free writing prospectus that we may authorize to be provided to you) related to the series of units being offered, as
well as the complete unit agreement that contains the terms of the units. We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the specific unit agreement that
contains the terms of the particular series of units we are offering, before the issuance of such units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves a high degree
of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties described under
the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement and any related free writing prospectus, and
discussed under the section entitled &ldquo;Risk Factors&rdquo; contained in our most recent Annual Report on Form&nbsp;10-K, as may
be updated by subsequent annual, quarterly and other reports that are incorporated by reference into this prospectus in their entirety.
The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown
or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future
results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to
anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of
operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a
loss of all or part of your investment. Please also read carefully the section below entitled &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_004"></A>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus, including the documents that
we incorporate by reference herein, contains, and any applicable prospectus supplement or free writing prospectus including the documents
we incorporate by reference therein may contain, forward-looking statements within the meaning of Section&nbsp;27A of the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section&nbsp;21E of the Exchange Act, including statements regarding our
future financial condition, business strategy and plans and objectives of management for future operations. Forward-looking statements
include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such
as &ldquo;believe,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;might,&rdquo; &ldquo;approximately,&rdquo; &ldquo;expect,&rdquo;
&ldquo;predict,&rdquo; &ldquo;could,&rdquo; &ldquo;potentially&rdquo; or the negative of these terms or other similar expressions. Forward-looking
statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discussions containing these forward-looking
statements may be found, among other places, in the sections entitled &ldquo;Business,&rdquo; &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; contained in the documents incorporated by reference
herein, including our most recent Annual Report on Form&nbsp;10-K and our Quarterly Reports on Form&nbsp;10-Q and our Current Reports
on Form&nbsp;8-K, as well as any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These statements relate to future events or our
future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results,
levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements.
We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties
under the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement, in any free writing prospectus we may
authorize for use in connection with a specific offering, and in the documents incorporated by reference herein. These statements reflect
our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. We undertake no
obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law.
Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will retain broad discretion over the use
of the net proceeds from the sale of the securities offered hereby. Except as described in any prospectus supplement or in any related
free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of the
securities offered by us hereunder primarily for working capital and general corporate purposes. We will set forth in the applicable
prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold
pursuant to the prospectus supplement or free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_006"></A>DESCRIPTION OF CAPITAL
STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following is a description of the material
terms of our capital stock. This is a summary only and does not purport to be complete. It is subject to and qualified in its entirety
by reference to our Articles of Incorporation and our Bylaws, each of which are incorporated by reference as an exhibit to the registration
statement of which this prospectus forms a part. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable
provisions of the Nevada Revised Statute (the &ldquo;NRS&rdquo;), for additional information.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">350,000,000 shares of common stock, par value $0.001 per share; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">10,000,000 shares of preferred stock, par value $0.001 per share.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Outstanding Shares</I>. As of April&nbsp;30,
2024, there were 17,277,371 shares of our common stock outstanding.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights</I>. The holders of the common
stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election
of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of the common stock entitled
to vote in any election of directors can elect all of the directors standing for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividend Rights</I>. Subject to preferences
that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any,
as may be declared from time to time by our board of directors out of legally available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Rights</I>. In the event of our
liquidation, dissolution or winding up, holders of the common stock will be entitled to share ratably in the net assets legally available
for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation
preference granted to the holders of any then outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Rights and Preferences</I>. The holders
of the common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable
to the common stock. The rights, preferences and privileges of the holders of the common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fully Paid and Nonassessable</I>. All of our
outstanding shares of common stock are fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary of terms of our preferred
stock is not complete. We will file as an exhibit to the registration statement of which this prospectus is a part or will incorporate
by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series
of preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable
prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred
stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, without further action
by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred
stock in one or more series and authorize their issuance. There are no shares of preferred stock designated or outstanding. These rights,
preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences,
sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater
than the rights of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors will fix the designations,
voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications,
limitations or restrictions thereof, in the certificate of designation relating to that series. We will describe in the applicable prospectus
supplement the terms of the series of preferred stock being offered, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the title and stated value;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the number of shares we are offering;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the liquidation preference per share;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the purchase price;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the dividend rate, period and payment date and method of calculation for dividends;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends
    will accumulate;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the procedures for any auction and remarketing;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the provisions for a sinking fund;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to
    exercise those redemption and repurchase rights;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any listing of the preferred stock on any securities exchange or market;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion
    price, or how it will be calculated, and the conversion period;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange
    price, or how it will be calculated, and the exchange period;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">voting rights of the preferred stock;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">preemptive rights;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">restrictions on transfer, sale or other assignment;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">whether interests in the preferred stock will be represented by depositary shares;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">a discussion of material United States federal income tax considerations applicable
    to the preferred stock;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the relative ranking and preferences of the preferred stock as to dividend rights
    and rights if we liquidate, dissolve or wind up our affairs;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any limitations on the issuance of any class or series of preferred stock ranking
    senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up
    our affairs; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any other specific terms, preferences, rights or limitations of, or restrictions
    on, the preferred stock.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of NRS, our Articles of Incorporation
and our Bylaws described below may have the effect of delaying, deferring or discouraging another party from acquiring control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;business combination&rdquo; provisions
of Sections 78.411 to 78.444, inclusive, of the NRS generally prohibit a Nevada corporation with at least 200 stockholders from engaging
in various &ldquo;combination&rdquo; transactions with any interested stockholder for a period of two years after the date of the transaction
in which the person became an interested stockholder, unless the transaction is approved by the board of directors prior to the date
the interested stockholder obtained such status or the combination is approved by the board of directors and thereafter is approved at
a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held
by disinterested stockholders, and extends beyond the expiration of the two-year period, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="width: 1px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 52px; padding-left: 0.5in; font-size: 10pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the combination was approved by the board of directors prior to the person becoming
    an interested stockholder or the transaction by which the person first became an interested stockholder was approved by the board
    of directors before the person became an interested stockholder or the combination is later approved by a majority of the voting
    power held by disinterested stockholders; or</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-left: 0.5in; font-size: 10pt; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-left: 0.5in; font-size: 10pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if the consideration to be paid by the interested stockholder is at least equal
    to the highest of: (a)&nbsp;the highest price per share paid by the interested stockholder within the two years immediately preceding
    the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is
    higher, (b)&nbsp;the market value per share of common stock on the date of announcement of the combination and the date the interested
    stockholder acquired the shares, whichever is higher, or (c)&nbsp;for holders of preferred stock, the highest liquidation value of
    the preferred stock, if it is higher.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;combination&rdquo; is generally defined
to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction
or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a)&nbsp;an aggregate market value equal to 5% or more
of the aggregate market value of the assets of the corporation, (b)&nbsp;an aggregate market value equal to 5% or more of the aggregate
market value of all outstanding shares of the corporation, (c)&nbsp;10% or more of the earning power or net income of the corporation,
and (d)&nbsp;certain other transactions with an interested stockholder or an affiliate or associate of an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, an &ldquo;interested stockholder&rdquo;
is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s voting
stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts
to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Control Share Acquisitions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;control share&rdquo; provisions of
Sections 78.378 to 78.3793, inclusive, of the NRS apply to &ldquo;issuing corporations&rdquo; that are Nevada corporations with at least
200 stockholders, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly
in Nevada. The control share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation&rsquo;s
stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&rsquo;s
disinterested stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than
a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds,
those shares in an offer or acquisition and acquired within 90 days thereof become &ldquo;control shares&rdquo; and such control shares
are deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares
are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders
who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their
shares in accordance with statutory procedures established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A corporation may elect to not be governed by,
or &ldquo;opt out&rdquo; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided
that the opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest,
that is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject
to these statutes if we are an &ldquo;issuing corporation&rdquo; as defined in such statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effect of the Nevada control share statutes
is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable,
could have the effect of discouraging takeovers of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Articles of Incorporation and Bylaws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation and Bylaws provide
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt">the authorized number of directors is determined by our board of directors;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt">directors may be removed only by the affirmative vote of the holders of at least a majority of our voting
    stock, whether for cause or without cause;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt">our Bylaws may be amended or repealed by our board of directors or by the affirmative vote of our stockholders;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt">special meetings of the stockholders may be called by Chairman of the board, if any, the Vice Chairman
    of the board, if any, or the President or upon request of stockholders owning a majority of the outstanding shares</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">our board of directors may fill vacancies on the board of directors;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our board of directors will be authorized to issue, without stockholder approval,
    preferred stock, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate
    as a &ldquo;poison pill&rdquo; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board
    of directors does not approve;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our stockholders do not have cumulative voting rights, and therefore our stockholders
    holding a majority of the shares of common stock outstanding will be able to elect all of our directors; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our stockholders must comply with advance notice provisions to bring business before
    or nominate directors for election at a stockholder meeting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Potential Effects of Authorized but Unissued
Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have shares of common stock available for
future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future
public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The existence of unissued and unreserved common
stock may enable our board of directors to issue shares to persons friendly to current management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations of Director Liability and Indemnification
of Directors, Officers and Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.138 provides that directors of a corporation
is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act
in his or her capacity as a director or officer unless: (a)&nbsp;the presumption that directors and officers acted in good faith on an
informed basis with a view toward the best interest of the corporation has been rebutted and (b)&nbsp;it is proven that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The director&rsquo;s or officer&rsquo;s act or failure to act constituted a breach
    of his or her fiduciary duties as a director or officer; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">such breach involved intentional misconduct, fraud or a knowing violation of law.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation and Bylaws provide
that we will indemnify our directors and officers to the fullest extent permitted by law and may indemnify employees and other agents.
Our Articles of Incorporation also provide that we are obligated to advance expenses incurred by a director or officer in advance of
the final disposition of any action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have obtained a policy of directors&rsquo;
and officers&rsquo; liability insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into separate indemnification
agreements with our directors and officers. These agreements, among other things, require us to indemnify our directors and officers
for any and all expenses (including reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts, witness
fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees) judgments, fines
and amounts paid in settlement actually and reasonably incurred by such directors or officers or on his or her behalf in connection with
any action or proceeding arising out of their services as one of our directors or officers, or any of our subsidiaries or any other company
or enterprise to which the person provides services at our request provided that such person follows the procedures for determining entitlement
to indemnification and advancement of expenses set forth in the indemnification agreement. We believe that these bylaw provisions and
indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitation of liability and indemnification
provisions in our Articles of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors for breach
of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an
action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed that, in the opinion
of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, there is no pending litigation or
proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any
threatened litigation or proceeding that may result in a claim for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing of the Common Stock on the NYSE American
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed for trading on the
NYSE American LLC under the symbol &ldquo;TOVX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our common
stock is Equiniti Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April&nbsp;30, 2024, we had options outstanding
to purchase an aggregate of 4,369,284 shares of common stock that were issued under our equity compensation plans. As of April&nbsp;30,
2024, there were 2,826,498 shares of common stock reserved for future issuance under our equity incentive plan.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series&nbsp;C Preferred Stock and Series&nbsp;D
Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April&nbsp;30, 2024, there are 275,000
shares of Series&nbsp;C Convertible Preferred Stock outstanding and 100,000 shares of Series&nbsp;D Convertible Preferred Stock outstanding,
each of which is convertible at a conversion price of $1.22 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_007"></A>DESCRIPTION OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized
below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any
debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under
a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture,
we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will issue the debt securities under the indenture
that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939,
as amended (the &ldquo;Trust Indenture Act&rdquo;). We have filed the form of indenture as an exhibit to the registration statement of
which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities
being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference
from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary of material provisions
of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture
applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement and any related free writing
prospectus related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the
terms of the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The indenture will not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may
be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially
all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to
give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue the debt securities issued under
the indenture as &ldquo;discount securities,&rdquo; which means they may be sold at a discount below their stated principal amount. These
debt securities, as well as other debt securities that are not issued at a discount, may be issued with &ldquo;original issue discount,&rdquo;
or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material
U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the title of the series of debt securities;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any limit upon the aggregate principal amount that may be issued;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the maturity date or dates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the form of the debt securities of the series;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the applicability of any guarantees;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">whether or not the debt securities will be secured or unsecured, and the terms of
    any secured debt;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">whether the debt securities rank as senior debt, senior subordinated debt, subordinated
    debt or any combination thereof, and the terms of any subordination;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if the price (expressed as a percentage of the aggregate principal amount thereof)
    at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount
    thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of
    such debt securities that is convertible into another security or the method by which any such portion shall be determined;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the interest rate or rates, which may be fixed or variable, or the method for determining
    the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest
    payment dates or the method for determining such dates;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our right, if any, to defer payment of interest and the maximum length of any such
    deferral period;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if applicable, the date or dates after which, or the period or periods during which,
    and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional
    redemption provisions and the terms of those redemption provisions;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the date or dates, if any, on which, and the price or prices at which we are obligated,
    pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase,
    the series of debt securities and the currency or currency unit in which the debt securities are payable;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the denominations in which we will issue the series of debt securities, if other
    than denominations of $1,000 and any integral multiple thereof;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any and all terms, if applicable, relating to any auction or remarketing of the
    debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which
    may be advisable in connection with the marketing of debt securities of that series;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any and all terms, if applicable, relating to any auction or remarketing of the
    debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which
    may be advisable in connection with the marketing of debt securities of that series;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any and all terms, if applicable, relating to any auction or remarketing of the
    debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which
    may be advisable in connection with the marketing of debt securities of that series;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">whether the debt securities of the series shall be issued in whole or in part in
    the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may
    be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if applicable, the provisions relating to conversion or exchange of any debt securities
    of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the
    conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our
    option or the holders&rsquo; option) conversion or exchange features, the applicable conversion or exchange period and the manner
    of settlement for any conversion or exchange;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if other than the full principal amount thereof, the portion of the principal amount
    of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">additions to or changes in the covenants applicable to the particular debt securities
    being issued, including, among others, the consolidation, merger or sale covenant;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">additions to or changes in the events of default with respect to the securities
    and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect
    to such securities to be due and payable;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">additions to or changes in or deletions of the provisions relating to covenant defeasance
    and legal defeasance;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">additions to or changes in the provisions relating to satisfaction and discharge
    of the indenture;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">additions to or changes in the provisions relating to the modification of the indenture
    both with and without the consent of holders of debt securities issued under the indenture;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the currency of payment of debt securities if other than U.S. dollars and the manner
    of determining the equivalent amount in U.S. dollars;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">whether interest will be payable in cash or additional debt securities at our or
    the holders&rsquo; option and the terms and conditions upon which the election may be made;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the terms and conditions, if any, upon which we will pay amounts in addition to
    the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &ldquo;United
    States person&rdquo; for federal tax purposes;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any restrictions on transfer, sale or assignment of the debt securities of the series;
    and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">any other specific terms, preferences, rights or limitations of, or restrictions
    on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by
    us or advisable under applicable laws or regulations.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will set forth in the applicable prospectus
supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities.
We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option
of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities
that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability
to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety.
However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture
or the debt securities, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Events of Default under the Indenture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect
to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if we fail to pay any installment of interest on any series of debt securities,
    as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a
    valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not
    constitute a default in the payment of interest for this purpose;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if we fail to pay the principal of, or premium, if any, on any series of debt securities
    as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment
    required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
    maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default
    in the payment of principal or premium, if any;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if we fail to observe or perform any other covenant or agreement contained in the
    debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure
    continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is
    a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt
    securities of the applicable series; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if specified events of bankruptcy, insolvency or reorganization occur.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an event of default with respect to debt securities
of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders
of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and
payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount
of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other
action on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of a majority in principal amount
of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its
consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured
the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of the indenture, if an
event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights
or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless
such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities
of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee,
or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the direction so given by the holder is not in conflict with any law or the applicable
    indenture; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">subject to its duties under the Trust Indenture Act, the trustee need not take any
    action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A holder of the debt securities of any series
will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only
if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the holder has given written notice to the trustee of a continuing event of default
    with respect to that series;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the holders of at least 25% in aggregate principal amount of the outstanding debt
    securities of that series have made written request,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">such holders have offered to the trustee indemnity satisfactory to it against the
    costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the trustee does not institute the proceeding, and does not receive from the holders
    of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within
    90 days after the notice, request and offer.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These limitations do not apply to a suit instituted
by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will periodically file statements with the
trustee regarding our compliance with specified covenants in the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We and the trustee may change an indenture without
the consent of any holders with respect to specific matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any
    series;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to comply with the provisions described above under &ldquo;Description of Debt Securities&mdash;Consolidation,
    Merger or Sale;&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions,
    conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence
    and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or
    to surrender any right or power conferred upon us in the indenture;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized
    amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to make any change that does not adversely affect the interests of any holder of debt securities
    of any series in any material respect;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to provide for the issuance of and establish the form and terms and conditions of the debt securities
    of any series as provided above under &ldquo;Description of Debt Securities&mdash;General&rdquo; to establish the form of any certifications
    required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the
    holders of any series of debt securities;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee;
    or</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">to comply with any requirements of the SEC in connection with the qualification of any indenture
    under the Trust Indenture Act.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under the indenture, the rights
of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a
majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide
otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following
changes only with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;&nbsp;&nbsp;</TD>
    <TD>extending the fixed maturity of any debt securities of any series;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">reducing the principal amount, reducing the rate of or extending the time of payment of interest,
    or reducing any premium payable upon the redemption of any series of any debt securities; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
    supplement, modification or waiver.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each indenture provides that we can elect to
be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including
obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">provide for payment;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">register the transfer or exchange of debt securities of the series;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">replace stolen, lost or mutilated debt securities of the series;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">pay principal of and premium and interest on any debt securities of the series;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">maintain paying agencies;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">hold monies for payment in trust;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">recover excess money held by the trustee;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">compensate and indemnify the trustee; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">appoint any successor trustee.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to exercise our rights to be discharged,
we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest
on, the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Form, Exchange and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will issue the debt securities of each series
only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations
of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent
global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another
depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities
of a series are issued in global form and as book-entry, a description of terms relating such securities will be set forth in the applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the option of the holder, subject to the terms
of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of
the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination
and of like tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of the indenture and the
limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present
the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed
if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated
by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose
no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will name in the applicable prospectus supplement
the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities.
We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office
through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the
debt securities of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we elect to redeem the debt securities of
any series, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">issue, register the transfer of, or exchange any debt securities of that series during a period beginning
    at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected
    for redemption and ending at the close of business on the day of the mailing; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">register the transfer of or exchange any debt securities so selected for redemption, in whole or
    in part, except the unredeemed portion of any debt securities we are redeeming in part.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trustee, other than during the occurrence
and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the
applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would
exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any
of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and
indemnity against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we otherwise indicate in the applicable
prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose
name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for
the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will pay principal of and any premium and
interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise
indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire
transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust
office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable
prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain
a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All money we pay to a paying agent or the trustee
for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years
after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter
may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The indenture and the debt securities will be
governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture
Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_008"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description, together with the
additional information we may include in any applicable prospectus supplement and in any related free writing prospectus, summarizes
the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase
common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or in
combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized
below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series
of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants
offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement
for a particular series of warrants may specify different or additional terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed or will file forms of the warrant
agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration
statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part,
or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant
certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements,
before the issuance of such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified
in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as
applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We
urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus,
as well as any related free writing prospectus, and the complete form of warrant and/or the warrant agreement and warrant certificate,
as applicable, and any supplemental agreements, that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the offering price and aggregate number of warrants offered;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the currency for which the warrants may be purchased;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the designation and terms of the securities with which the warrants are issued and the number of
    warrants issued with each such security or each principal amount of such security;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the date on and after which the warrants and the related securities will be separately transferable;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable
    upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon
    such exercise;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">in the case of warrants to purchase common stock or preferred stock, the number of shares of common
    stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may
    be purchased upon such exercise;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the effect of any merger, consolidation, sale or other disposition of our business on the warrant
    agreements and the warrants;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the terms of any rights to redeem or call the warrants;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any provisions for changes to or adjustments in the exercise price or number of securities issuable
    upon exercise of the warrants;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the dates on which the right to exercise the warrants will commence and expire;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the manner in which the warrant agreements and warrants may be modified;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">a discussion of material United States federal income tax consequences of holding or exercising the
    warrants;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">the terms of the securities issuable upon exercise of the warrants; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before exercising their warrants, holders of
warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends,
    if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">in the case of warrants to purchase debt securities, the right to receive payments of principal of,
    or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant will entitle the holder to purchase
the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at
any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of
business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant or warrant certificate representing
the warrants to be exercised together with specified information, and paying the required amount to the warrant agent, if applicable,
in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of any warrant
certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to
any warrant agent in connection with the exercise of the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon receipt of payment and the warrant or warrant
certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other
office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable
upon such exercise. If fewer than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new
warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the applicable
prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants
or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enforceability of Rights by Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant agent, if any, will act solely as
our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility
to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the
related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the
securities purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_009"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description, together with the
additional information we may include in any applicable prospectus supplement and related free writing prospectus, summarizes the material
terms and provisions of the units that we may offer under this prospectus. We may issue units consisting of any combination of the other
types of securities offered under this prospectus in one or more series. We will issue each unit so that the holder of the unit is also
the holder of each security included in the unit. As a result, the holder of a unit will have the rights and obligations of a holder
of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not
be held or transferred separately, at any time or at any time before a specified date. We may evidence each series of units by unit certificates
that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or
trust company that we select. We will indicate the name and address of any unit agent in the applicable prospectus supplement relating
to a particular series of units. The summary below and that contained in any prospectus supplement is qualified in its entirety by reference
to all of the provisions of the unit agreement and/or unit certificate, and depositary arrangements, if applicable. We urge you to read
the applicable prospectus supplements and any related free writing prospectuses related to the units that we may offer under this prospectus,
as well as the complete unit agreement and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of
the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit
agreement and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of the particular series of units
we are offering, and any supplemental agreements, before the issuance of such units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will describe in the applicable prospectus
supplement the terms of the series of units being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">the designation and terms of the units and of the securities comprising the units, including whether
    and under what circumstances those securities may be held or transferred separately;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the
    securities composing the units;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">whether the units will be issued in fully registered or global form; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">any other terms of the units.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_016"></A>LEGAL OWNERSHIP OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can issue securities in registered form or
in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have
securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this
purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the securities. We refer to those persons
who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &ldquo;indirect
holders&rdquo; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in
book-entry form or in street name will be indirect holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Book-Entry Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue securities in book-entry form only,
as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities
registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate
in the depositary&rsquo;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial
interests in the securities on behalf of themselves or their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="b_010"></A>Only the person in whose
name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary
or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and
we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants,
which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under
agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, investors in a global security will
not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial
institution that participates in the depositary&rsquo;s book-entry system or holds an interest through a participant. As long as the
securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Street Name Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may terminate a global security or issue securities
that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &ldquo;street
name.&rdquo; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution
that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains
at that institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For securities held in street name, we or any
applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names
the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on
those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but
only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities
in street name will be indirect holders, not holders, of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our obligations, as well as the obligations of
any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations
to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case
whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global
form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, once we make a payment or give a
notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with
its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain
the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with
a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders,
and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special Considerations for Indirect Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you hold securities through a bank, broker
or other financial institution, either in book-entry form because the securities are represented by one or more global securities or
in street name, you should check with your own institution to find out:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">how it handles securities payments and notices;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">whether it imposes fees or charges;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">how it would handle a request for the holders&rsquo; consent, if ever required;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">whether and how you can instruct it to send you securities registered in your own name so you can
    be a holder, if that is permitted in the future;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">how it would exercise rights under the securities if there were a default or other event triggering
    the need for holders to act to protect their interests; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">if the securities are in book-entry form, how the depositary&rsquo;s rules&nbsp;and procedures will
    affect these matters.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A global security is a security that represents
one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities
will have the same terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each security issued in book-entry form will
be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee
that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the
applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities
issued in book-entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A global security may not be transferred to or
registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations
arise. We describe those situations below under &ldquo;&mdash;Special Situations When a Global Security Will Be Terminated.&rdquo; As
a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities
represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests
must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary
or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder
of the security, but only an indirect holder of a beneficial interest in the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the prospectus supplement for a particular
security indicates that the security will be issued in global form only, then the security will be represented by a global security at
all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry
clearing system or decide that the securities may no longer be held through any book-entry clearing system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Considerations for Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an indirect holder, an investor&rsquo;s rights
relating to a global security will be governed by the account rules&nbsp;of the investor&rsquo;s financial institution and of the depositary,
as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead
deal only with the depositary that holds the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are issued only as global securities,
an investor should be aware of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global
    certificates for his or her interest in the securities, except in the special situations we describe below;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">an investor will be an indirect holder and must look to his or her own bank or broker for payments
    on the securities and protection of his or her legal rights relating to the securities, as we describe above;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">an investor may not be able to sell interests in the securities to some insurance companies and to
    other institutions that are required by law to own their securities in non-book-entry form;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">an investor may not be able to pledge his or her interest in the global security in circumstances
    where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the
    pledge to be effective;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the depositary&rsquo;s policies, which may change from time to time, will govern payments, transfers,
    exchanges and other matters relating to an investor&rsquo;s interest in the global security;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">we and any applicable trustee have no responsibility for any aspect of the depositary&rsquo;s actions
    or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary
    in any way;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">the depositary may, and we understand that DTC will, require that those who purchase and sell interests
    in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do
    so as well; and&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">financial institutions that participate in the depositary&rsquo;s book-entry system, and through
    which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other
    matters relating to the securities.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There may be more than one financial intermediary
in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Situations When a Global Security
Will Be Terminated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a few special situations described below,
a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After
that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult
their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be
direct holders. We have described the rights of holders and street name investors above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the applicable
prospectus supplement, a global security will terminate when the following special situations occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as
    depositary for that global security and we do not appoint another institution to act as depositary within 90 days;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">if we notify any applicable trustee that we wish to terminate that global security; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">if an event of default has occurred with regard to securities represented by that global security
    and has not been cured or waived.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable prospectus supplement may also
list additional situations for terminating a global security that would apply only to the particular series of securities covered by
the applicable prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is
responsible for deciding the names of the institutions that will be the initial direct holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the securities from time to time
pursuant to underwritten public offerings, direct sales to the public, &ldquo;at the market&rdquo; offerings, negotiated transactions,
block trades or a combination of these methods. We may sell the securities to or through one or more underwriters or dealers (acting
as principal or agent), through agents, or directly to one or more purchasers. We may distribute securities from time to time in one
or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">at a fixed price or prices, which may be changed;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">at market prices prevailing at the time of sale;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">at prices related to such prevailing market prices; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">at negotiated prices.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus supplement or supplements (and any
related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities,
including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the name or names of the underwriters, dealers, agents or other purchasers, if any;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">the purchase price of the securities or other consideration therefor, and the proceeds we will receive
    from the sale;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any option to purchase additional shares or other options under which underwriters, dealers, agents
    or other purchasers may purchase additional securities from us;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any agency fees or underwriting discounts to be allowed or paid to the agent or underwriters and
    other items constituting agents&rsquo; or underwriters&rsquo; compensation;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any public offering price;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any discounts or concessions allowed or reallowed or paid to dealers; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any securities exchange or market on which the securities may be listed.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only underwriters named in the prospectus supplement
will be underwriters of the securities offered by the prospectus supplement. Dealers and agents participating in the distribution of
the securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting
discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If underwriters are used in the sale, they will
acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will
be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting
syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters
will be obligated to purchase all of the securities offered by the prospectus supplement other than securities covered by any option
to purchase additional shares or other option. If a dealer is used in the sale of securities, we, or an underwriter, will sell the securities
to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer
at the time of resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of
the transaction. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time
to time. We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement,
naming the underwriter, dealer or agent, the nature of any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell securities directly or through agents
we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions
we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts
basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may authorize agents or underwriters to solicit
offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe
the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may provide agents, dealers and underwriters
with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments
that the agents, dealers or underwriters may make with respect to these liabilities. Agents, dealers and underwriters or their affiliates
may engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All securities we may offer, other than common
stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but
will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of
the trading markets for any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any underwriter may engage in overallotment,
stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size,
which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids
do not exceed a specified maximum price. Syndicate covering or other short-covering transactions involve purchases of the securities,
either through exercise of the option to purchase additional shares or in the open market after the distribution is completed, to cover
short positions. Short covering transactions involve purchases of the securities in the open market after the distribution is completed
to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally
sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price
of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any
time. These transactions may be effected on any exchange or over-the-counter market or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any underwriters, dealers or agents that are
qualified market makers on the NYSE American LLC may engage in passive market making transactions in our common stock on the NYSE American
LLC in accordance Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement
of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified
as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent
bid for such security; if all independent bids are lowered below the passive market maker&rsquo;s bid, however, the passive market maker&rsquo;s
bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities
at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The specific terms of any lock-up provisions in respect of any given
offering will be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The anticipated date of delivery of offered securities
will be set forth in the applicable prospectus supplement relating to each offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_012"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The validity
of the shares of common stock being offered by this prospectus is being passed upon by&nbsp;</FONT>Parsons Behle&nbsp;&amp; Latimer,
Reno, Nevada. Blank Rome LLP, New York, New York has acted as securities counsel to Theriva Biologics,&nbsp;Inc.&nbsp; Additional legal
matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.
A partner of Blank Rome LLP has options to purchase shares of stock of Theriva Biologics,&nbsp;Inc. that represent less than 1% of the
outstanding shares of common stock of Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_013"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Theriva
Biologics,&nbsp;Inc. as of December&nbsp;31, 2023 and 2022 and for each of the two years in the period ended December&nbsp;31, 2023 incorporated
by reference in this prospectus and in the registration statement of which this prospectus forms a part have been so incorporated in
reliance on the report of BDO USA, P.C, an independent registered public accounting firm, given on the authority of said firm as experts
in auditing and accounting. The report on the consolidated financial statements contains an explanatory paragraph regarding the Company's
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_014"></A>WHERE YOU CAN FIND MORE
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we
refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor
any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these
securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as
of any date other than the date on the front page&nbsp;of this prospectus, regardless of the time of delivery of this prospectus or any
sale of the securities offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s website at <I>www.sec.gov</I>.
Our SEC filings are also available on our website, <I>www.therivabio.com</I> under the heading &ldquo;Investor Relations&mdash;SEC Filings.&rdquo;
The reference to our website is an inactive textual reference only, the information contained in, and that can be accessed through our
website, is not incorporated into and is not a part of this prospectus. We make available on our website our SEC filings as soon as reasonably
practicable after those reports are filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_015"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information from other documents that we file with it, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus
supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this prospectus
and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the
SEC (Commission File No.&nbsp;001-12584):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">Our Annual Report on <FONT STYLE="color: Black"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit">Form
    10-K</A></FONT> for the fiscal year ended December&nbsp;31, 2023 filed with the SEC on March&nbsp;25, 2024;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">Our Current Reports on Form&nbsp;8-K filed with the SEC on <FONT STYLE="color: Black"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924011395/tm245387d1_8k.htm" STYLE="-sec-extract: exhibit">February
    7, 2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050037/tm2412300d1_8k.htm" STYLE="-sec-extract: exhibit">April
    22, 2024</A> (other than as set forth therein), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050307/tm2412300d2_8k.htm" STYLE="-sec-extract: exhibit">April
    23, 2024</A> (other than as set forth therein) and May 2, 2024;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">The description of our common stock set forth in (i)&nbsp;our registration statements on <FONT STYLE="color: blue"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016307000379/s11-7491_8a.htm" STYLE="-sec-extract: exhibit">Form
    8-A12B</A></FONT>, filed with the SEC on June&nbsp;20, 2007 (File No.&nbsp;001-12584) and (ii) <FONT STYLE="color: blue"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000141057824000293/tmb-20231231xex4d3.htm" STYLE="-sec-extract: exhibit">Exhibit
    4.3</A></FONT>&mdash;Description of Securities to our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31,
    2023.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference any future filings
(other than current reports furnished under Item 2.02 or Item 7.01 of Form&nbsp;8-K and exhibits filed on such form that are related
to such items unless such Form&nbsp;8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or
15(d)&nbsp;of the Exchange Act, including those made (i)&nbsp;on or after the date of the initial filing of the registration statement
of which this prospectus forms a part and prior to effectiveness of such registration statement, and (ii)&nbsp;on or after the date of
this prospectus but prior to the termination of the offering (i.e., until the earlier of the date on which all of the securities registered
hereunder have been sold or the registration statement of which this prospectus forms a part has been withdrawn). Information in such
future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically
be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to
be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents
incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated
by reference into such documents. You should direct any requests for documents to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Theriva Biologics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite&nbsp;270&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, Maryland 20850&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone (301) 417-4364&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access these documents, free of
charge, on the SEC&rsquo;s website at <I>www.sec.gov</I> or on our website at <I>https://ir.therivabio.com/sec-filings</I>. The information
contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or
any accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule&nbsp;412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on information contained
in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers
to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>The information contained in this
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy
these securities in any jurisdiction where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>Subject to Completion, Dated May&nbsp;2,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2413199d1_s3img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $1,235,303 of Shares&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into an <FONT STYLE="background-color: white">Amended
and Restated At Market Issuance Sales Agreement, dated February&nbsp;9, 2021, as amended by Amendment No.&nbsp;1 thereto, dated May&nbsp;3,
2021, and Amendment No. 2 thereto, dated May 2, 2024 (the &ldquo;Sales Agreement&rdquo;), with A.G.P./Alliance Global Partners (the &ldquo;Sales
Agent&rdquo;)</FONT> relating to the sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price
of up to $1,235,303 from time to time through or to the Sales Agent, acting as sales agent or principal.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of shares of our common stock, if any,
under this prospectus will be made in sales deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule&nbsp;415(a)(4)&nbsp;promulgated
under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). The Sales Agent is not required to sell any specific
amount, but will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices,
on mutually agreed terms between the sales agent and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As sales agent, A.G.P. is entitled to compensation
at a fixed commission rate equal to 3.0% of the gross proceeds of each sale of shares of our common stock. In connection with the sale
of our shares of common stock on our behalf, the Sales Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of
the Securities Act and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have also agreed
to provide indemnification and contribution to the Sales Agent with respect to certain liabilities, including liabilities under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the NYSE American
under the symbol &ldquo;TOVX.&rdquo; &nbsp;On April&nbsp;29, 2024, the last reported sale price of our common stock on the NYSE American
was $0.42 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, the aggregate
market value of our outstanding common stock held by non-affiliates is approximately $10,508,889, which is calculated based on 17,026,717
shares of our outstanding common stock held by non-affiliates and a price of $0.6172 per share, the closing price of our common stock
on March&nbsp;20, 2024, which is the highest closing sale price of our common stock on the NYSE American LLC within the prior 60 days
of this prospectus. During the prior twelve calendar month period that ends on and includes the date hereof, we have offered and sold
$2,267,660 of shares of our common stock pursuant to General Instruction I.B.6 to Form&nbsp;S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock involves a high
degree of risk. Before making an investment decision, please read the information under the heading &ldquo;<FONT STYLE="color: Black"><A HREF="#a_005">Risk Factors</A></FONT>&rdquo; beginning on page&nbsp;S-5 of this prospectus supplement and in the documents incorporated by reference into
this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>A.G.P.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 89%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 11%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_001"><FONT STYLE="color: blue">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_001">S-1</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_002"><FONT STYLE="color: blue">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002">S-2</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_003"><FONT STYLE="color: blue">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">S-3</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_004"><FONT STYLE="color: blue">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">S-4</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_005"><FONT STYLE="color: blue">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">S-5</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_006"><FONT STYLE="color: blue">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">S-7</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_007"><FONT STYLE="color: blue">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">S-7</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="#a_008"><U>DILUTION</U></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">S-8</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_009"><FONT STYLE="color: blue">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009">S-9</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="#a_010"><FONT STYLE="color: blue">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010">S-10</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_011"><FONT STYLE="color: blue">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011">S-10</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="#a_012"><FONT STYLE="color: blue">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012">S-10</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_013"><FONT STYLE="color: blue">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">S-10</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to part of a registration
statement on Form&nbsp;S-3 that we have filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) utilizing a &ldquo;shelf&rdquo;
registration process. Under this shelf registration process, we may sell any combination of the securities described in our base prospectus
included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $200,000,000. The $1,235,303
of shares of common stock that may be offered, issued and sold under this prospectus is included in the $200,000,000 of securities that
may be offered, issued and sold by us pursuant to our shelf registration statement. In connection with such offers and when accompanied
by the base prospectus included in the registration statement of which this prospectus is a part, this prospectus will be deemed a prospectus
supplement to such base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the offering of our
shares of common stock. Before buying any of our shares of common stock that we are offering, we urge you to carefully read this prospectus,
together with the information incorporated by reference as described under the headings &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation of Certain Information by Reference&rdquo; in this prospectus. These documents contain important information
that you should consider when making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus describes the terms of this offering
of our shares of common stock and also adds to and updates information contained in the documents incorporated by reference into this
prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information
contained in any document incorporated by reference into this prospectus that was filed with the SEC before the date of this prospectus,
on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent
with a statement in another document having a later date (for example, a document incorporated by reference into this prospectus) the
statement in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in or incorporated by reference in this prospectus and in any free writing prospectus that we have authorized for use in connection with
this offering. We have not, and the Sales Agent has not, authorized anyone to provide you with different information. If anyone provides
you with different or inconsistent information, you should not rely on it. We are not, and the Sales Agent is not, making an offer to
sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing
in this prospectus, the documents incorporated by reference in this prospectus, and in any free writing prospectus that we have authorized
for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition,
results of operations and prospects may have changed since those dates. You should carefully read this prospectus, the documents incorporated
by reference in this prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in
their entirety before making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains and incorporates by
reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available
information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information
and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry
data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties
and are subject to change based on various factors, including those discussed under the heading &ldquo;Risk Factors&rdquo; in this prospectus
and under similar headings in the other documents that are incorporated by reference into this prospectus. Accordingly, investors should
not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated herein or as the
context otherwise requires, references in this prospectus to &ldquo;Theriva,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo; and similar references refer to&nbsp;<FONT STYLE="background-color: white">Theriva Biologics,&nbsp;Inc.</FONT>, an
entity incorporated under the laws of the State of Nevada, and where appropriate our consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus, including the documents that
we incorporate by reference herein, may contain, forward-looking statements within the meaning of Section&nbsp;27A of the Securities
Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (&ldquo;the Exchange Act&rdquo;), including statements regarding
our future financial condition, business strategy and plans and objectives of management for future operations. Forward-looking statements
include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such
as &ldquo;believe,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;might,&rdquo; &ldquo;approximately,&rdquo; &ldquo;expect,&rdquo;
&ldquo;predict,&rdquo; &ldquo;could,&rdquo; &ldquo;potentially&rdquo; or the negative of these terms or other similar expressions. Forward-looking
statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discussions containing these forward-looking
statements may be found, among other places, in the sections entitled &ldquo;Business,&rdquo; &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; contained in the documents incorporated by reference
in this prospectus, including our most recent Annual Report on Form&nbsp;10-K and our Quarterly Reports on Form&nbsp;10-Q, as well as
any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These statements relate to future events or our
future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results,
levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements.
We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties
under the section entitled &ldquo;Risk Factors&rdquo; included in our most recent Annual Report on Form&nbsp;10-K and our Quarterly Reports
on Form&nbsp;10-Q, as well as any amendments thereto, filed with the SEC, which are incorporated by reference into this prospectus. Additional
factors are discussed under the section entitled &ldquo;Risk Factors&rdquo; in this prospectus and any free writing prospectus and under
similar headings in the other documents that are incorporated by reference into this prospectus. These statements reflect our current
views with respect to future events and are based on assumptions and subject to risks and uncertainties. New risks and uncertainties
arise from time to time, and it is impossible for us to predict these events or how they may affect us. We undertake no obligation to
revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks
and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary highlights information
contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may be important
to purchasers of our securities. This summary is not intended to be complete and does not contain all of the information that you should
consider before deciding to invest in our securities. You should read this entire prospectus carefully, especially the &ldquo;Risk Factors&rdquo;
section beginning on page&nbsp;S-3 and other documents or information included or incorporated by reference in this prospectus before
making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are a diversified
clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result
of the acquisition (the &ldquo;Acquisition&rdquo;) in March&nbsp;2022 of Theriva Biologics, S.L. (&ldquo;VCN&rdquo;, formerly named VCN
Biosciences, S.L.), we began transitioning our strategic focus to oncology, which is now our primary focus, through the development of
VCN&rsquo;s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve
access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient&rsquo;s
immune system. Our lead product candidate, VCN-01, a clinical stage oncolytic human adenovirus that is modified to express an enzyme,
PH20 hyaluronidase, is currently being administered in a Phase 2 clinical study for the treatment of pancreatic cancer, a Phase 1 clinical
study for the treatment of retinalblastoma, a Phase 1 clinical study for the treatment of &nbsp;head and neck squamous cell carcinoma
and a Phase 1 clinical study for the treatment of solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Prior to the Acquisition,
our focus was on developing therapeutics designed to treat gastrointestinal (GI) diseases which included our clinical development candidates:
(1)&nbsp;SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV)&nbsp;beta-lactam antibiotics within
the GI tract to prevent microbiome damage, thereby preventing overgrowth and infection by pathogenic organisms such&nbsp;<I>Clostridioides
difficile</I>&nbsp;infection (CDI) and vancomycin resistant Enterococci (VRE), and reducing the incidence and severity of acute graft-versus-host-disease
(aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2)&nbsp;SYN-020, a recombinant oral formulation of the enzyme
intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. As part
of our strategic transformation into an oncology focused company, we are exploring value creation options for our SYN-004 and SYN-020
assets, including out-licensing or partnering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2413199d1_s3img004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>*Based on management&rsquo;s current
beliefs and expectations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>allo-HCT</B>&nbsp;allogeneic
hematopoietic cell transplant.&nbsp;<B>CPI</B>&nbsp;immune checkpoint inhibitor.&nbsp;<B>HNSCC</B>&nbsp;head and neck squamous cell carcinoma.&nbsp;<B>IV</B>&nbsp;intravenous.&nbsp;<B>IVit</B>&nbsp;intravitreal.&nbsp;<B>ODD</B>&nbsp;Orphan
Drug Designation. For other abbreviations see the text.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><SUP>1</SUP>Additional
products with preclinical proof-of-concept include SYN-006 (carbapenemase) to prevent aGVHD and infection by carbapenem resistant enterobacteriaceae
and SYN-007 (ribaxamase) DR to prevent antibiotic associated diarrhea with oral &beta;-lactam antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><SUP>2</SUP>Depending
on funding/partnership. SYN-004 may enter an FDA-agreed Phase 3 clinical trial for the treatment of CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><SUP>3</SUP>We have
an option-license agreement with Massachusetts General Hospital to develop SYN-020 in several potential indications related to inflammation
and gut barrier dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT>We
have an option agreement with Sant Joan de D&eacute;u-Barcelona Children&rsquo;s Hospital to license their intellectual property rights
related to the use of VCN-01 in combination with topoisomerase I inhibitor chemotherapies for the treatment of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B><A NAME="a_004"></A>THE OFFERING</B></TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="text-indent: 4.3pt; width: 68%">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; width: 6%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD>Issuer</TD>
    <TD><FONT STYLE="background-color: white">Theriva Biologics,&nbsp;Inc.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common stock to be offered by us</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">pursuant to this prospectus</P></TD>
    <TD STYLE="text-align: justify">Up to 2,941,197 shares of our common stock having an aggregate offering price
of up to approximately $1,235,303 at an assumed offering price of $0.42 per share, which was the last reported sale price of our common
stock on the NYSE American on April&nbsp;29, 2024.</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common stock to be outstanding</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">after the offering</P></TD>
    <TD STYLE="text-align: justify">Up to 20,218,568 (as more fully described in the notes following this table),
assuming sales of approximately $1,235,303 shares of our common stock, or 2,941,197 shares of our common stock in this offering at an
assumed offering price of $0.42 per share, which was the last reported sale price of our common stock on the NYSE American on April&nbsp;29,
2024. The actual number of shares issued will vary depending on the sales price under this offering.<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">Manner of offering</TD>
    <TD STYLE="text-align: justify">&ldquo;At the market offering&rdquo; that may be made from time to time for our common stock in the
    United States through or to A.G.P., as sales agent or principal. See the section entitled &ldquo;<A HREF="#a_009">Plan of Distribution</A>.&rdquo;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">Use of proceeds</TD>
    <TD STYLE="text-align: justify">We currently intend to use the net proceeds from this offering for working capital and general corporate
    purposes, including, including, to acquire, license or invest in assets, businesses, technologies, product candidates or other intellectual
    property, to make milestone payments and to repurchase securities. See &ldquo;<A HREF="#a_006">Use of Proceeds</A>.&rdquo;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">Risk factors</TD>
    <TD STYLE="text-align: justify">You should read the &ldquo;<A HREF="#a_005">Risk Factors</A>&rdquo; section of this prospectus and in the documents incorporated
    by reference in this prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock.</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NYSE American</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trading Symbol</P></TD>
    <TD STYLE="text-align: justify">TOVX</TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless
we indicate otherwise, all information in this prospectus is based on 17,277,371 shares outstanding as of April&nbsp;30, 2024. The number
of shares outstanding as used throughout this prospectus, unless otherwise indicated, excludes:<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4,369,284 shares of our common stock issuable upon the exercise of
outstanding stock options as of April&nbsp;30, 2024, with a weighted average exercise price of $1.67 per share;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,459,016 shares of our common stock issuable upon conversion of our
Series&nbsp;C Preferred Stock and Series&nbsp;D Preferred Stock as of April&nbsp;30, 2024; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,826,498 additional shares of our common stock reserved for future
issuance under our equity incentive plans as of April&nbsp;30, 2024.</P></TD>
    <TD STYLE="border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 0.75pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our common stock involves a high
degree of risk, and you should be able to bear the complete loss of your investment. You should consider carefully the risks described
below and those described under the section captioned &ldquo;Risk Factors&rdquo; contained in our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit">Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2023</A>, any subsequent Annual Reports on Form&nbsp;10-K, any subsequent
Quarterly Reports on Form&nbsp;10-Q or Current Reports on Form&nbsp;8-K, and all other information contained or incorporated by reference
into this prospectus and documents incorporated by reference into this prospectus before deciding whether to purchase any of the common
stock being offered under this prospectus. If any of the risks actually occur, our business, consolidated financial condition or results
of operations could be adversely affected. In such case, the trading price of our common stock could decline and you could lose all or
part of your investment. Our actual results could differ materially from those anticipated in the forward-looking statements made throughout
this prospectus as a result of different factors, including the risks we face described below. Unless we have indicated otherwise or
the context otherwise requires, references in this prospectus or the documents incorporated by reference herein and therein to the &ldquo;Company,&rdquo;
&ldquo;Theriva Biologics,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Theriva Biologics,&nbsp;Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management will have broad discretion
over the use of proceeds from this offering and may not use the proceeds effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion over
the use of proceeds from this offering. We intend to use the net proceeds from this offering, if any, for working capital and general
corporate purposes, including, to acquire, license or invest in assets, businesses, technologies, product candidates or other intellectual
property, to make milestone payments and to repurchase securities. Our management will have considerable discretion in the application
of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being
used appropriately. The net proceeds, if any, may be used for corporate purposes that do not improve our operating results or enhance
the value of our common stock. The failure of our management to use these funds effectively could have a material adverse effect on our
business and cause the market price of our common stock to decline. Pending their use, we may invest the net proceeds from this offering
in short-term, investment-grade, interest-bearing instruments and U.S. government securities. These investments may not yield a favorable
return to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If you purchase shares of our common stock
sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares. In addition,
we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The price per share of our common stock being
offered may be higher than the net tangible book value per share of our outstanding common stock prior to this offering. Assuming that
an aggregate of 2,941,197 shares of our common stock are sold at a price of $0.42 per share, the last reported sale price of our common
stock on the NYSE American on April&nbsp;29, 2024, new investors in this offering will incur immediate dilution of $(0.35) per share,
representing the difference between our as adjusted net tangible book value per share as of December&nbsp;31, 2023 after giving effect
to this offering and the assumed price. For a more detailed discussion of the foregoing, see the section entitled &ldquo;Dilution&rdquo;
elsewhere in this prospectus. To the extent that our outstanding stock options or warrants are exercised, there will be further dilution
to new investors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our need for future financing may result
in the issuance of additional securities which will cause investors to experience dilution</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash requirements may vary from those now
planned depending upon numerous factors. We expect to require additional capital until our operations generate sufficient revenue to
cover our expenses. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.
There are no other commitments by any person for future financing. Our securities may be offered to other investors at a price lower
than the price per share offered to current stockholders, or upon terms which may be deemed more favorable than those offered to current
stockholders. In addition, the issuance of securities in any future financing may dilute an investor&rsquo;s equity ownership and have
the effect of depressing the market price for our securities. Moreover, we may issue derivative securities, including options and/or
warrants, from time to time, to procure qualified personnel or for other business reasons. The issuance of any such derivative securities,
which is at the discretion of our Board of Directors, may further dilute the equity ownership of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell shares or other securities in any
other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing
shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional
shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower
than the price per share paid by investors in this offering. No assurance can be given as to our ability to procure additional financing,
if required, and on terms deemed favorable to us. To the extent additional capital is required and cannot be raised successfully, we
may then have to limit our then current operations and/or may have to curtail certain, if not all, of our business objectives and plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have additional securities available
for issuance, which, if issued, could adversely affect the rights of the holders of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation, as amended (the
&ldquo;Articles of Incorporation&rdquo;), authorizes the issuance of 350,000,000 shares of our common stock and 10,000,000 shares of
preferred stock. In certain circumstances, shares of our common stock, as well as the awards available for issuance under our equity
incentive plans, can be issued by our Board of Directors, without stockholder approval. Any future issuances of such stock would further
dilute the percentage ownership of us held by holders of our common stock and preferred stock. In addition, the issuance of certain securities,
including pursuant to the terms of our stockholder rights plan, may be used as an &ldquo;anti-takeover&rdquo; device without further
action on the part of our stockholders, and may adversely affect the holders of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we do not intend to declare cash
dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common
stock for any return on their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As stated above, we have never declared or paid
cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion
of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, we expect that only
appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Resales of our common stock in the public
market during this offering by our stockholders may cause the market price of our common stock to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue shares of our common stock from
time to time in connection with this offering. This issuance from time to time of these new shares of our common stock, or our ability
to issue these shares of our common stock in this offering, could result in resales of our common stock by our current stockholders concerned
about the potential dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The actual number of shares we will issue
under the sales agreement, at any one time or in total, is uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain limitations in the sales agreement
with the sales agent and compliance with applicable law, we have the discretion to deliver placement notices to the sales agent at any
time throughout the term of the sales agreement. The number of shares that are sold by the sales agent after delivering a placement notice
will fluctuate based on the market price of the common stock during the sales period and limits we set with the sales agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The shares of common stock offered under
this prospectus and documents incorporated by reference into this prospectus may be sold in &ldquo;at the market offerings,&rdquo; and
investors who buy shares at different times will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors who purchase shares under this prospectus
and documents incorporated by reference into this prospectus at different times will likely pay different prices, and so may experience
different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers
of shares sold, and there is no minimum or maximum sales price. Investors may experience declines in the value of their shares as a result
of share sales made at prices lower than the prices they paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue and sell shares of our common stock
having aggregate gross proceeds of up to $1,235,303 from time to time under this prospectus and the documents incorporated by reference
herein and therein. Because there is no minimum offering amount required as a condition to close this offering, the actual total offering
amount, commissions and proceeds to us, if any, are not determinable at this time. The amount of proceeds from this offering will depend
upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will
be able to sell any shares of our common stock under or fully utilize the Sales Agreement with A.G.P. as a source of financing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds, if any, from
the sales of shares of our common stock offered by this prospectus for working capital and general corporate purposes, including, to
acquire, license or invest in assets, businesses, technologies, product candidates or other intellectual property, to make milestone
payments and to repurchase securities. We have broad discretion in determining how the proceeds of this offering will be used, and our
discretion is not limited by the aforementioned possible uses. Our Board of Directors believes the flexibility in application of the
net proceeds is prudent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, we cannot
specify with certainty all of the particular uses for the net proceeds to be received from this offering. The amounts and timing of our
actual expenditures will depend on numerous factors including our operating costs and the amount of funding, if any, received from grants.
Accordingly, our management will have broad discretion in the application of the net proceeds, and investors will be relying on the judgment
of management regarding the application of the net proceeds from the offering. We may find it necessary or advisable to reallocate the
net proceeds of this offering; however, any such reallocation would be substantially limited to the categories set forth above as we
do not intend to use the net proceeds for other purposes. Pending such uses set forth above, we plan to invest the net proceeds in government
securities and other short-term investment grade, marketable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
on our capital stock and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. We expect
to retain all available funds and future earnings, if any, to fund the development and growth of our business. Any future determination
to pay dividends, if any, on our common stock will be at the discretion of our Board of Directors and will depend on, among other factors,
our results of operations, financial condition, capital requirements and contractual restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our net tangible book
value as of December&nbsp;31, 2023 was approximately $14.24&nbsp;million, or $0.831 per share. Net tangible book value per share is determined
by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December&nbsp;31,
2023. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers
of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">After giving effect to
the sale of 2,941,197&nbsp;shares of our common stock in this offering at an assumed offering price of $0.42 per share, which is the closing
price of our common stock on the NYSE American on April&nbsp;29, 2024, and after deducting the sales agent fees and estimated offering
expenses payable by us, our as adjusted net tangible book value as of December&nbsp;31, 2023 would have been approximately $15.48&nbsp;million,
or $0.77&nbsp;per share. This represents an immediate decrease in as adjusted net tangible book value of $0.065&nbsp;per share to existing
stockholders and an immediate dilution of $(0.35)&nbsp;per share to new investors purchasing securities in this offering. The following
table illustrates this per share dilution:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed public offering price per share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.42</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per share as of December&nbsp;31, 2023</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.831</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in net tangible book value per share attributable to this offering</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.065</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible book value per share as of December&nbsp;31, 2023, after giving effect to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.77</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors purchasing our common stock in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">(<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.35)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above discussion and table&nbsp;<FONT STYLE="background-color: white">is
based on 17,148,049 shares of our common stock outstanding as of December&nbsp;31, 2023, as adjusted for the adjustments set forth above
and excludes as of December&nbsp;31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">4,375,781
                                            shares of our common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $1.80 per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">2,459,016
                                            shares of our common stock issuable upon conversion of our Series&nbsp;C Preferred Stock
                                            and Series&nbsp;D Preferred Stock;  and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">2,826,498
                                            additional shares of our common stock reserved for future issuance under our equity incentive
                                            plans.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above illustration of dilution per share
to investors participating in this offering assumes no exercise of outstanding options to purchase our common stock or outstanding warrants
to purchase shares of our common stock. To the extent that any of these outstanding options or warrants are exercised or we issue additional
shares under our equity incentive plans, there will be further dilution to new investors. In addition, we may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We entered into the Sales Agreement with A.G.P.
under which we may issue and sell from time-to-time shares of our common stock having an aggregate offering price of up to $1,235,303
to or through A.G.P., acting as our sales agent or principal. The sales of shares of our common stock, if any, under this prospectus supplement
will be made at market prices by any method deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule&nbsp;415(a)(4)&nbsp;under
the Securities Act.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each time that we wish to issue and sell shares
of our common stock under the sales agreement, we will provide the Sales Agent with a placement notice describing the amount of shares
to be sold, the time period during which sales are requested to be made, any limitation on the amount of shares of our common stock that
may be sold in any single day, any minimum price below which sales may not be made or any minimum price requested for sales in a given
time period and any other instructions relevant to such requested sales. Upon receipt of a placement notice, the Sales Agent, acting
as our sales agent, will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state
and federal laws, rules&nbsp;and regulations and the rules&nbsp;of the NYSE American, to sell shares of our common stock under the terms
and subject to the conditions of the placement notice and the sales agreement. We or the Sales Agent may suspend the offering of shares
of our common stock pursuant to a placement notice upon notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until May&nbsp;28, 2024, settlement for sales
of shares of common stock, unless the parties agree otherwise, will occur on the second trading day following the date on which any sales
are made in return for payment of the net proceeds to us. After May&nbsp;28, 2024, settlement for sales of shares of common stock, unless
the parties agree otherwise, will occur on the first trading day following the date on which any sales are made in return for payment
of the net proceeds to us. There are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account.
Sales of shares of our common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust
Company or by such other means as we and the Sales Agent may agree upon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agent will be entitled to compensation
at a fixed commission rate of 3.0% of the gross proceeds from the sale of shares of our common stock on our behalf pursuant to the sales
agreement. Pursuant to the terms of the sales agreement, we agreed to reimburse the Sales Agent for the documented fees and costs of
its legal counsel reasonably incurred in connection with entering into the transactions contemplated by the Sales Agreement in an amount
not to exceed $50,000 in the aggregate, in addition to up to $10,000 annually for the Sales Agent&rsquo;s counsel&rsquo;s fees and any
incidental expenses to be reimbursed by us. We will report at least quarterly the number of shares of common stock sold through the Sales
Agent under the Sales Agreement, the net proceeds to us and the compensation paid by us to the Sales Agent in connection with the sales
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the total expenses for this
offering, excluding compensation payable to the Sales Agent and certain expenses reimbursable to the Sales Agent under the terms of the
Sales Agreement, will be approximately $200,000. The remaining sales proceeds, after deducting any expenses payable by us and any transaction
fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds
for the sale of such shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because there are no minimum sale requirements
as a condition to this offering, the actual total public offering price, commissions and net proceeds to us, if any, are not determinable
at this time. The actual dollar amount and number of shares of common stock we sell through this prospectus will be dependent, among
other things, on market conditions and our capital raising requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the sale of shares of common
stock on our behalf, the Sales Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and
the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification
and contribution to the Sales Agent against certain civil liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agent will not engage in any market
making activities involving shares of our common stock while the offering is ongoing under this prospectus if such activity would be
prohibited under Regulation M or other anti-manipulation rules&nbsp;under the Securities Act. As our sales agent, the Sales Agent will
not engage in any transactions that stabilizes shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering pursuant to the Sales Agreement
will terminate upon the earlier of (i)&nbsp;the sale of all shares of common stock subject to the sales agreement and (ii)&nbsp;termination
of the sales agreement as permitted therein. We may terminate the sales agreement in our sole discretion at any time by giving one (1)&nbsp;day&rsquo;s
prior notice to the Sales Agent. The Sales Agent may terminate the Sales Agreement under the circumstances specified in the sales agreement
and in its sole discretion at any time by giving five (5)&nbsp;days&rsquo; prior notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales agent and/or its affiliates have provided,
and may in the future provide, various investment banking and other financial services for us, for which services they have received
and may in the future receive customary fees. In addition, the Sales Agent served as a financial advisor with respect to our search for
strategic alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus may be made available in electronic
format on a website maintained by the Sales Agent, and the Sales Agent may distribute this prospectus electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Blank Rome LLP, New York, New York is representing
us in connection with the offering. <FONT STYLE="background-color: white">The validity of the shares of Common Stock being offered by
this prospectus is being passed upon by&nbsp;</FONT>Parsons Behle&nbsp;&amp; Latimer, Reno, Nevada. Duane Morris LLP, New York, New York
is acting as counsel for the Sales Agent in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, an attorney
of Blank Rome LLP beneficially owns securities exercisable to purchase shares of our Common Stock that represent less than 1% of our
outstanding shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Theriva
Biologics,&nbsp;Inc. as of December&nbsp;31, 2023 and 2022 and for each of the two years in the period ended December&nbsp;31, 2023 incorporated
by reference in this prospectus and in the registration statement of which this prospectus forms a part have been so incorporated in
reliance on the report of BDO USA, P.C, an independent registered public accounting firm, given on the authority of said firm as experts
in auditing and accounting. The report on the consolidated financial statements contains an explanatory paragraph regarding the Company&rsquo;s
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>WHERE YOU CAN FIND MORE
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we
refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor
any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these
securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as
of any date other than the date on the front page&nbsp;of this prospectus, regardless of the time of delivery of this prospectus or any
sale of the securities offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s website at <I>www.sec.gov</I>.
Our SEC filings are also available on our website, <I>www.therivabio.com</I> under the heading &ldquo;Investor Relations&mdash;SEC Filings.&rdquo;
The reference to our website is an inactive textual reference only, the information contained in, and that can be accessed through our
website, is not incorporated into and is not a part of this prospectus. We make available on our website our SEC filings as soon as reasonably
practicable after those reports are filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information from other documents that we file with it, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus
supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this prospectus
and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the
SEC (Commission File No.&nbsp;001-12584):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: justify">Our Annual Report on <FONT STYLE="color: blue"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit">Form
    10-K</A></FONT> for the fiscal year ended December&nbsp;31, 2023 filed with the SEC on March&nbsp;25, 2023;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">Our Current Reports on Form&nbsp;8-K filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924011395/tm245387d1_8k.htm" STYLE="-sec-extract: exhibit">February
    7, 2024,</A> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050037/tm2412300d1_8k.htm" STYLE="-sec-extract: exhibit">April
    22, 2024</A> (other than as set forth therein), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050307/tm2412300d2_8k.htm" STYLE="-sec-extract: exhibit">April
    23, 2024</A> (other than as set forth therein) and May 2, 2024; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">The description of our common stock set forth in (i)&nbsp;our registration statements on <FONT STYLE="color: blue"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016307000379/s11-7491_8a.htm" STYLE="-sec-extract: exhibit">Form&nbsp;8-A12B</A></FONT>,
    filed with the SEC on June&nbsp;20, 2007 (File No.&nbsp;001-12584) and (ii) <A HREF="https://www.sec.gov/Archives/edgar/data/894158/000141057824000293/tmb-20231231xex4d3.htm" STYLE="-sec-extract: exhibit">Exhibit
    4.3</A>&mdash;Description of Securities to our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2023.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference any future filings
(other than current reports furnished under Item 2.02 or Item 7.01 of Form&nbsp;8-K and exhibits filed on such form that are related
to such items unless such Form&nbsp;8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or
15(d)&nbsp;of the Exchange Act, including those made (i)&nbsp;on or after the date of the initial filing of the registration statement
of which this prospectus forms a part and prior to effectiveness of such registration statement, and (ii)&nbsp;on or after the date of
this prospectus but prior to the termination of the offering (i.e., until the earlier of the date on which all of the securities registered
hereunder have been sold or the registration statement of which this prospectus forms a part has been withdrawn). Information in such
future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically
be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to
be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents
incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated
by reference into such documents. You should direct any requests for documents to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Theriva Biologics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite&nbsp;270&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, Maryland 20850&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone (301) 417-4364&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access these documents, free of
charge, on the SEC&rsquo;s website at <I>www.sec.gov</I> or on our website at <I>https://ir.therivabio.com/sec-filings</I>. The information
contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or
any accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule&nbsp;412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on information contained
in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers
to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2413199d1_s3img005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $1,235,303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>A.G.P.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -3.25in; text-align: center; text-indent: 285pt">, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -3.25in; text-align: center; text-indent: 285pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -3.25in; text-align: center; text-indent: 285pt"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following sets forth
the estimated costs and expenses, all of which shall be borne by Theriva Biologics,&nbsp;Inc. (the &ldquo;Registrant&rdquo;), in connection
with the offering of the securities pursuant to this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">SEC registration fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">FINRA filing fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">30,500</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt">Transfer agent and registrar expenses</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">(1)&nbsp;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(1)&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(1)&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Printing and engraving expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(1)&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*</P></TD>
    <TD STYLE="width: 97%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: -0.05pt">These
                           fees are calculated based on the securities offered and the number of issuances and, accordingly, cannot be
                           estimated at this time. An estimate of the aggregate expenses in connection with the sale and distribution
                           of securities being offered will be included in the applicable prospectus supplement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: -0.05pt">&nbsp;&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: -0.05pt">Excludes
    the registration fee previously paid in connection with unsold securities pursuant to Rule&nbsp;415(a)(6).</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Indemnification of Directors and
Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;78.138 of the Nevada Revised Statute
provides that, subject to certain exceptions, a director or officer is not individually liable to the corporation or its stockholders
or creditors for any damages as a result of any act or failure to act in his capacity as a director or officer unless the presumption
that the director or officer acted in good faith, on an informed basis and with a view to the interest of the corporation is rebutted
and it is proven that (1)&nbsp;his act or failure to act constituted a breach of his fiduciary duties as a director or officer and (2)&nbsp;his
breach of those duties involved intentional misconduct, fraud or a knowing violation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This provision is intended to afford directors
and officers protection against and to limit their potential liability for monetary damages resulting from suits alleging a breach of
the duty of care by a director or officer. As a consequence of this provision, stockholders of our company will be unable to recover
monetary damages against directors or officers for action taken by them that may constitute negligence or gross negligence in performance
of their duties unless such conduct falls within one of the foregoing exceptions. The provision, however, does not alter the applicable
standards governing a director&rsquo;s or officer&rsquo;s fiduciary duty and does not eliminate or limit the right of our company or
any stockholder to obtain an injunction or any other type of non-monetary relief in the event of a breach of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant&rsquo;s Articles of Incorporation,
as amended, and amended and restated bylaws provide for indemnification of directors, officers, employees or agents of the Registrant
to the fullest extent permitted by Nevada law (as amended from time to time). Section&nbsp;78.7502 of the Nevada Revised Statute provides
that &nbsp;a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right
of the corporation, by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is
or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise or as a manager of a limited-liability company, against expenses, including attorneys&rsquo; fees,
judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit or
proceeding if the&nbsp; person is not liable as provided above and acted in good faith and in a manner he or she reasonably believed
to be in, or not opposed to, the best interest of a company and, with respect to any criminal action or proceeding, had no reasonable
cause to behave his conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant has entered into separate indemnification
agreements with each of the registrant&rsquo;s directors and certain of the registrant&rsquo;s officers which require the registrant,
among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant has an insurance policy in place
that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any underwriting agreement, agency agreement,
equity distribution agreement or similar agreement that the Registrant may enter into will likely provide for indemnification by any
underwriters or agents of the Registrant, its directors, its officers who sign the registration statement and the Registrant&rsquo;s
controlling persons for some liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The exhibits
to this registration statement are listed in the Exhibit&nbsp;Index to this registration statement, which immediately precedes the Signature
Page&nbsp;and which Exhibit&nbsp;Index is hereby incorporated by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">To file, during any period in which offers or sales are being made, a post-effective amendment to
    this registration statement:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(i)</TD>
    <TD STYLE="text-align: justify">To include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(ii)</TD>
    <TD STYLE="text-align: justify">To reflect in the prospectus any facts or events arising after the effective date of the registration
    statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
    change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
    of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
    from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant
    to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum
    aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;
    and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(iii)</TD>
    <TD STYLE="text-align: justify">To include any material information with respect to the plan of distribution not previously disclosed
    in the registration statement or any material change to such information in the registration statement;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided, however</I>, that the undertakings
set forth in paragraphs (1)(i), (1)(ii)&nbsp;and (1)(iii)&nbsp;above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&nbsp;13
or Section&nbsp;15(d)&nbsp;of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference
in this registration statement or are contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;that is part of this
registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(2)</TD>
    <TD STYLE="text-align: justify">That, for the purpose of determining any liability under the Securities Act, each such post-effective
    amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
    securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(3)</TD>
    <TD STYLE="text-align: justify">To remove from registration by means of a post-effective amendment any of the securities being registered
    which remain unsold at the termination of the offering.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(4)</TD>
    <TD STYLE="text-align: justify">That, for the purpose of determining liability under the Securities Act to any purchaser:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(i)</TD>
    <TD STYLE="text-align: justify">Each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;shall be deemed to be
    part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement;
    and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(ii)</TD>
    <TD STYLE="text-align: justify">Each prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7)&nbsp;as part
    of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii),
    or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a)&nbsp;of the Securities Act shall be deemed
    to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after
    effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in
    Rule&nbsp;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed
    to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus
    relates, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. <I>Provided,
    however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made
    in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
    registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify
    any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any
    such document immediately prior to such effective date.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(5)</TD>
    <TD STYLE="text-align: justify">That, for the purpose of determining liability of the registrant under the Securities Act to any
    purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities
    of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities
    to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned
    registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(i)</TD>
    <TD STYLE="text-align: justify">any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required
    to be filed pursuant to Rule&nbsp;424;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(ii)</TD>
    <TD STYLE="text-align: justify">any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
    registrant or used or referred to by the undersigned registrant;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(iii)</TD>
    <TD STYLE="text-align: justify">the portion of any other free writing prospectus relating to the offering containing material information
    about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">(iv)</TD>
    <TD STYLE="text-align: justify">any other communication that is an offer in the offering made by the undersigned registrant to the
    purchaser.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(6)</TD>
    <TD STYLE="text-align: justify">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s
    annual report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act (and, where applicable, each filing of an employee
    benefit plan&rsquo;s annual report pursuant to Section&nbsp;15(d)&nbsp;of the Exchange Act) that is incorporated by reference in
    the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
    offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(7)</TD>
    <TD STYLE="text-align: justify">To file an application for the purpose of determining the eligibility of the trustee to act under
    subsection (a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act in accordance with the rules&nbsp;and regulations prescribed by
    the SEC under Section&nbsp;305(b)(2)&nbsp;of the Trust Indenture Act.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(8)</TD>
    <TD STYLE="text-align: justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
    officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised
    that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore,
    unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of
    expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
    suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
    the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
    of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
    Act and will be governed by the final adjudication of such issue.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: black 1.5pt solid"><B>Exhibit&nbsp;Number</B></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 91%; border-bottom: black 1.5pt solid; text-align: justify"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465921016924/tm216028d1_ex1-1.htm" STYLE="-sec-extract: exhibit">1.1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465921016924/tm216028d1_ex1-1.htm" STYLE="-sec-extract: exhibit">Amended
    and Restated At Market Issuance Sales Agreement, dated February&nbsp;9, 2021, by and among Synthetic Biologics,&nbsp;Inc., B. Riley
    Securities,&nbsp;Inc. and A.G.P./Alliance Global Partners (Incorporated by reference to Exhibit&nbsp;1.1 of the Registrant&rsquo;s
    Current Report on Form&nbsp;8-K filed February&nbsp;9, 2021, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465921060274/tm2114499d2_ex1-2.htm" STYLE="-sec-extract: exhibit">1.2</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465921060274/tm2114499d2_ex1-2.htm" STYLE="-sec-extract: exhibit">Amendment
    No.&nbsp;1 to the Amended and Restated At Market Issuance Sales Agreement (Incorporated by reference to Exhibit&nbsp;1.1 of the Registrant&rsquo;s
    Current Report on Form&nbsp;8-K filed May&nbsp;3, 2021, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465924056146/tm2413223d1_ex10-3.htm" STYLE="-sec-extract: exhibit">1.3</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465924056146/tm2413223d1_ex10-3.htm" STYLE="-sec-extract: exhibit">Amendment No.&nbsp;2 to the Amended and Restated At Market Issuance Sales Agreement (Incorporated
    by reference to Exhibit&nbsp;10.3 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed May&nbsp;2, 2024, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>1.4**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Form&nbsp;of Underwriting Agreement</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">3.1</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">Certificate
    of Incorporation, as amended&nbsp;(Incorporated by reference to (i)&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016308000665/s11-8824_ex31.htm" STYLE="-sec-extract: exhibit">Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed October&nbsp;16, 2008, File No.&nbsp;001-12584</A>,&nbsp;(ii)&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/894158/000095012401502861/c64437ex3-1.txt" STYLE="-sec-extract: exhibit">Exhibit&nbsp;3.1 of the Registrant&rsquo;s Quarterly Report on Form&nbsp;10-Q for the quarterly period ended June&nbsp;30, 2001 filed August&nbsp;14, 2001, File No.&nbsp;001-12584</A>;
    and (iii)&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/894158/0000921895-98-000694.txt" STYLE="-sec-extract: exhibit">Exhibits 3.1, 4.1 and 4.2 of the Registrant&rsquo;s Quarterly Report on Form&nbsp;10-Q for the quarterly period ended June&nbsp;30, 1998 filed August&nbsp;14, 1998, File No.&nbsp;001-12584.</A>)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex31.htm" STYLE="-sec-extract: exhibit">3.2</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex31.htm" STYLE="-sec-extract: exhibit">Articles
    of Merger (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed October&nbsp;19,
    2009, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex32.htm" STYLE="-sec-extract: exhibit">3.3</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex32.htm" STYLE="-sec-extract: exhibit">Certificate
    of Merger filed with the Secretary of State of Delaware (Incorporated by reference to Exhibit&nbsp;3.2 of the Registrant&rsquo;s
    Current Report on Form&nbsp;8-K filed October&nbsp;19, 2009, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex33.htm" STYLE="-sec-extract: exhibit">3.4</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex33.htm" STYLE="-sec-extract: exhibit">Articles
    of Incorporation filed with the Nevada Secretary of State (Incorporated by reference to Exhibit&nbsp;3.3 of the Registrant&rsquo;s
    Current Report on Form&nbsp;8-K filed October&nbsp;19, 2009, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420412009508/v302955_ex3-1.htm" STYLE="-sec-extract: exhibit">3.5</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420412009508/v302955_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report
    on Form&nbsp;8-K filed February&nbsp;16, 2012, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420415031962/v411020_ex3-1.htm" STYLE="-sec-extract: exhibit">3.6</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420415031962/v411020_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation. (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant's Current Report on
    Form&nbsp;8-K filed May&nbsp;18, 2015, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420417047316/v474831_ex3-1.htm" STYLE="-sec-extract: exhibit">3.7</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420417047316/v474831_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation. (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report
    on Form&nbsp;8-K filed September&nbsp;8, 2017, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex3-1.htm" STYLE="-sec-extract: exhibit">3.8</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Designations for Series&nbsp;A Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit&nbsp;3.1
    of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed September&nbsp;12, 2017, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418043710/tv500716_ex3-1.htm" STYLE="-sec-extract: exhibit">3.9</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418043710/tv500716_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Change Pursuant to NRS 78. 209 (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K
    filed August&nbsp;13, 2018, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418050928/tv503400_ex3-1.htm" STYLE="-sec-extract: exhibit">3.10</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418050928/tv503400_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report
    on Form&nbsp;8-K filed September&nbsp;26, 2018, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex3-1.htm" STYLE="-sec-extract: exhibit">3.11</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Designations for Series&nbsp;B Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit&nbsp;3.1
    of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed October&nbsp;15, 2018, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex3-2.htm" STYLE="-sec-extract: exhibit">3.12</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex3-2.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Designations for Series&nbsp;B Preferred Stock to Certificate of Incorporation (Incorporated by reference
    to Exhibit&nbsp;3.2 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed October&nbsp;15, 2018, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465921009794/tm214840d1_ex3-1.htm" STYLE="-sec-extract: exhibit">3.13</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465921009794/tm214840d1_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to the Certificate of Designation for the Series&nbsp;A Convertible Preferred Stock (Incorporated by reference to Exhibit&nbsp;3.1
    of the Registrant&rsquo;s Current Report on Form&nbsp;8-K/A filed on February&nbsp;1, 2021 File No.&nbsp;001-12584.)</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white; width: 8%"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922082251/tm2221681d1_ex3-1.htm" STYLE="-sec-extract: exhibit">3.14</A></TD>
    <TD STYLE="background-color: white; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 91%"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922082251/tm2221681d1_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Change filed with the Secretary of State of the State of Nevada on July&nbsp;21, 2022 (effective as of July&nbsp;25, 2022) (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed on July&nbsp;25, 2022 (File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922084301/tm2222078d1_ex3-1.htm" STYLE="-sec-extract: exhibit">3.15</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922084301/tm2222078d1_ex3-1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Certificate of Designation of Series&nbsp;C Convertible Preferred Stock (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed on July&nbsp;29, 2022 (File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922084301/tm2222078d1_ex3-2.htm" STYLE="-sec-extract: exhibit">3.16</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922084301/tm2222078d1_ex3-2.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Certificate of Designation of Series&nbsp;D Convertible Preferred Stock (Incorporated by reference to Exhibit&nbsp;3.2 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed on July&nbsp;29, 2022 (File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922107928/tm2228052d1_ex3-1.htm" STYLE="-sec-extract: exhibit">3.17</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922107928/tm2228052d1_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed on October&nbsp;12, 2022 (File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922107928/tm2228052d1_ex3-2.htm" STYLE="-sec-extract: exhibit">3.18</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922107928/tm2228052d1_ex3-2.htm" STYLE="-sec-extract: exhibit">Certificate of Change to Articles of Incorporation (Incorporated by reference to Exhibit&nbsp;3.2 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed on October&nbsp;12, 2022 (File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922107928/tm2228052d1_ex3-3.htm" STYLE="-sec-extract: exhibit">3.19</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465922107928/tm2228052d1_ex3-3.htm" STYLE="-sec-extract: exhibit">Amended and Restated By-Laws Synthetic Biologics,&nbsp;Inc. Adopted and Effective October&nbsp;12, 2022 (Incorporated by reference to Exhibit&nbsp;3.3 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed on October&nbsp;12, 2022 (File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: white"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465923090511/tm2323521d1_ex3-1.htm" STYLE="-sec-extract: exhibit">3.20</A></TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/894158/000110465923090511/tm2323521d1_ex3-1.htm" STYLE="-sec-extract: exhibit">Second Amended and Restated Bylaws (Incorporated by reference to Exhibit&nbsp;3.1 of the Registrant&rsquo;s Current Report on Form&nbsp;8-K filed August&nbsp;11, 2023, File No.&nbsp;001-12584.)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z8.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1476963/000155335013000103/heat_ex4z8.htm" STYLE="-sec-extract: exhibit">Specimen Common Stock Certificate (incorporated by reference to Exhibit&nbsp;4.8 to the Registration Statement on Form&nbsp;S-1 with the Securities and Exchange Commission on May&nbsp;6, 2013 (File No.&nbsp;333-188365)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.2**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Specimen Preferred Stock Certificate and Form&nbsp;of Certificate of Designation of Preferred Stock</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2413199d1_ex4-3.htm" STYLE="-sec-extract: exhibit">4.3*</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm2413199d1_ex4-3.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Indenture</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.4**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Form&nbsp;of Debt Securities</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.5**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Form&nbsp;of Common Stock Warrant Agreement and Warrant Certificate</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.6**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Form&nbsp;of Preferred Stock Warrant Agreement and Warrant Certificate</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4.7**</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Form&nbsp;of Debt Securities Warrant Agreement and Warrant Certificate</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.8**</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Form&nbsp;of Unit Agreement</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2413199d1_ex5-1a.htm" STYLE="-sec-extract: exhibit">5.1(a)*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2413199d1_ex5-1a.htm" STYLE="-sec-extract: exhibit">Opinion of Parsons Behle&nbsp;&amp; Latimer</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2413199d1_ex5-1b.htm" STYLE="-sec-extract: exhibit">&nbsp;5.1(b)</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2413199d1_ex5-1b.htm" STYLE="-sec-extract: exhibit">Opinion of Blank Rome LLP</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2413199d1_ex23-1.htm" STYLE="-sec-extract: exhibit">23.1*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2413199d1_ex23-1.htm" STYLE="-sec-extract: exhibit">Consent of BDO USA, P.C.,&nbsp;Independent Registered Public Accounting Firm</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2413199d1_ex5-1a.htm" STYLE="-sec-extract: exhibit">23.2*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2413199d1_ex5-1a.htm" STYLE="-sec-extract: exhibit">Consent of Parsons Behle&nbsp;&amp; Latimer (included in Exhibit&nbsp;5.1(a))</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2413199d1_ex5-1b.htm" STYLE="-sec-extract: exhibit">&nbsp;23.3*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2413199d1_ex5-1b.htm" STYLE="-sec-extract: exhibit">Consent of Blank Rome LLP (included in Exhibit&nbsp;5.1(b))</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="#aCCP_001">24.1*</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#aCCP_001">Power of Attorney (included on the signature page)</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>25.1***</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Statement of Eligibility of Trustee under the Indenture</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2413199d1_ex-filingfees.htm" STYLE="-sec-extract: exhibit">107*</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm2413199d1_ex-filingfees.htm" STYLE="-sec-extract: exhibit">Calculation of Filing Fee Table</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">*</TD>
    <TD STYLE="width: 95%; text-align: justify">Filed herewith.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">**</TD>
    <TD STYLE="text-align: justify">To be filed, if applicable, by amendment or by a report filed under the Exchange Act and incorporated
    herein by reference.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">***</TD>
    <TD STYLE="text-align: justify">To be filed separately, if applicable, in accordance with the requirements of Section&nbsp;305(b)(2)&nbsp;of
    the Trust Indenture Act of 1939 as amended, and the appropriate rules&nbsp;and regulations thereunder.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="aCCP_001"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form&nbsp;S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Rockville, State of Maryland, on the 2<SUP>nd</SUP> day of May, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>THERIVA BIOLOGICS,&nbsp;INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ Steven A. Shallcross</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Steven A. Shallcross</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer and Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KNOW ALL PERSONS BY THESE PRESENTS, that each
person whose signature appears below hereby constitutes and appoints Steven A. Shallcross, as his true and lawful agent, proxy and attorney-in-fact,
with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to (i)&nbsp;act
on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration
statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule&nbsp;462(b)&nbsp;under
the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii)&nbsp;act on, sign and file such certificates,
instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii)&nbsp;act on and file any
supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed
pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act of 1933, as amended, and (iv)&nbsp;take any and all actions which may be necessary
or appropriate to be done, as fully for all intents and purposes as he might or could do in person, hereby approving, ratifying and confirming
all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: center"><B>Signature</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%; text-align: center"><B>Title</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 18%; text-align: center"><B>Date</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; vertical-align: bottom">/s/ Steven A. Shallcross</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer, Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Steven A. Shallcross</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) and Member of the Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May&nbsp;2, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Jeffrey J. Kraws</TD>
    <TD>&nbsp;</TD>
    <TD>Member of the Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May&nbsp;2, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Jeffrey J. Kraws</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Jeffrey Wolf</TD>
    <TD>&nbsp;</TD>
    <TD>Member of the Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May&nbsp;2, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Jeffrey Wolf</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ John Monahan, Ph. D.</TD>
    <TD>&nbsp;</TD>
    <TD>Member of the Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May&nbsp;2, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>John Monahan, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>tm2413199d1_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THERIVA BIOLOGICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Iss</B>u<B>er</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[TRUSTEE],</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDENTURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dated as of ______, 202_</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in; width: 15%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 81%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>PAGE</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;1 DEFINITIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;1.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Definitions of Terms</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Designation and Terms of Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Form&nbsp;of Securities and Trustee&rsquo;s Certificate</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Denominations: Provisions for Payment</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Execution and Authentications</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Registration of Transfer and Exchange</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.06</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Temporary Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.07</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Mutilated, Destroyed, Lost or Stolen Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.08</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Cancellation</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.09</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Benefits of Indenture</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.10</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Authenticating Agent</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.11</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Global Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.12</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">CUSIP Numbers</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;3 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">16</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Redemption</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">16</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Notice of Redemption</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">16</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 15%; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; text-align: justify"><FONT STYLE="font-size: 10pt">Payment Upon Redemption</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Sinking Fund</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Satisfaction of Sinking Fund Payments with Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.06</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Redemption of Securities for Sinking Fund</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;4 COVENANTS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;4.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Payment of Principal, Premium and Interest</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;4.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Maintenance of Office or Agency</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">19</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;4.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Paying Agents</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">19</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;4.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Appointment to Fill Vacancy in Office of Trustee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;5 SECURITYHOLDERS&rsquo; LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 15%; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;5.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; text-align: justify"><FONT STYLE="font-size: 10pt">Company to Furnish Trustee Names and Addresses of Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;5.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Preservation Of Information; Communications With Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;5.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Reports by the Company</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;5.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Reports by the Trustee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">22</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;6 REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">22</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;6.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Events of Default</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">22</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;6.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Collection of Indebtedness and Suits for Enforcement by Trustee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">24</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;6.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Application of Moneys Collected</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">25</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 15%; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;6.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; text-align: justify"><FONT STYLE="font-size: 10pt">Limitation on Suits</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">26</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;6.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Rights and Remedies Cumulative; Delay or Omission Not Waiver</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">26</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;6.06</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Control by Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">27</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;6.07</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Undertaking to Pay Costs</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">27</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;7 CONCERNING THE TRUSTEE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">28</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Certain Duties and Responsibilities of Trustee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">28</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Certain Rights of Trustee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">29</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Trustee Not Responsible for Recitals or Issuance or Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">31</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">May&nbsp;Hold Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">32</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Moneys Held in Trust</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">32</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.06</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Compensation and Reimbursement</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">32</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.07</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Reliance on Officer&rsquo;s Certificate</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">33</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.08</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Disqualification; Conflicting Interests</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">33</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.09</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Corporate Trustee Required; Eligibility</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">33</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.10</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Resignation and Removal; Appointment of Successor</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">34</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.11</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Acceptance of Appointment By Successor</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">35</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.12</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Merger, Conversion, Consolidation or Succession to Business</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">36</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 15%; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.13</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; text-align: justify"><FONT STYLE="font-size: 10pt">Preferential Collection of Claims Against the Company</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">37</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;7.14</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Notice of Default</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">37</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;8 CONCERNING THE SECURITYHOLDERS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">37</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 15%; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;8.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; text-align: justify"><FONT STYLE="font-size: 10pt">Evidence of Action by Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">37</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;8.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Proof of Execution by Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">38</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;8.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Who May&nbsp;be Deemed Owners</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">38</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;8.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Certain Securities Owned by Company Disregarded</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;8.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Actions Binding on Future Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;9 SUPPLEMENTAL INDENTURES</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;9.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Supplemental Indentures Without the Consent of Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;9.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Supplemental Indentures With Consent of Securityholders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">41</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;9.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Effect of Supplemental Indentures</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">41</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;9.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Securities Affected by Supplemental Indentures</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">41</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;9.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Execution of Supplemental Indentures</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">42</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;10 SUCCESSOR ENTITY</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">42</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;10.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Company May&nbsp;Consolidate, Etc.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">42</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;10.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Successor Entity Substituted</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">43</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;11 SATISFACTION AND DISCHARGE</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">43</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;11.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Satisfaction and Discharge of Indenture</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">43</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;11.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Discharge of Obligations</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">44</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;11.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Deposited Moneys to be Held in Trust</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">44</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;11.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Payment of Moneys Held by Paying Agents</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">44</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;11.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Repayment to Company</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">45</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(CONTINUED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>PAGE</B></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">45</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 15%; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;12.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; text-align: justify"><FONT STYLE="font-size: 10pt">No Recourse</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">45</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 8.1pt; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;13 MISCELLANEOUS PROVISIONS</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">45</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.01</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Effect on Successors and Assigns</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">45</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.02</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Actions by Successor</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">46</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.03</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Surrender of Company Powers</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">46</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 15%; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 81%; text-align: justify"><FONT STYLE="font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">46</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.05</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Governing Law; Jury Trial Waiver</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">46</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.06</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Treatment of Securities as Debt</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.07</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Certificates and Opinions as to Conditions Precedent</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.08</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Payments on Business Days</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.09</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Conflict with Trust Indenture Act</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.10</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.11</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Separability</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.12</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Compliance Certificates</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.13</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Patriot Act</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.14</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Force Majeure</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in; text-align: justify; text-indent: -8.1pt"><FONT STYLE="font-size: 10pt">Section&nbsp;13.12</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Table of Contents; Headings</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDENTURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>INDENTURE</B>, dated as
of ______, 202__, among Theriva Biologics,&nbsp;Inc., a Nevada corporation (the &ldquo;Company&rdquo;), and [<B>TRUSTEE</B>], as trustee
(the &ldquo;Trustee&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>WHEREAS</B>, for its lawful
corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities
(hereinafter referred to as the &ldquo;Securities&rdquo;), in an unlimited aggregate principal amount to be issued from time to time in
one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of
the Trustee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>WHEREAS</B>, to provide
the terms and conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized the
execution of this Indenture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>WHEREAS</B>, all things
necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>NOW, THEREFORE</B>, in
consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted and agreed as follows
for the equal and ratable benefit of the holders of Securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;1.01 Definitions of
Terms.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The terms defined in this
Section&nbsp;(except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise
requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in
this Section&nbsp;and shall include the plural as well as the singular. All other terms used in this Indenture that are defined in the
Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except
as herein or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires), shall have the
meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this
instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Authenticating
Agent</I></B>&rdquo; means the Trustee or an authenticating agent with respect to all or any of the series of Securities appointed by
the Trustee pursuant to Section&nbsp;2.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Bankruptcy Law</I></B>&rdquo;
means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Board of Directors</I></B>&rdquo;
means the Board of Directors (or the functional equivalent thereof) of the Company or any duly authorized committee of such Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Board Resolution</I></B>&rdquo;
means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board
of Directors (or duly authorized committee thereof) and to be in full force and effect on the date of such certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Business Day</I></B>&rdquo;
means, with respect to any series of Securities, any day other than a day on which federal or state banking institutions in the Borough
of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated by law, executive
order or regulation to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Commission</I></B>&rdquo;
means the Securities and Exchange Commission, as from time to time constituted, created under the Exchange Act, or, if at any time after
the execution of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust Indenture
Act, then the body performing such duties at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Company</I></B>&rdquo;
means Theriva Biologics,&nbsp;Inc., a corporation duly organized and existing under the laws of the State of Nevada, and, subject to the
provisions of Article&nbsp;Ten, shall also include its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Corporate Trust
Office</I></B>&rdquo; means the office of the Trustee at which, at any particular time, its corporate trust business shall be principally
administered, which office at the date hereof is located at [_____].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Custodian</I></B>&rdquo;
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Defaulted Interest</I></B>&rdquo;
has the meaning set forth in Section&nbsp;2.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Depositary</I></B>&rdquo;
means, with respect to Securities of any series for which the Company shall determine that such Securities will be issued as a Global
Security, The Depository Trust Company, another clearing agency, or any successor registered as a clearing agency under the Exchange Act,
or other applicable statute or regulation, which, in each case, shall be designated by the Company pursuant to either Section&nbsp;2.01
or 2.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Event of Default</I></B>&rdquo;
means, with respect to Securities of a particular series, any event specified in Section&nbsp;6.01, continued for the period of time,
if any, therein designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Exchange Act</I></B>&rdquo;
means the United States Securities and Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated by the Commission
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term &ldquo;<B><I>given</I></B>&rdquo;,
&ldquo;<B><I>mailed</I></B>&rdquo;, &ldquo;<B><I>notify</I></B>&rdquo; or &ldquo;<B><I>sent</I></B>&rdquo; with respect to any notice
to be given to a Securityholder pursuant to this Indenture, shall mean notice (x)&nbsp;given to the Depositary (or its designee) pursuant
to the standing instructions from the Depositary or its designee, including by electronic mail in accordance with accepted practices or
procedures at the Depositary (in the case of a Global Security) or (y)&nbsp;mailed to such Holder by first class mail, postage prepaid,
at its address as it appears on the Security Register (in the case of a definitive Security). Notice so &ldquo;given&rdquo; shall be deemed
to include any notice to be &ldquo;mailed&rdquo; or &ldquo;delivered,&rdquo; as applicable, under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Global Security</I></B>&rdquo;
means a Security issued to evidence all or a part of any series of Securities which is executed by the Company and authenticated and delivered
by the Trustee to the Depositary or pursuant to the Depositary&rsquo;s instruction, all in accordance with the Indenture, which shall
be registered in the name of the Depositary or its nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Governmental
Obligations</I></B>&rdquo; means securities that are (a)&nbsp;direct obligations of the United States of America for the payment of which
its full faith and credit is pledged or (b)&nbsp;obligations of a Person controlled or supervised by and acting as an agency or instrumentality
of the United States of America, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United
States of America that, in either case, are not callable or redeemable at the option of the issuer thereof at any time prior to the stated
maturity of the Securities, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to
any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such custodian
for the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian is not authorized
to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect
of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary
receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>herein</I></B>&rdquo;,
&ldquo;<B><I>hereof</I>&rdquo;</B> and &ldquo;<B><I>hereunder</I></B>&rdquo;, and other words of similar import, refer to this Indenture
as a whole and not to any particular Article, Section&nbsp;or other subdivision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Indenture</I></B>&rdquo;
means this instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental
hereto entered into in accordance with the terms hereof and shall include the terms of particular series of Securities established as
contemplated by Section&nbsp;2.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Interest Payment
Date</I></B>&rdquo;, when used with respect to any installment of interest on a Security of a particular series, means the date specified
in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date on which
an installment of interest with respect to Securities of that series is due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Officer</I></B>&rdquo;
means, with respect to the Company, the chairman of the Board of Directors, a chief executive officer, a president, a chief financial
officer, a chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any
assistant treasurer, the controller or any assistant controller or the secretary or any assistant secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Officer&rsquo;s
Certificate</I></B>&rdquo; means a certificate signed by any Officer. Each such certificate shall include the statements provided for
in Section&nbsp;13.07, if and to the extent required by the provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Opinion of Counsel</I></B>&rdquo;
means an opinion in writing subject to customary exceptions of legal counsel, who may be an employee of or counsel for the Company, that
is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section&nbsp;13.07,
if and to the extent required by the provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Outstanding</I></B>&rdquo;,
when used with reference to Securities of any series, means, subject to the provisions of Section&nbsp;8.04, as of any particular time,
all Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a)&nbsp;Securities
theretofore canceled by the Trustee or any paying agent, or delivered to the Trustee or any paying agent for cancellation or that have
previously been canceled; (b)&nbsp;Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations
in the necessary amount shall have been deposited in trust with the Trustee or with any paying agent (other than the Company) or shall
have been set aside and segregated in trust by the Company (if the Company shall act as its own paying agent); provided, however, that
if such Securities or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have
been given as provided in Article&nbsp;Three, or provision satisfactory to the Trustee shall have been made for giving such notice; and
(c)&nbsp;Securities in lieu of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the
terms of Section&nbsp;2.07.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Person</I></B>&rdquo;
means any individual, corporation, partnership, joint venture, joint-stock company, limited liability company, association, trust, unincorporated
organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Predecessor
Security</I></B>&rdquo; of any particular Security means every previous Security evidencing all or a portion of the same debt as that
evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section&nbsp;2.07
in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same debt as the lost, destroyed or stolen Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Responsible
Officer</I></B>&rdquo; when used with respect to the Trustee means any officer within the Corporate Trust Office of the Trustee (or any
successor group of the Trustee) or any other officer of the Trustee customarily performing functions similar to those performed by any
of the above designated officers and also means, with respect to a particular corporate trust matter, any other officer to whom such matter
is referred because of his or her knowledge of and familiarity with the particular subject and in each case who shall have direct responsibility
for the administration of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Securities</I></B>&rdquo;
has the meaning stated in the first recital of this Indenture and more particularly means any Securities authenticated and delivered under
this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;<B><I>Securities Act</I></B>&rdquo; means
the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Securityholder</I></B>&rdquo;,
&ldquo;<B><I>holder of Securities</I></B>&rdquo;, &ldquo;<B><I>registered holder</I></B>&rdquo;, or other similar term, means the Person
or Persons in whose name or names a particular Security is registered on the Security Register kept for that purpose in accordance with
the terms of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Security Register</I></B>&rdquo;
and &ldquo;<B><I>Security Registrar</I></B>&rdquo; shall have the meanings as set forth in Section&nbsp;2.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Subsidiary</I></B>&rdquo;
means, with respect to any Person, any corporation, association, partnership or other business entity of which more than 50% of the total
voting power of shares of capital stock or other interests (including partnership interests) entitled (without regard to the occurrence
of any contingency) to vote in the election of directors, managers, general partners or trustees thereof is at the time owned or controlled,
directly or indirectly, by (i)&nbsp;such Person; (ii)&nbsp;such Person and one or more Subsidiaries of such Person; or (iii)&nbsp;one
or more Subsidiaries of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Trustee</I></B>&rdquo;
means, and, subject to the provisions of Article&nbsp;Seven, shall also include its successors and assigns, and, if at any time there
is more than one Person acting in such capacity hereunder, &ldquo;Trustee&rdquo; shall mean each such Person. The term &ldquo;Trustee&rdquo;
as used with respect to a particular series of the Securities shall mean the trustee with respect to that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B><I>Trust Indenture
Act</I></B>&rdquo; means the Trust Indenture Act of 1939, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>&ldquo;U.S.A. Patriot
Act&rdquo;</I></B> means the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001, Pub. L. 107-56, as amended and signed into law October&nbsp;26, 2001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION
AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCHANGE OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;2.01 Designation
and Terms of Securities</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The aggregate
principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued
in one or more series up to the aggregate principal amount of Securities of that series from time to time authorized by or pursuant to
a Board Resolution or pursuant to one or more indentures supplemental hereto. Prior to the initial issuance of Securities of any series,
there shall be established in or pursuant to a Board Resolution, and set forth in an Officer&rsquo;s Certificate, or established in one
or more indentures supplemental hereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(1)</B>&nbsp;the title of
the Securities of the series (which shall distinguish the Securities of that series from all other Securities);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(2)</B>&nbsp;any limit upon
the aggregate principal amount of the Securities of that series that may be authenticated and delivered under this Indenture (except for
Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(3)</B>&nbsp;the maturity
date or dates on which the principal of the Securities of the series is payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(4)</B>&nbsp;the form of
the Securities of the series including the form of the certificate of authentication for such series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(5)</B>&nbsp;the applicability
of any guarantees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(6)</B>&nbsp;whether or not
the Securities will be secured or unsecured, and the terms of any secured debt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(7)</B>&nbsp;whether the
Securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(8)</B>&nbsp;if the price
(expressed as a percentage of the aggregate principal amount thereof) at which such Securities will be issued is a price other than the
principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof,
or if applicable, the portion of the principal amount of such Securities that is convertible into another security or the method by which
any such portion shall be determined;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(9)</B>&nbsp;the interest
rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the
dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(10)</B>&nbsp;the Company&rsquo;s
right, if any, to defer the payment of interest and the maximum length of any such deferral period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(11)</B> if applicable, the
date or dates after which, or the period or periods during which, and the price or prices at which, the Company may at its option, redeem
the series of Securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(12)</B> the date or dates,
if any, on which, and the price or prices at which the Company is obligated, pursuant to any mandatory sinking fund or analogous fund
provisions or otherwise, to redeem, or at the Securityholder&rsquo;s option to purchase, the series of Securities and the currency or
currency unit in which the Securities are payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(13)</B> the denominations
in which the Securities of the series shall be issuable, if other than denominations of one thousand U.S. dollars ($1,000) or any integral
multiple thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(14)</B> any and all terms,
if applicable, relating to any auction or remarketing of the Securities of that series and any security for the obligations of the Company
with respect to such Securities and any other terms which may be advisable in connection with the marketing of Securities of that series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(15)</B> whether the Securities
of the series shall be issued in whole or in part in the form of a Global Security or Securities; the terms and conditions, if any, upon
which such Global Security or Securities may be exchanged in whole or in part for other individual Securities; and the Depositary for
such Global Security or Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(16)</B> if applicable, the
provisions relating to conversion or exchange of any Securities of the series and the terms and conditions upon which such Securities
will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may
be adjusted, any mandatory or optional (at the Company&rsquo;s option or the holders&rsquo; option) conversion or exchange features, the
applicable conversion or exchange period and the manner of settlement for any conversion or exchange, which may, without limitation, include
the payment of cash as well as the delivery of securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(17)</B> if other than the
full principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable upon declaration
of acceleration of the maturity thereof pursuant to Section&nbsp;6.01;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(18)</B> additions to or
changes in the covenants applicable to the series of Securities being issued, including, among others, the consolidation, merger or sale
covenant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(19)</B> additions to or
changes in the Events of Default with respect to the Securities and any change in the right of the Trustee or the Securityholders to declare
the principal, premium, if any, and interest, if any, with respect to such Securities to be due and payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(20)</B> additions to or
changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(21)</B> additions to or
changes in the provisions relating to satisfaction and discharge of this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(22)</B> additions to or
changes in the provisions relating to the modification of this Indenture both with and without the consent of Securityholders of Securities
issued under this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(23)</B> the currency of
payment of Securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(24)</B> whether interest
will be payable in cash or additional Securities at the Company&rsquo;s or the Securityholders&rsquo; option and the terms and conditions
upon which the election may be made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(25)</B> the terms and conditions,
if any, upon which the Company shall pay amounts in addition to the stated interest, premium, if any and principal amounts of the Securities
of the series to any Securityholder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(26)</B> any restrictions
on transfer, sale or assignment of the Securities of the series; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(27)</B> any other specific
terms, preferences, rights or limitations of, or restrictions on, the Securities, any other additions or changes in the provisions of
this Indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All Securities of any one
series shall be substantially identical except as may otherwise be provided in or pursuant to any such Board Resolution or in any indentures
supplemental hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the terms of the
series are established by action taken pursuant to a Board Resolution of the Company, a copy of an appropriate record of such action shall
be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or prior to the delivery of the
Officer&rsquo;s Certificate of the Company setting forth the terms of the series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Securities of any particular
series may be issued at various times, with different dates on which the principal or any installment of principal is payable, with different
rates of interest, if any, or different methods by which rates of interest may be determined, with different dates on which such interest
may be payable and with different redemption dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.02 Form&nbsp;of Securities
and Trustee&rsquo;s Certificate.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Securities of any series
and the Trustee&rsquo;s certificate of authentication to be borne by such Securities shall be substantially of the tenor and purport as
set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth in an Officer&rsquo;s Certificate,
and they may have such letters, numbers or other marks of identification or designation and such legends or endorsements printed, lithographed
or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be
required to comply with any law or with any rule&nbsp;or regulation made pursuant thereto or with any rule&nbsp;or regulation of any securities
exchange on which Securities of that series may be listed, or to conform to usage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.03 Denominations:
Provisions for Payment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Securities shall be issuable
as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to Section&nbsp;2.01(a)(13).
The Securities of a particular series shall bear interest payable on the dates and at the rate specified with respect to that series.
Subject to Section&nbsp;2.01(a)(23), the principal of and the interest on the Securities of any series, as well as any premium thereon
in case of redemption or repurchase thereof prior to maturity, and any cash amount due upon conversion or exchange thereof, shall be payable
in the coin or currency of the United States of America that at the time is legal tender for public and private debt, at the office or
agency of the Company maintained for that purpose. Each Security shall be dated the date of its authentication. Interest on the Securities
shall be computed on the basis of a 360-day year composed of twelve 30-day months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The interest installment
on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities of that series
shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is registered at the close of business
on the regular record date for such interest installment. In the event that any Security of a particular series or portion thereof is
called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior
to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as provided in
Section&nbsp;3.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any interest on any Security
that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date for Securities of the same series (herein
called &ldquo;Defaulted Interest&rdquo;) shall forthwith cease to be payable to the registered holder on the relevant regular record date
by virtue of having been such holder; and such Defaulted Interest shall be paid by the Company, at its election, as provided in clause
(1)&nbsp;or clause (2)&nbsp;below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(1)</B>&nbsp;The Company
may make payment of any Defaulted Interest on Securities to the Persons in whose names such Securities (or their respective Predecessor
Securities) are registered in the Security Register at the close of business on a special record date for the payment of such Defaulted
Interest, which shall be fixed in the following manner: the Company shall notify the Trustee in writing of the amount of Defaulted Interest
proposed to be paid on each such Security and the date of the proposed payment, and at the same time the Company shall deposit with the
Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements
satisfactory to the Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in trust
for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special
record date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10 days prior to the date of the
proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly
notify the Company of such special record date and, in the name and at the expense of the Company, shall cause notice of the proposed
payment of such Defaulted Interest and the special record date therefor to be sent, to each Securityholder not less than 10 days prior
to such special record date. Notice of the proposed payment of such Defaulted Interest and the special record date therefor having been
sent as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names such Securities (or their respective Predecessor
Securities) are registered in the Security Register on such special record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(2)</B>&nbsp;The Company
may make payment of any Defaulted Interest on any Securities in any other lawful manner not inconsistent with the requirements of any
securities exchange on which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice
given by the Company to the Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed practicable
by the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise set forth
in a Board Resolution or one or more indentures supplemental hereto establishing the terms of any series of Securities pursuant to Section&nbsp;2.01
hereof, the term &ldquo;regular record date&rdquo; as used in this Section&nbsp;with respect to a series of Securities and any Interest
Payment Date for such series shall mean either the fifteenth day of the month immediately preceding the month in which an Interest Payment
Date established for such series pursuant to Section&nbsp;2.01 hereof shall occur, if such Interest Payment Date is the first day of a
month, or the first day of the month in which an Interest Payment Date established for such series pursuant to Section&nbsp;2.01 hereof
shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the foregoing
provisions of this Section, each Security of a series delivered under this Indenture upon transfer of or in exchange for or in lieu of
any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other
Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.04 Execution and
Authentications.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Securities shall be signed
on behalf of the Company by one of its Officers. Signatures may be in the form of a manual or facsimile signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company may use the facsimile
signature of any Person who shall have been an Officer (at the time of execution), notwithstanding the fact that at the time the Securities
shall be authenticated and delivered or disposed of such Person shall have ceased to be such an officer of the Company. The Securities
may contain such notations, legends or endorsements required by law, stock exchange rule&nbsp;or usage. Each Security shall be dated the
date of its authentication by the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A Security shall not be valid
until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such signature shall be conclusive
evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the
benefits of this Indenture. At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver
Securities of any series executed by the Company to the Trustee for authentication, together with a written order of the Company for the
authentication and delivery of such Securities, signed by an Officer, and the Trustee in accordance with such written order shall authenticate
and deliver such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the Company&rsquo;s
delivery of any such authentication order to the Trustee at any time after the initial issuance of Securities under this Indenture, the
Trustee shall be provided with, and (subject to Sections 315(a)&nbsp;through 315(d)&nbsp;of the Trust Indenture Act) shall be fully protected
in relying upon, (1)&nbsp;an Opinion of Counsel or reliance letter and (2)&nbsp;an Officer&rsquo;s Certificate stating that all conditions
precedent to the execution, authentication and delivery of such Securities are in conformity with the provisions of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Trustee shall not be
required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect the Trustee&rsquo;s own
rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the
Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.05 Registration of
Transfer and Exchange.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;Securities
of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose, for other
Securities of such series of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to
cover any tax or other governmental charge in relation thereto, all as provided in this Section. In respect of any Securities so surrendered
for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the
Security or Securities of the same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not
contemporaneously outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;The Company
shall keep, or cause to be kept, at its office or agency designated for such purpose a register or registers (herein referred to as the
&ldquo;Security Register&rdquo;) in which, subject to such reasonable regulations as it may prescribe, the Company shall register the
Securities and the transfers of Securities as in this Article&nbsp;provided and which at all reasonable times shall be open for inspection
by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein provided shall be appointed
as authorized by Board Resolution or Supplemental Indenture (the &ldquo;Security Registrar&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon surrender for transfer
of any Security at the office or agency of the Company designated for such purpose, the Company shall execute, the Trustee shall authenticate
and such office or agency shall deliver in the name of the transferee or transferees a new Security or Securities of the same series as
the Security presented for a like aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company initially appoints
the Trustee as initial Security Registrar for each series of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All Securities presented
or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so required by the Company
or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company or the Security Registrar,
duly executed by the registered holder or by such holder&rsquo;s duly authorized attorney in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;Except as
provided pursuant to Section&nbsp;2.01 pursuant to a Board Resolution, and set forth in an Officer&rsquo;s Certificate, or established
in one or more indentures supplemental to this Indenture, no service charge shall be made for any exchange or registration of transfer
of Securities, or issue of new Securities in case of partial redemption of any series or repurchase, conversion or exchange of less than
the entire principal amount of a Security, but the Company may require payment of a sum sufficient to cover any tax or other governmental
charge in relation thereto, other than exchanges pursuant to Section&nbsp;2.06, Section&nbsp;3.03(b)&nbsp;and Section&nbsp;9.04 not involving
any transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;The
Company and the Security Registrar shall not be required (i)&nbsp;to issue, exchange or register the transfer of any Securities
during a period beginning at the opening of business 15 days before the day of the sending of a notice of redemption of less than
all the Outstanding Securities of the same series and ending at the close of business on the day of such sending, nor (ii)&nbsp;to
register the transfer of or exchange any Securities of any series or portions thereof called for redemption or surrendered for
repurchase, but not validly withdrawn, other than the unredeemed portion of any such Securities being redeemed in part or not
surrendered for repurchase, as the case may be. The provisions of this Section&nbsp;2.05 are, with respect to any Global Security,
subject to Section&nbsp;2.11 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Trustee shall have no
obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Indenture or
under applicable law with respect to any transfer of any interest in any Security (including any transfers between or among Depositary
participants or beneficial owners of interests in any Global Security) other than to require delivery of such certificates and other documentation
or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine
the same to determine substantial compliance as to form with the express requirements hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.06 Temporary Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pending the preparation of
definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary Securities (printed,
lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in the form of the definitive
Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be appropriate for temporary Securities,
all as may be determined by the Company. Every temporary Security of any series shall be executed by the Company and be authenticated
by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities of such
series. Without unnecessary delay the Company will execute and will furnish definitive Securities of such series and thereupon any or
all temporary Securities of such series may be surrendered in exchange therefor (without charge to the Securityholders), at the office
or agency of the Company designated for the purpose, and the Trustee shall authenticate and such office or agency shall deliver in exchange
for such temporary Securities an equal aggregate principal amount of definitive Securities of such series, unless the Company advises
the Trustee to the effect that definitive Securities need not be executed and furnished until further notice from the Company. Until so
exchanged, the temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive Securities
of such series authenticated and delivered hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.07 Mutilated, Destroyed,
Lost or Stolen Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In case any temporary
or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding sentence)
shall execute, and upon the Company&rsquo;s request the Trustee (subject as aforesaid) shall authenticate and deliver, a new
Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the mutilated
Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a
substituted Security shall furnish to the Company and the Trustee such security or indemnity as may be required by them to save each
of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee
evidence to their satisfaction of the destruction, loss or theft of the applicant&rsquo;s Security and of the ownership thereof. The
Trustee may authenticate any such substituted Security and deliver the same upon the written request or authorization of any officer
of the Company. Upon the issuance of any substituted Security, the Company may require the payment of a sum sufficient to cover any
tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of
the Trustee) connected therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In case any Security that
has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead of issuing a substitute
Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant
for such payment shall furnish to the Company and the Trustee such security or indemnity as they may require to save them harmless, and,
in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of
such Security and of the ownership thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every replacement Security
issued pursuant to the provisions of this Section&nbsp;shall constitute an additional contractual obligation of the Company whether or
not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to
all the benefits of this Indenture equally and proportionately with any and all other Securities of the same series duly issued hereunder.
All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement
or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies,
notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement or payment of negotiable
instruments or other securities without their surrender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.08 Cancellation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All Securities surrendered
for the purpose of payment, redemption, repurchase, exchange, registration of transfer or conversion shall, if surrendered to the Company
or any paying agent (or any other applicable agent), be delivered to the Trustee for cancellation, or, if surrendered to the Trustee,
shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions
of this Indenture. On request of the Company at the time of such surrender, the Trustee shall deliver to the Company canceled Securities
held by the Trustee. In the absence of such request the Trustee may dispose of canceled Securities in accordance with its standard procedures
and deliver a certificate of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition
shall not operate as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered
to the Trustee for cancellation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.09 Benefits of Indenture.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Nothing in this Indenture
or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties hereto and the holders
of the Securities any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant, condition
or provision herein contained; all such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the
holders of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.10 Authenticating
Agent.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">So long as any of the Securities
of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities which the Trustee shall
have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate Securities of
such series issued upon exchange, transfer or partial redemption, repurchase or conversion thereof, and Securities so authenticated shall
be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder.
All references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating
Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital
and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized
or in which it is doing business to conduct a trust business, and that is otherwise authorized under such laws to conduct such business
and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to be
eligible in accordance with these provisions, it shall resign immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any Authenticating Agent
may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time (and upon
request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating
Agent and to the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may appoint
an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of its appointment
hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating
Agent pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.11 Global Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;If the Company
shall establish pursuant to Section&nbsp;2.01 that the Securities of a particular series are to be issued as a Global Security, then the
Company shall execute and the Trustee shall, in accordance with Section&nbsp;2.04, authenticate and deliver, a Global Security that (i)&nbsp;shall
represent, and shall be denominated in an amount equal to the aggregate principal amount of, all of the Outstanding Securities of such
series, (ii)&nbsp;shall be registered in the name of the Depositary or its nominee, (iii)&nbsp;shall be delivered by the Trustee to the
Depositary or pursuant to the Depositary&rsquo;s instruction (or if the Depositary names the Trustee as its custodian, retained by the
Trustee), and (iv)&nbsp;shall bear a legend substantially to the following effect: &ldquo;Except as otherwise provided in Section&nbsp;2.11
of the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor
Depositary or to a nominee of such successor Depositary.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;Notwithstanding
the provisions of Section&nbsp;2.05, the Global Security of a series may be transferred, in whole but not in part and in the manner provided
in Section&nbsp;2.05, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected
or approved by the Company or to a nominee of such successor Depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;If at any
time the Depositary for a series of the Securities notifies the Company that it is unwilling or unable to continue as Depositary for such
series or if at any time the Depositary for such series shall no longer be registered or in good standing under the Exchange Act, or other
applicable statute or regulation, and a successor Depositary for such series is not appointed by the Company within 90 days after the
Company receives such notice or becomes aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing
and the Company has received a request from the Depositary or from the Trustee, this Section&nbsp;2.11 shall no longer be applicable to
the Securities of such series and the Company will execute, and subject to Section&nbsp;2.04, the Trustee will authenticate and deliver
the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate principal
amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In addition, the Company
may at any time determine that the Securities of any series shall no longer be represented by a Global Security and that the provisions
of this Section&nbsp;2.11 shall no longer apply to the Securities of such series. In such event the Company will execute and, subject
to Section&nbsp;2.04, the Trustee, upon receipt of an Officer&rsquo;s Certificate evidencing such determination by the Company, will authenticate
and deliver the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate
principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. Upon the exchange
of the Global Security for such Securities in definitive registered form without coupons, in authorized denominations, the Global Security
shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to
this Section&nbsp;2.11(c)&nbsp;shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions
from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities to the Depositary
for delivery to the Persons in whose names such Securities are so registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;2.12 CUSIP Numbers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company in issuing the
Securities may use &ldquo;CUSIP&rdquo; numbers (if then generally in use), and, if so, the Trustee shall use &ldquo;CUSIP&rdquo; numbers
in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the
correctness of such numbers either as printed on the Securities or as contained in any notice of a redemption and that reliance may be
placed only on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect
in or omission of such numbers. The Company will promptly notify the Trustee of any change in the &ldquo;CUSIP&rdquo; numbers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE&nbsp;3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;3.01 Redemption.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company may redeem the
Securities of any series issued hereunder on and after the dates and in accordance with the terms established for such series pursuant
to Section&nbsp;2.01 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;3.02 Notice of Redemption.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;In case the
Company shall desire to exercise such right to redeem all or, as the case may be, a portion of the Securities of any series in accordance
with any right the Company reserved for itself to do so pursuant to Section&nbsp;2.01 hereof, the Company shall, or shall cause the Trustee
to, give notice of such redemption to holders of the Securities of such series to be redeemed by mailing, first class postage prepaid
(or with regard to any Global Security held in book entry form, by electronic mail in accordance with the applicable procedures of the
Depositary), a notice of such redemption not less than 30 days and not more than 90 days before the date fixed for redemption of that
series to such Securityholders, unless a shorter period is specified in the Securities to be redeemed. Any notice that is mailed in the
manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered holder receives the notice.
In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption in whole or in part,
or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Securities of such series
or any other series. In the case of any redemption of Securities prior to the expiration of any restriction on such redemption provided
in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an Officer&rsquo;s Certificate
evidencing compliance with any such restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each such notice of redemption
shall identify the Securities to be redeemed (including CUSIP numbers, if any), specify the date fixed for redemption and the redemption
price at which Securities of that series are to be redeemed, and shall state that payment of the redemption price of such Securities to
be redeemed will be made at the office or agency of the Company, upon presentation and surrender of such Securities, that interest accrued
to the date fixed for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue
and that the redemption is from a sinking fund, if such is the case. If less than all the Securities of a series are to be redeemed, the
notice to the holders of Securities of that series to be redeemed in part shall specify the particular Securities to be so redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In case any Security is to
be redeemed in part only, the notice that relates to such Security shall state the portion of the principal amount thereof to be redeemed,
and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such series in
principal amount equal to the unredeemed portion thereof will be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;If less than
all the Securities of a series are to be redeemed, the Company shall give the Trustee at least 45 days&rsquo; notice (unless a shorter
notice shall be satisfactory to the Trustee) in advance of the date fixed for redemption as to the aggregate principal amount of Securities
of the series to be redeemed, and thereupon the Securities to be redeemed shall be selected, by lot, on a pro rata basis, or in such other
manner as the Company shall deem appropriate and fair in its discretion and that may provide for the selection of a portion or portions
(equal to one thousand U.S. dollars ($1,000) or any integral multiple thereof) of the principal amount of such Securities of a denomination
larger than $1,000, the Securities to be redeemed and shall thereafter promptly notify the Company in writing of the numbers of the Securities
to be redeemed, in whole or in part. The Company may, if and whenever it shall so elect, by delivery of instructions signed on its behalf
by an Officer, instruct the Trustee or any paying agent to call all or any part of the Securities of a particular series for redemption
and to give notice of redemption in the manner set forth in this Section, such notice to be in the name of the Company or its own name
as the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any
such paying agent, the Company shall deliver or cause to be delivered to, or permit to remain with, the Trustee or such paying agent,
as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts therefrom, sufficient to enable
the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;3.03 Payment Upon Redemption.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;If the giving
of notice of redemption shall have been completed as above provided, the Securities or portions of Securities of the series to be redeemed
specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption
price, together with interest accrued to, but excluding, the date fixed for redemption and interest on such Securities or portions of
Securities shall cease to accrue on and after the date fixed for redemption, unless the Company shall default in the payment of such redemption
price and accrued interest with respect to any such Security or portion thereof. On presentation and surrender of such Securities on or
after the date fixed for redemption at the place of payment specified in the notice, said Securities shall be paid and redeemed at the
applicable redemption price for such series, together with interest accrued thereon to, but excluding, the date fixed for redemption (but
if the date fixed for redemption is an Interest Payment Date, the interest installment payable on such date shall be payable to the registered
holder at the close of business on the applicable record date pursuant to Section&nbsp;2.03).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;Upon presentation
of any Security of such series that is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the
office or agency where the Security is presented shall deliver to the Securityholder thereof, at the expense of the Company, a new Security
of the same series of authorized denominations in principal amount equal to the unredeemed portion of the Security so presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;3.04 Sinking Fund.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The provisions of Sections
3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except as otherwise specified
as contemplated by Section&nbsp;2.01 for Securities of such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The minimum amount of any
sinking fund payment provided for by the terms of Securities of any series is herein referred to as a &ldquo;mandatory sinking fund payment,&rdquo;
and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to as an &ldquo;optional
sinking fund payment&rdquo;. If provided for by the terms of Securities of any series, the cash amount of any sinking fund payment may
be subject to reduction as provided in Section&nbsp;3.05. Each sinking fund payment shall be applied to the redemption of Securities of
any series as provided for by the terms of Securities of such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;3.05 Satisfaction of
Sinking Fund Payments with Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company (i)&nbsp;may
deliver Outstanding Securities of a series and (ii)&nbsp;may apply as a credit Securities of a series that have been redeemed either at
the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking fund payments
pursuant to the terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to
the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of such series,
provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such purpose by
the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and the amount of
such sinking fund payment shall be reduced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;3.06 Redemption of
Securities for Sinking Fund.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not less than 45 days prior
to each sinking fund payment date for any series of Securities (unless a shorter period shall be satisfactory to the Trustee), the Company
will deliver to the Trustee an Officer&rsquo;s Certificate specifying the amount of the next ensuing sinking fund payment for that series
pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering and crediting Securities of that
series pursuant to Section&nbsp;3.05 and the basis for such credit and will, together with such Officer&rsquo;s Certificate, deliver to
the Trustee any Securities to be so delivered. Not less than 30 days before each such sinking fund payment date the Securities to be redeemed
upon such sinking fund payment date shall be selected in the manner specified in Section&nbsp;3.02 and the Company shall cause notice
of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in Section&nbsp;3.02. Such
notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Section&nbsp;3.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;4.01 Payment of Principal,
Premium and Interest.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company will duly
and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that series at the
time and place and in the manner provided herein and established with respect to such Securities. Payments of principal on the
Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check drawn on and
mailed to the address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar
wire transfer to, a U.S. dollar account if such Securityholder shall have furnished wire instructions to the Trustee no later than
15 days prior to the relevant payment date. Payments of interest on the Securities may be made at the time provided herein and
established with respect to such Securities by U.S. dollar check mailed to the address of the Securityholder entitled thereto as
such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account if such Securityholder
shall have furnished wire instructions in writing to the Security Registrar and the Trustee no later than 15 days prior to the
relevant payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;4.02 Maintenance of
Office or Agency.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">So long as any series of
the Securities remain Outstanding, the Company agrees to maintain an office or agency with respect to each such series and at such other
location or locations as may be designated as provided in this Section&nbsp;4.02, where (i)&nbsp;Securities of that series may be presented
for payment, (ii)&nbsp;Securities of that series may be presented as herein above authorized for registration of transfer and exchange,
and (iii)&nbsp;notices and demands to or upon the Company in respect of the Securities of that series and this Indenture may be given
or served, such designation to continue with respect to such office or agency until the Company shall, by written notice signed by any
officer authorized to sign an Officer&rsquo;s Certificate and delivered to the Trustee, designate some other office or agency for such
purposes or any of them. If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish
the Trustee with the address thereof, such presentations, notices and demands may be made or served at the Corporate Trust Office of the
Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, notices and demands. The Company
initially appoints the Corporate Trust Office of the Trustee as its paying agent with respect to the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;4.03 Paying Agents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;If the Company
shall appoint one or more paying agents for all or any series of the Securities, other than the Trustee, the Company will cause each such
paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions
of this Section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(1)</B>&nbsp;that it will
hold all sums held by it as such agent for the payment of the principal of (and premium, if any) or interest on the Securities of that
series (whether such sums have been paid to it by the Company or by any other obligor of such Securities) in trust for the benefit of
the Persons entitled thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(2)</B>&nbsp;that it will
give the Trustee notice of any failure by the Company (or by any other obligor of such Securities) to make any payment of the principal
of (and premium, if any) or interest on the Securities of that series when the same shall be due and payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(3)</B>&nbsp;that it will,
at any time during the continuance of any failure referred to in the preceding paragraph (a)(2)&nbsp;above, upon the written request of
the Trustee, forthwith pay to the Trustee all sums so held in trust by such paying agent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(4)</B>&nbsp;that it will
perform all other duties of paying agent as set forth in this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;If the Company
shall act as its own paying agent with respect to any series of the Securities, it will on or before each due date of the principal of
(and premium, if any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons
entitled thereto a sum sufficient to pay such principal (and premium, if any) or interest so becoming due on Securities of that series
until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such
action, or any failure (by it or any other obligor on such Securities) to take such action. Whenever the Company shall have one or more
paying agents for any series of Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any
Securities of that series, deposit with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming
due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or interest, and (unless such paying
agent is the Trustee) the Company will promptly notify the Trustee of this action or failure so to act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;Notwithstanding
anything in this Section&nbsp;to the contrary, (i)&nbsp;the agreement to hold sums in trust as provided in this Section&nbsp;is subject
to the provisions of Section&nbsp;11.05, and (ii)&nbsp;the Company may at any time, for the purpose of obtaining the satisfaction and
discharge of this Indenture or for any other purpose, pay, or direct any paying agent to pay, to the Trustee all sums held in trust by
the Company or such paying agent, such sums to be held by the Trustee upon the same terms and conditions as those upon which such sums
were held by the Company or such paying agent; and, upon such payment by the Company or any paying agent to the Trustee, the Company or
such paying agent shall be released from all further liability with respect to such money.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;4.04 Appointment to
Fill Vacancy in Office of Trustee.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company, whenever necessary
to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section&nbsp;7.10, a Trustee, so that there
shall at all times be a Trustee hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITYHOLDERS&rsquo; LISTS AND REPORTS BY
THE COMPANY AND THE TRUSTEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;5.01 Company to Furnish
Trustee Names and Addresses of Securityholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company will furnish
or cause to be furnished to the Trustee (a)&nbsp;within 15 days after each regular record date (as defined in Section&nbsp;2.03) a list,
in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such
regular record date, provided that the Company shall not be obligated to furnish or cause to furnish such list at any time that the list
shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b)&nbsp;at such other times as
the Trustee may request in writing within 30 days after the receipt by the Company of any such request, a list of similar form and content
as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no such list need
be furnished for any series for which the Trustee shall be the Security Registrar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;5.02 Preservation Of
Information; Communications With Securityholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The Trustee
shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the holders of Securities
contained in the most recent list furnished to it as provided in Section&nbsp;5.01 and as to the names and addresses of holders of Securities
received by the Trustee in its capacity as Security Registrar (if acting in such capacity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;The Trustee
may destroy any list furnished to it as provided in Section&nbsp;5.01 upon receipt of a new list so furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;Securityholders
may communicate as provided in Section&nbsp;312(b)&nbsp;of the Trust Indenture Act with other Securityholders with respect to their rights
under this Indenture or under the Securities, and, in connection with any such communications, the Trustee shall satisfy its obligations
under Section&nbsp;312(b)&nbsp;of the Trust Indenture Act in accordance with the provisions of Section&nbsp;312(b)&nbsp;of the Trust Indenture
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Section&nbsp;5.03 Reports by the
Company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The Company
will at all times comply with Section&nbsp;314(a)&nbsp;of the Trust Indenture Act. The Company covenants and agrees to provide (which
delivery may be via electronic mail) to the Trustee within 30 days, after the Company files the same with the Commission, copies of the
annual reports and of the information, documents and other reports (or copies of such portions of any of the foregoing as the Commission
may from time to time by rules&nbsp;and regulations prescribe) that the Company is required to file with the Commission pursuant to Section&nbsp;13
or Section&nbsp;15(d)&nbsp;of the Exchange Act; provided, however, the Company shall not be required to deliver to the Trustee any correspondence
filed with the Commission or any materials for which the Company has sought and received confidential treatment by the Commission; and
provided further, that so long as such filings by the Company are available on the Commission&rsquo;s Electronic Data Gathering, Analysis
and Retrieval System (EDGAR), or any successor system, such filings shall be deemed to have been filed with the Trustee for purposes hereof
without any further action required by the Company. For the avoidance of doubt, a failure by the Company to file annual reports, information
and other reports with the Commission within the time period prescribed thereof by the Commission shall not be deemed a breach of this
Section&nbsp;5.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;Delivery
of reports, information and documents to the Trustee under Section&nbsp;5.03 is for informational purposes only and the information
and the Trustee&rsquo;s receipt of the foregoing shall not constitute constructive notice of any information contained therein, or
determinable from information contained therein including the Company&rsquo;s compliance with any of their covenants thereunder (as
to which the Trustee is entitled to rely exclusively on an Officer&rsquo;s Certificate). The Trustee is under no duty to examine any
such reports, information or documents delivered to the Trustee or filed with the Commission via EDGAR to ensure compliance with the
provision of this Indenture or to ascertain the correctness or otherwise of the information or the statements contained therein. The
Trustee shall have no responsibility or duty whatsoever to ascertain or determine whether the above referenced filings with the
Commission on EDGAR (or any successor system) has occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;5.04 Reports
by the Trustee</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;If required
by Section&nbsp;313(a)&nbsp;of the Trust Indenture Act, the Trustee, within sixty (60) days after each May&nbsp;1, shall send to the Securityholders
a brief report dated as of such May&nbsp;1, which complies with Section&nbsp;313(a)&nbsp;of the Trust Indenture Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;The Trustee
shall comply with Section&nbsp;313(b)&nbsp;and 313(c)&nbsp;of the Trust Indenture Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;A copy of
each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the Company, with each securities
exchange upon which any Securities are listed (if so listed) and also with the Commission. The Company agrees to notify the Trustee when
any Securities become listed on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS
ON EVENT OF DEFAULT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;6.01 Events
of Default</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;Whenever used
herein with respect to Securities of a particular series, &ldquo;Event of Default&rdquo; means any one or more of the following events
that has occurred and is continuing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(1)</B>&nbsp;the Company
defaults in the payment of any installment of interest upon any of the Securities of that series, as and when the same shall become due
and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period
by the Company in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of interest
for this purpose;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(2)</B>&nbsp;the Company
defaults in the payment of the principal of (or premium, if any, on) any of the Securities of that series as and when the same shall become
due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous
fund established with respect to that series; provided, however, that a valid extension of the maturity of such Securities in accordance
with the terms of any indenture supplemental hereto shall not constitute a default in the payment of principal or premium, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(3)</B>&nbsp;the Company
fails to observe or perform any other of its covenants or agreements with respect to that series contained in this Indenture or otherwise
established with respect to that series of Securities pursuant to Section&nbsp;2.01 hereof (other than a covenant or agreement that has
been expressly included in this Indenture solely for the benefit of one or more series of Securities other than such series) for a period
of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a
&ldquo;Notice of Default&rdquo; hereunder, shall have been given to the Company by the Trustee, by registered or certified mail, or to
the Company and the Trustee by the holders of at least 25% in principal amount of the Securities of that series at the time Outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(4)</B>&nbsp;the Company
pursuant to or within the meaning of any Bankruptcy Law (i)&nbsp;commences a voluntary case, (ii)&nbsp;consents to the entry of an order
for relief against it in an involuntary case, (iii)&nbsp;consents to the appointment of a Custodian of it or for all or substantially
all of its property or (iv)&nbsp;makes a general assignment for the benefit of its creditors; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(5)</B>&nbsp;a court of competent
jurisdiction enters an order under any Bankruptcy Law that (i)&nbsp;is for relief against the Company in an involuntary case, (ii)&nbsp;appoints
a Custodian of the Company for all or substantially all of its property or (iii)&nbsp;orders the liquidation of the Company, and the order
or decree remains unstayed and in effect for 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;In each and
every such case (other than an Event of Default specified in clause (4)&nbsp;or clause (5)&nbsp;above), unless the principal of all the
Securities of that series shall have already become due and payable, either the Trustee or the holders of not less than 25% in aggregate
principal amount of the Securities of that series then Outstanding hereunder, by notice in writing to the Company (and to the Trustee
if given by such Securityholders), may declare the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities
of that series to be due and payable immediately, and upon any such declaration the same shall become and shall be immediately due and
payable. If an Event of Default specified in clause (4)&nbsp;or clause (5)&nbsp;above occurs, the principal of and accrued and unpaid
interest on all the Securities of that series shall automatically be immediately due and payable without any declaration or other act
on the part of the Trustee or the holders of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;At any time
after the principal of (and premium, if any, on) and accrued and unpaid interest on the Securities of that series shall have been so declared
due and payable, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter
provided, the holders of a majority in aggregate principal amount of the Securities of that series then Outstanding hereunder, by written
notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if: (i)&nbsp;the Company has paid or
deposited with the Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the
principal of (and premium, if any, on) any and all Securities of that series that shall have become due otherwise than by acceleration
(with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon
overdue installments of interest, at the rate per annum expressed in the Securities of that series to the date of such payment or deposit)
and the amount payable to the Trustee under Section&nbsp;7.06, and (ii)&nbsp;any and all Events of Default under the Indenture with respect
to such series, other than the nonpayment of principal on (and premium, if any, on) and accrued and unpaid interest on Securities of that
series that shall not have become due by their terms, shall have been remedied or waived as provided in Section&nbsp;6.06.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No such rescission and annulment
shall extend to or shall affect any subsequent default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;In case the
Trustee shall have proceeded to enforce any right with respect to Securities of that series under this Indenture and such proceedings
shall have been discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined
adversely to the Trustee, then and in every such case, subject to any determination in such proceedings, the Company and the Trustee shall
be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee
shall continue as though no such proceedings had been taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;6.02 Collection
of Indebtedness and Suits for Enforcement by Trustee</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The Company
covenants that (i)&nbsp;in case it shall default in the payment of any installment of interest on any of the Securities of a series, or
in any payment required by any sinking or analogous fund established with respect to that series as and when the same shall have become
due and payable, and such default shall have continued for a period of 90 days, or (ii)&nbsp;in case it shall default in the payment of
the principal of (or premium, if any, on) any of the Securities of a series when the same shall have become due and payable, whether upon
maturity of the Securities of a series or upon redemption or upon declaration or otherwise then, upon demand of the Trustee, the Company
will pay to the Trustee, for the benefit of the holders of the Securities of that series, the whole amount that then shall have been become
due and payable on all such Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon
the overdue principal (and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon
overdue installments of interest at the rate per annum expressed in the Securities of that series; and, in addition thereto, such further
amount as shall be sufficient to cover the costs and expenses of collection, and the amount payable to the Trustee under Section&nbsp;7.06.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;If the Company
shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled
and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute
any such action or proceeding to judgment or final decree, and may enforce any such judgment or final decree against the Company or other
obligor upon the Securities of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity
out of the property of the Company or other obligor upon the Securities of that series, wherever situated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;In case
of any receivership, insolvency, liquidation, bankruptcy, reorganization, readjustment, arrangement, composition or judicial
proceedings affecting the Company, or its creditors or property, the Trustee shall have power to intervene in such proceedings and
take any action therein that may be permitted by the court and shall (except as may be otherwise provided by law) be entitled to
file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the Trustee
and of the holders of Securities of such series allowed for the entire amount due and payable by the Company under the Indenture at
the date of institution of such proceedings and for any additional amount that may become due and payable by the Company after such
date, and to collect and receive any moneys or other property payable or deliverable on any such claim, and to distribute the same
after the deduction of the amount payable to the Trustee under Section&nbsp;7.06; and any receiver, assignee or trustee in
bankruptcy or reorganization is hereby authorized by each of the holders of Securities of such series to make such payments to the
Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Securityholders, to pay to
the Trustee any amount due it under Section&nbsp;7.06.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;All rights
of action and of asserting claims under this Indenture, or under any of the terms established with respect to Securities of that series,
may be enforced by the Trustee without the possession of any of such Securities, or the production thereof at any trial or other proceeding
relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express
trust, and any recovery of judgment shall, after provision for payment to the Trustee of any amounts due under Section&nbsp;7.06, be for
the ratable benefit of the holders of the Securities of such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In case of an Event of Default
hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate
judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either at law or in equity or
in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in the Indenture or in aid of
the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture
or by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Nothing contained herein
shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder any plan of reorganization,
arrangement, adjustment or composition affecting the Securities of that series or the rights of any Securityholder thereof or to authorize
the Trustee to vote in respect of the claim of any Securityholder in any such proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;6.03 Application
of Moneys Collected</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any moneys collected by the
Trustee pursuant to this Article&nbsp;with respect to a particular series of Securities shall be applied in the following order, at the
date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal (or premium, if any) or interest,
upon presentation of the Securities of that series, and notation thereon of the payment, if only partially paid, and upon surrender thereof
if fully paid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">FIRST: To the payment of
costs and expenses of collection and of all amounts payable to the Trustee under Section&nbsp;7.06;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">SECOND: To the payment of
the amounts then due and unpaid upon Securities of such series for principal (and premium, if any) and interest, in respect of which or
for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts
due and payable on such Securities for principal (and premium, if any) and interest, respectively; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">THIRD: To the payment of
the remainder, if any, to the Company or any other Person lawfully entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;6.04 Limitation
on Suits</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No holder of any Security
of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any suit, action or proceeding
in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or trustee, or for any other
remedy hereunder, unless (i)&nbsp;such Securityholder previously shall have given to the Trustee written notice of an Event of Default
and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided;
(ii)&nbsp;the holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall have
made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; (iii)&nbsp;such
Securityholder or Securityholders shall have offered to the Trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred in compliance with such request; (iv)&nbsp;the Trustee for 90 days after its receipt of such notice, request and offer
of indemnity, shall have failed to institute any such action, suit or proceeding and (v)&nbsp;during such 90 day period, the holders of
a majority in principal amount of the Securities of that series do not give the Trustee a direction inconsistent with the request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notwithstanding anything
contained herein to the contrary or any other provisions of this Indenture, the right of any holder of any Security to receive payment
of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due dates expressed
in such Security (or in the case of redemption, on the redemption date), or to institute suit for the enforcement of any such payment
on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such holder and by accepting
a Security hereunder it is expressly understood, intended and covenanted by the taker and holder of every Security of such series with
every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall have any right in any
manner whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of the holders
of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder, or to enforce any
right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all holders of Securities
of such series. For the protection and enforcement of the provisions of this Section, each and every Securityholder and the Trustee shall
be entitled to such relief as can be given either at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;6.05 Rights
and Remedies Cumulative; Delay or Omission Not Waiver</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;Except as
otherwise provided in Section&nbsp;2.07, all powers and remedies given by this Article&nbsp;to the Trustee or to the Securityholders shall,
to the extent permitted by law, be deemed cumulative and not exclusive of any other powers and remedies available to the Trustee or the
holders of the Securities, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements
contained in this Indenture or otherwise established with respect to such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;No delay or
omission of the Trustee or of any holder of any of the Securities to exercise any right or power accruing upon any Event of Default occurring
and continuing as aforesaid shall impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence
therein; and, subject to the provisions of Section&nbsp;6.04, every power and remedy given by this Article&nbsp;or by law to the Trustee
or the Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;6.06 Control
by Securityholders</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The holders of a majority
in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance with Section&nbsp;8.04,
shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising
any trust or power conferred on the Trustee with respect to such series; provided, however, that such direction shall not be in conflict
with any rule&nbsp;of law or with this Indenture or subject the Trustee in its sole discretion to personal liability. Subject to the provisions
of Section&nbsp;7.01, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by
a Responsible Officer or officers of the Trustee, determine that the proceeding so directed, subject to the Trustee&rsquo;s duties under
the Trust Indenture Act, would involve the Trustee in personal liability or might be unduly prejudicial to the Securityholders not involved
in the proceeding. The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding affected
thereby, determined in accordance with Section&nbsp;8.04, may on behalf of the holders of all of the Securities of such series waive any
past default in the performance of any of the covenants contained herein or established pursuant to Section&nbsp;2.01 with respect to
such series and its consequences, except a default in the payment of the principal of, or premium, if any, or interest on, any of the
Securities of that series as and when the same shall become due by the terms of such Securities otherwise than by acceleration (unless
such default has been cured and a sum sufficient to pay all matured installments of interest and principal and any premium has been deposited
with the Trustee (in accordance with Section&nbsp;6.01(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured
for all purposes of this Indenture and the Company, the Trustee and the holders of the Securities of such series shall be restored to
their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or impair
any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;6.07 Undertaking
to Pay Costs</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All parties to this Indenture
agree, and each holder of any Securities by such holder&rsquo;s acceptance thereof shall be deemed to have agreed, that any court may
in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee
for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of
such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys&rsquo; fees and expenses,
against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party
litigant; but the provisions of this Section&nbsp;shall not apply to any suit instituted by the Trustee, to any suit instituted by any
Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any
series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or
interest on any Security of such series, on or after the respective due dates expressed in such Security or established pursuant to this
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONCERNING THE TRUSTEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.01 Certain
Duties and Responsibilities of Trustee</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The Trustee,
prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing of all Events of Default
with respect to the Securities of that series that may have occurred, shall undertake to perform with respect to the Securities of such
series such duties and only such duties as are specifically set forth in this Indenture, and no implied covenants shall be read into this
Indenture against the Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been
cured or waived), the Trustee shall exercise with respect to Securities of that series such of the rights and powers vested in it by this
Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances
in the conduct of his or her own affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;No provision
of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to
act, or its own willful misconduct, except that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(i)</B>&nbsp;prior to the
occurrence of an Event of Default with respect to the Securities of a series and after the curing or waiving of all such Events of Default
with respect to that series that may have occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(A)</B>&nbsp;the duties and
obligations of the Trustee shall with respect to the Securities of such series be determined solely by the express provisions of this
Indenture, and the Trustee shall not be liable with respect to the Securities of such series except for the performance of such duties
and obligations as are specifically set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture
against the Trustee; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(B)</B>&nbsp;in the absence
of bad faith on the part of the Trustee, the Trustee may with respect to the Securities of such series conclusively rely, as to the truth
of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and
conforming to the requirements of this Indenture; but in the case of any such certificates or opinions that by any provision hereof are
specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not
they conform to the requirements of this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)</B>&nbsp;the Trustee
shall not be liable to any Securityholder or to any other Person for any error of judgment made in good faith by a Responsible Officer
or Responsible Officers of the Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)</B>&nbsp;the Trustee
shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the
holders of not less than a majority in principal amount of the Securities of any series at the time Outstanding relating to the time,
method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon
the Trustee under this Indenture with respect to the Securities of that series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)</B>&nbsp;none of the
provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial
liability in the performance of any of its duties or in the exercise of any of its rights or powers if there is reasonable ground for
believing that the repayment of such funds or liability is not reasonably assured to it under the terms of this Indenture or adequate
indemnity against such risk is not reasonably assured to it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(v)</B>&nbsp;The Trustee
shall not be required to give any bond or surety in respect of the performance of its powers or duties hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(vi)</B>&nbsp;The permissive
right of the Trustee to do things enumerated in this Indenture shall not be construed as a duty of the Trustee; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(vii)</B>&nbsp;No Trustee
shall have any duty or responsibility for any act or omission of any other Trustee appointed with respect to a series of Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.02 Certain
Rights of Trustee</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as otherwise provided
in Section&nbsp;7.01:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The Trustee
may conclusively rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument,
opinion, report, notice, request, consent, order, approval, bond, security or other paper or document believed by it to be genuine and
to have been signed or presented by the proper party or parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;Any request,
direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed
in the name of the Company by any authorized Officer of the Company (unless other evidence in respect thereof is specifically prescribed
herein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;The Trustee
may consult with counsel and the opinion or written advice of such counsel or, if requested, any Opinion of Counsel shall be full and
complete authorization and protection in respect of any action taken or suffered or omitted hereunder in good faith and in reliance thereon;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;The Trustee
shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order or direction
of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee
security or indemnity reasonably acceptable to the Trustee against the costs, expenses and liabilities that may be incurred therein or
thereby; nothing contained herein shall, however, relieve the Trustee of the obligation, upon the occurrence of an Event of Default with
respect to a series of the Securities (that has not been cured or waived), to exercise with respect to Securities of that series such
of the rights and powers vested in it by this Indenture, and to use the same degree of care and skill in their exercise, as a prudent
man would exercise or use under the circumstances in the conduct of his or her own affairs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)</B>&nbsp;The Trustee
shall not be liable for any action taken or omitted to be taken by it in good faith and believed by it to be authorized or within the
discretion or rights or powers conferred upon it by this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(f)</B>&nbsp;The Trustee
shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion,
report, notice, request, consent, order, approval, bond, security, or other papers or documents or inquire as to the performance by the
Company of one of its covenants under this Indenture, unless requested in writing so to do by the holders of not less than a majority
in principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section&nbsp;8.04);
provided, however, that if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred
by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded
to it by the terms of this Indenture, the Trustee may require security or indemnity reasonably acceptable to the Trustee against such
costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination shall be paid by the
Company or, if paid by the Trustee, shall be repaid by the Company upon demand;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(g)</B>&nbsp;The Trustee
may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents or attorneys
and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care
by it hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(h)</B>&nbsp;In no event
shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or
caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts
of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions
of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts
which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(i)</B>&nbsp;In no event
shall the Trustee be responsible or liable for special, indirect, punitive or consequential loss or damage of any kind whatsoever (including,
but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and
regardless of the form of action; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(j)</B>&nbsp;The Trustee
agrees to accept and act upon instructions or directions pursuant to this Indenture sent by unsecured e-mail, facsimile transmission or
other similar unsecured electronic methods; provided, however, that such instructions or directions shall be signed by an authorized representative
of the party providing such instructions or directions. If the party elects to give the Trustee e-mail or facsimile instructions (or instructions
by a similar electronic method) and the Trustee in its discretion elects to act upon such instructions, the Trustee&rsquo;s understanding
of such instructions shall be deemed controlling. The Trustee shall not be liable for any losses, costs or expenses arising directly or
indirectly from the Trustee&rsquo;s reliance upon and compliance with such instructions notwithstanding such instructions conflict or
are inconsistent with a subsequent written instruction. The party providing electronic instructions agrees to assume all risks arising
out of the use of such electronic methods to submit instructions and directions to the Trustee, including without limitation the risk
of the Trustee acting on unauthorized instructions, and the risk or interception and misuse by third parties. The Trustee may request
that the Company deliver an Officer&rsquo;s Certificate setting forth the names of individuals and/or titles of officers authorized at
such time to furnish the Trustee with Officer&rsquo;s Certificates, Company Orders and any other matters or directions pursuant to this
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(k)</B>&nbsp;The rights,
privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to be indemnified, are
extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder and under the Securities, and each agent, custodian
or other person employed to act under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(l)</B>&nbsp;The Trustee
shall not be deemed to have knowledge of any Default or Event of Default (other than an Event of Default constituting the failure to pay
the interest on, or the principal of, the Securities if the Trustee also serves the paying agent for such Securities) until the Trustee
shall have received written notification in the manner set forth in this Indenture or a Responsible Officer of the Trustee shall have
obtained actual knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.03 Trustee
Not Responsible for Recitals or Issuance or Securities</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The recitals
contained herein and in the Securities shall be taken as the statements of the Company, and the Trustee assumes no responsibility for
the correctness of the same. The Trustee shall not be responsible for any statement in any registration statement, prospectus, or any
other document in connection with the sale of Securities. The Trustee shall not be responsible for any rating on the Securities or any
action or omission of any rating agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;The Trustee
makes no representations as to the validity or sufficiency of this Indenture or of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;The Trustee
shall not be accountable for the use or application by the Company of any of the Securities or of the proceeds of such Securities, or
for the use or application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant
to Section&nbsp;2.01, or for the use or application of any moneys received by any paying agent other than the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.04 May&nbsp;Hold
Securities</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Trustee or any paying
agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights
it would have if it were not Trustee, paying agent or Security Registrar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.05 Moneys
Held in Trust</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of Section&nbsp;11.05, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes
for which they were received, but need not be segregated from other funds except to the extent required by law. The Trustee shall be under
no liability for interest on any moneys received by it hereunder except such as it may agree with the Company to pay thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.06 Compensation
and Reimbursement</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The Company
shall pay to the Trustee for each of its capacities hereunder from time to time compensation for its services as the Company and the Trustee
shall from time to time agree upon in writing. The Trustee&rsquo;s compensation shall not be limited by any law on compensation of a trustee
of an express trust. The Company shall reimburse the Trustee upon request for all reasonable out-of-pocket expenses incurred by it. Such
expenses shall include the reasonable compensation and expenses of the Trustee&rsquo;s agents and counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;The Company
shall indemnify each of the Trustee in each of its capacities hereunder against any loss, liability or expense (including the cost of
defending itself and including the reasonable compensation and expenses of the Trustee&rsquo;s agents and counsel) incurred by it except
as set forth in Section&nbsp;7.06(c)&nbsp;in the exercise or performance of its powers, rights or duties under this Indenture as Trustee
or Agent. The Trustee shall notify the Company promptly of any claim for which it may seek indemnity. The Company shall defend the claim
and the Trustee shall cooperate in the defense. The Trustee may have one separate counsel and the Company shall pay the reasonable fees
and expenses of such counsel. The Company need not pay for any settlement made without its consent, which consent shall not be unreasonably
withheld. This indemnification shall apply to officers, directors, employees, shareholders and agents of the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;The Company
need not reimburse any expense or indemnify against any loss or liability incurred by the Trustee or by any officer, director, employee,
shareholder or agent of the Trustee through negligence or bad faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;To ensure
the Company&rsquo;s payment obligations in this Section, the Trustee shall have a lien prior to the Securities on all funds or property
held or collected by the Trustee, except that held in trust to pay principal of or interest on particular Securities. When the Trustee
incurs expenses or renders services in connection with an Event of Default specified in Section&nbsp;6.01(4)&nbsp;or (5), the expenses
(including the reasonable fees and expenses of its counsel) and the compensation for services in connection therewith are to constitute
expenses of administration under any bankruptcy law. The provisions of this Section&nbsp;7.06 shall survive the termination of this Indenture
and the resignation or removal of the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.07 Reliance
on Officer&rsquo;s Certificate</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as otherwise provided
in Section&nbsp;7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it reasonably necessary
or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder, such matter
(unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part
of the Trustee, be deemed to be conclusively proved and established by an Officer&rsquo;s Certificate delivered to the Trustee and such
certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action
taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.08 Disqualification;
Conflicting Interests</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Trustee has or shall
acquire any &ldquo;conflicting interest&rdquo; within the meaning of Section&nbsp;310(b)&nbsp;of the Trust Indenture Act, the Trustee
and the Company shall in all respects comply with the provisions of Section&nbsp;310(b)&nbsp;of the Trust Indenture Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.09 Corporate
Trustee Required; Eligibility</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There shall at all times
be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and doing business under
the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a corporation or other Person
permitted to act as trustee by the Commission, authorized under such laws to exercise corporate trust powers, having a combined capital
and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision or examination by federal, state, territorial,
or District of Columbia authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If such corporation or other
Person publishes reports of condition at least annually, pursuant to law or to the requirements of the aforesaid supervising or examining
authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other Person shall be deemed
to be its combined capital and surplus as set forth in its most recent report of condition so published. The Company may not, nor may
any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee. In case at any
time the Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign immediately in
the manner and with the effect specified in Section&nbsp;7.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.10 Resignation
and Removal; Appointment of Successor</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The Trustee
or any successor hereafter appointed may at any time resign with respect to the Securities of one or more series by giving written notice
thereof to the Company and the Securityholders of such series. Upon receiving such notice of resignation, the Company shall promptly appoint
a successor trustee with respect to Securities of such series by written instrument, in duplicate, executed by order of the Board of Directors,
one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee
shall have been so appointed and have accepted appointment within 30 days after the sending of such notice of resignation, the resigning
Trustee may petition any court of competent jurisdiction for the appointment of a successor trustee with respect to Securities of such
series, or any Securityholder of that series who has been a bona fide holder of a Security or Securities for at least six months may on
behalf of himself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may
thereupon after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;In case at
any time any one of the following shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)</B>&nbsp;the Trustee
shall fail to comply with the provisions of Section&nbsp;7.08 after written request therefor by the Company or by any Securityholder who
has been a bona fide holder of a Security or Securities for at least six months; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)</B>&nbsp;the Trustee
shall cease to be eligible in accordance with the provisions of Section&nbsp;7.09 and shall fail to resign after written request therefor
by the Company or by any such Securityholder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)</B>&nbsp;the Trustee
shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver
of the Trustee or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee
or of its property or affairs for the purpose of rehabilitation, conservation or liquidation; then, in any such case, the Company may
remove the Trustee with respect to all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order
of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee,
or any Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder
and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of
a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint
a successor trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;The holders
of a majority in aggregate principal amount of the Securities of any series at the time Outstanding may at any time remove the Trustee
with respect to such series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;Any resignation
or removal of the Trustee and appointment of a successor trustee with respect to the Securities of a series pursuant to any of the provisions
of this Section&nbsp;shall become effective upon acceptance of appointment by the successor trustee as provided in Section&nbsp;7.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)</B>&nbsp;Any successor
trustee appointed pursuant to this Section&nbsp;may be appointed with respect to the Securities of one or more series or all of such series,
and at any time there shall be only one Trustee with respect to the Securities of any particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.11 Acceptance
of Appointment By Successor</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;In case of
the appointment hereunder of a successor trustee with respect to all Securities, every such successor trustee so appointed shall execute,
acknowledge and deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation
or removal of the retiring Trustee shall become effective and such successor trustee, without any further act, deed or conveyance, shall
become vested with all the rights, powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor
trustee, such retiring Trustee shall, upon payment of any amounts due to it pursuant to the provisions of Section&nbsp;7.06, execute and
deliver an instrument transferring to such successor trustee all the rights, powers, and trusts of the retiring Trustee and shall duly
assign, transfer and deliver to such successor trustee all property and money held by such retiring Trustee hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;In case of
the appointment hereunder of a successor trustee with respect to the Securities of one or more (but not all) series, the Company, the
retiring Trustee and each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture
supplemental hereto wherein each successor trustee shall accept such appointment and which (i)&nbsp;shall contain such provisions as shall
be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties
of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee relates,
(ii)&nbsp;shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties
of the retiring Trustee with respect to the Securities of that or those series as to which the retiring Trustee is not retiring shall
continue to be vested in the retiring Trustee, and (iii)&nbsp;shall add to or change any of the provisions of this Indenture as shall
be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that
nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of the same trust, that each such Trustee
shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee
and that no Trustee shall be responsible for any act or failure to act on the part of any other Trustee hereunder; and upon the execution
and delivery of such supplemental indenture the resignation or removal of the retiring Trustee shall become effective to the extent provided
therein, such retiring Trustee shall with respect to the Securities of that or those series to which the appointment of such successor
trustee relates have no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations
vested in the Trustee under this Indenture, and each such successor trustee, without any further act, deed or conveyance, shall become
vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to
which the appointment of such successor trustee relates; but, on request of the Company or any successor trustee, such retiring Trustee
shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by such supplemental indenture, the property
and money held by such retiring Trustee hereunder with respect to the Securities of that or those series to which the appointment of such
successor trustee relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;Upon request
of any such successor trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and confirming
to such successor trustee all such rights, powers and trusts referred to in paragraph (a)&nbsp;or (b)&nbsp;of this Section, as the case
may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;No successor
trustee shall accept its appointment unless at the time of such acceptance such successor trustee shall be qualified and eligible under
this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)</B>&nbsp;Upon acceptance
of appointment by a successor trustee as provided in this Section, the Company shall send notice of the succession of such trustee hereunder
to the Securityholders. If the Company fails to transmit such notice within ten days after acceptance of appointment by the successor
trustee, the successor trustee shall cause such notice to be transmitted at the expense of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.12 Merger,
Conversion, Consolidation or Succession to Business</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any corporation into which
the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion
or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially all the corporate trust
business of the Trustee, including the administration of the trust created by this Indenture, shall be the successor of the Trustee hereunder,
provided that such corporation shall be qualified under the provisions of Section&nbsp;7.08 and eligible under the provisions of Section&nbsp;7.09,
without the execution or filing of any paper or any further act on the part of any of the parties hereto, anything herein to the contrary
notwithstanding. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor
by merger, conversion or consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated
with the same effect as if such successor Trustee had itself authenticated such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.13 Preferential
Collection of Claims Against the Company</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Trustee shall comply
with Section&nbsp;311(a)&nbsp;of the Trust Indenture Act, excluding any creditor relationship described in Section&nbsp;311(b)&nbsp;of
the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section&nbsp;311(a)&nbsp;of the Trust Indenture
Act to the extent included therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;7.14 Notice
of Default</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any Event of Default occurs
and is continuing and if such Event of Default is known to a Responsible Officer of the Trustee, the Trustee shall send to each Securityholder
in the manner and to the extent provided in Section&nbsp;313(c)&nbsp;of the Trust Indenture Act notice of the Event of Default within
the earlier of 90 days after it occurs and 30 days after it is known to a Responsible Officer of the Trustee or written notice of it is
received by the Trustee, unless such Event of Default has been cured; <I>provided, however</I>, that, except in the case of a default
in the payment of the principal of (or premium, if any) or interest on any Security, the Trustee shall be protected in withholding such
notice if and so long as the Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the
interest of the Securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONCERNING THE SECURITYHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;8.01 Evidence
of Action by Securityholders</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Whenever in this Indenture
it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities of a particular
series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of
any other action), the fact that at the time of taking any such action the holders of such majority or specified percentage of that series
have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities
of that series in person or by agent or proxy appointed in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Company shall solicit
from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver or other action, the Company
may, at its option, as evidenced by an Officer&rsquo;s Certificate, fix in advance a record date for such series for the determination
of Securityholders entitled to give such request, demand, authorization, direction, notice, consent, waiver or other action, but the Company
shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver
or other action may be given before or after the record date, but only the Securityholders of record at the close of business on the record
date shall be deemed to be Securityholders for the purposes of determining whether Securityholders of the requisite proportion of Outstanding
Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver
or other action, and for that purpose the Outstanding Securities of that series shall be computed as of the record date; provided, however,
that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall
become effective pursuant to the provisions of this Indenture not later than six months after the record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;8.02 Proof
of Execution by Securityholders</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of Section&nbsp;7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization) or his or
her agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;The fact and
date of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;The ownership
of Securities shall be proved by the Security Register of such Securities or by a certificate of the Security Registrar thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Trustee may require such additional proof
of any matter referred to in this Section&nbsp;as it shall deem necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;8.03 Who
May&nbsp;be Deemed Owners</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the due presentment
for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar may deem and treat
the Person in whose name such Security shall be registered upon the books of the Security Registrar as the absolute owner of such Security
(whether or not such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone other than
the Security Registrar) for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to Section&nbsp;2.03)
interest on such Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor any Security Registrar
shall be affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;8.04 Certain
Securities Owned by Company Disregarded</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In determining whether the
holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any direction, consent or waiver
under this Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series
or by any Person directly or indirectly controlling or controlled by or under common control with the Company or any other obligor on
the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except
that for the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent or waiver, only Securities
of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been pledged in
good faith may be regarded as Outstanding for the purposes of this Section, if the pledgee shall establish to the satisfaction of the
Trustee the pledgee&rsquo;s right so to act with respect to such Securities and that the pledgee is not a Person directly or indirectly
controlling or controlled by or under direct or indirect common control with the Company or any such other obligor. In case of a dispute
as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;8.05 Actions
Binding on Future Securityholders</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At any time prior to (but
not after) the evidencing to the Trustee, as provided in Section&nbsp;8.01, of the taking of any action by the holders of the majority
or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such
action, any holder of a Security of that series that is shown by the evidence to be included in the Securities the holders of which have
consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section&nbsp;8.02, revoke
such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall be conclusive
and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange therefor,
on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made upon such
Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular
series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the
holders of all the Securities of that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUPPLEMENTAL INDENTURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;9.01 Supplemental
Indentures Without the Consent of Securityholders</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to any supplemental
indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and at any time enter into an indenture
or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent
of the Securityholders, for one or more of the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;to cure any
ambiguity, defect, or inconsistency herein or in the Securities of any series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;to comply
with Article&nbsp;Ten;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;to provide
for uncertificated Securities in addition to or in place of certificated Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)</B>&nbsp;to add to
the covenants, restrictions, conditions or provisions relating to the Company for the benefit of the holders of all or any series of Securities
(and if such covenants, restrictions, conditions or provisions are to be for the benefit of less than all series of Securities, stating
that such covenants, restrictions, conditions or provisions are expressly being included solely for the benefit of such series), to make
the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions
an Event of Default, or to surrender any right or power herein conferred upon the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)</B>&nbsp;to add to,
delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication,
and delivery of Securities, as herein set forth;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(f)</B>&nbsp;to make any
change that does not adversely affect the rights of any Securityholder in any material respect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(g)</B>&nbsp;to provide
for the issuance of and establish the form and terms and conditions of the Securities of any series as provided in Section&nbsp;2.01,
to establish the form of any certifications required to be furnished pursuant to the terms of this Indenture or any series of Securities,
or to add to the rights of the holders of any series of Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(h)</B>&nbsp;to evidence
and provide for the acceptance of appointment hereunder by a successor trustee; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(i)</B>&nbsp;to comply
with any requirements of the Commission or any successor in connection with the qualification of this Indenture under the Trust Indenture
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Trustee is hereby authorized
to join with the Company in the execution of any such supplemental indenture, and to make any further appropriate agreements and stipulations
that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee&rsquo;s
own rights, duties or immunities under this Indenture or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any supplemental indenture
authorized by the provisions of this Section&nbsp;may be executed by the Company and the Trustee without the consent of the holders of
any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section&nbsp;9.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;9.02 Supplemental
Indentures With Consent of Securityholders</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With the consent (evidenced
as provided in Section&nbsp;8.01) of the holders of not less than a majority in aggregate principal amount of the Securities of each series
affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board Resolution, and
the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the
provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating
any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered by Section&nbsp;9.01
the rights of the holders of the Securities of such series under this Indenture; provided, however, that no such supplemental indenture
shall, without the consent of the holders of each Security then Outstanding and affected thereby, (a)&nbsp;extend the fixed maturity of
any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon,
or reduce any premium payable upon the redemption thereof or (b)&nbsp;reduce the aforesaid percentage of Securities, the holders of which
are required to consent to any such supplemental indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">It shall not be necessary
for the consent of the Securityholders of any series affected thereby under this Section&nbsp;to approve the particular form of any proposed
supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;9.03 Effect
of Supplemental Indentures</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the execution of any
supplemental indenture pursuant to the provisions of this Article&nbsp;or of Section&nbsp;10.01, this Indenture shall, with respect to
such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations,
duties and immunities under this Indenture of the Trustee, the Company and the holders of Securities of the series affected thereby shall
thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms
and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for
any and all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;9.04 Securities
Affected by Supplemental Indentures</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Securities of any series
affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant to the provisions
of this Article&nbsp;or of Section&nbsp;10.01, may bear a notation in form approved by the Company, provided such form meets the requirements
of any securities exchange upon which such series may be listed, as to any matter provided for in such supplemental indenture. If the
Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of Directors, to any
modification of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated by the Trustee
and delivered in exchange for the Securities of that series then Outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;9.05 Execution
of Supplemental Indentures</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the request of the Company,
accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon the filing with the Trustee
of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the
execution of such supplemental indenture unless such supplemental indenture affects the Trustee&rsquo;s own rights, duties or immunities
under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be obligated to enter into such supplemental
indenture. The Trustee, subject to the provisions of Section&nbsp;7.01, shall receive an Officer&rsquo;s Certificate or an Opinion of
Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article&nbsp;is authorized or permitted by the
terms of this Article&nbsp;and that all conditions precedent to the execution of the supplemental indenture have been complied with; provided,
however, that such Officer&rsquo;s Certificate or Opinion of Counsel need not be provided in connection with the execution of a supplemental
indenture that establishes the terms of a series of Securities pursuant to Section&nbsp;2.01 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Promptly after the execution
by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Company shall (or shall direct
the Trustee to) send a notice, setting forth in general terms the substance of such supplemental indenture, to the Securityholders of
all series affected thereby .as their names and addresses appear upon the Security Register. Any failure of the Company to send, or cause
the sending of, such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental
indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUCCESSOR ENTITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;10.01 Company
May&nbsp;Consolidate, Etc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Nothing contained in
this Indenture shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated
with the Company) or successive consolidations or mergers in which the Company or its successor or successors shall be a party or
parties, or shall prevent any sale, conveyance, transfer or other disposition of the property of the Company or its successor or
successors as an entirety, or substantially as an entirety, to any other Person (whether or not affiliated with the Company or its
successor or successors); provided, however, the Company hereby covenants and agrees that, upon any such consolidation or merger (in
each case, if the Company is not the survivor of such transaction) or any such sale, conveyance, transfer or other disposition
(other than a sale, conveyance, transfer or other disposition to a Subsidiary of the Company), the due and punctual payment of the
principal of (premium, if any) and interest on all of the Securities of all series in accordance with the terms of each series,
according to their tenor, and the due and punctual performance and observance of all the covenants and conditions of this Indenture
with respect to each series or established with respect to such series pursuant to Section&nbsp;2.01 to be kept or performed by the
Company shall be expressly assumed, by supplemental indenture (which shall conform to the provisions of the Trust Indenture Act, as
then in effect) reasonably satisfactory in form to the Trustee executed and delivered to the Trustee by the entity formed by such
consolidation, or into which the Company shall have been merged, or by the entity which shall have acquired such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;10.02 Successor
Entity Substituted</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;In case of
any such consolidation, merger, sale, conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental
indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section&nbsp;10.01
on all of the Securities of all series Outstanding, such successor entity shall succeed to and be substituted for the Company with the
same effect as if it had been named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations
and covenants under this Indenture and the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;In case of
any such consolidation, merger, sale, conveyance, transfer or other disposition, such changes in phraseology and form (but not in substance)
may be made in the Securities thereafter to be issued as may be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)</B>&nbsp;Nothing contained
in this Article&nbsp;shall require any action by the Company in the case of a consolidation or merger of any Person into the Company where
the Company is the survivor of such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the
property of any other Person (whether or not affiliated with the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SATISFACTION AND DISCHARGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;11.01 Satisfaction
and Discharge of Indenture</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If at any time: (a)&nbsp;the
Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated and not delivered to
the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that shall have been replaced
or paid as provided in Section&nbsp;2.07 and Securities for whose payment money or Governmental Obligations have theretofore been deposited
in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged from such trust, as provided
in Section&nbsp;11.05); or (b)&nbsp;all such Securities of a particular series not theretofore delivered to the Trustee for cancellation
shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption
within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company shall deposit or
cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination thereof,
sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof
delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the Trustee
for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for
redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder with respect to
such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except for the
provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03, 7.10, 11.5 and 13.04, that shall survive until the date of maturity or redemption
date, as the case may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of the
Company and at the cost and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging this
Indenture with respect to such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;11.02 Discharge
of Obligations</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If at any time all such Securities
of a particular series not heretofore delivered to the Trustee for cancellation or that have not become due and payable as described in
Section&nbsp;11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of
Governmental Obligations sufficient to pay at maturity or upon redemption all such Securities of that series not theretofore delivered
to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity
or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder
by the Company with respect to such series, then after the date such moneys or Governmental Obligations, as the case may be, are deposited
with the Trustee the obligations of the Company under this Indenture with respect to such series shall cease to be of further effect except
for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10, 11.05 and 13.04 hereof that shall survive until such Securities
shall mature and be paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Thereafter, Sections 7.06
and 11.05 shall survive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;11.03 Deposited
Moneys to be Held in Trust</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All moneys or Governmental
Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be available for payment as
due, either directly or through any paying agent (including the Company acting as its own paying agent), to the holders of the particular
series of Securities for the payment or redemption of which such moneys or Governmental Obligations have been deposited with the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;11.04 Payment
of Moneys Held by Paying Agents</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the satisfaction
and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent under the provisions of this Indenture
shall, upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall be released from all further liability
with respect to such moneys or Governmental Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;11.05 Repayment
to Company</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any moneys or Governmental
Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of principal of or premium,
if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by the holders of such Securities
for at least two years after the date upon which the principal of (and premium, if any) or interest on such Securities shall have respectively
become due and payable, or such other shorter period set forth in applicable escheat or abandoned or unclaimed property law, shall be
repaid to the Company on May&nbsp;31 of each year or upon the Company&rsquo;s request or (if then held by the Company) shall be discharged
from such trust; and thereupon the paying agent and the Trustee shall be released from all further liability with respect to such moneys
or Governmental Obligations, and the holder of any of the Securities entitled to receive such payment shall thereafter, as a general creditor,
look only to the Company for the payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS
AND DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;12.01 No
Recourse</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No recourse under or upon
any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or otherwise in respect thereof,
shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor
or successor corporation, either directly or through the Company or any such predecessor or successor corporation, whether by virtue of
any constitution, statute or rule&nbsp;of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood
that this Indenture and the obligations issued hereunder are solely corporate obligations, and that no such personal liability whatever
shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors as such, of the Company or of any
predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby authorized, or under or by reason
of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom; and that any
and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any
and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of
the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in
any of the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the
execution of this Indenture and the issuance of such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.01 Effect
on Successors and Assigns</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All the covenants, stipulations,
promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors and assigns, whether so expressed
or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.02 Actions
by Successor</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any act or proceeding by
any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of the Company shall
and may be done and performed with like force and effect by the corresponding board, committee or officer of any corporation that shall
at the time be the lawful successor of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.03 Surrender
of Company Powers</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company by instrument
in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the powers reserved to the
Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.04 Notices</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as otherwise expressly
provided herein, any notice, request or demand that by any provision of this Indenture is required or permitted to be given, made or served
by the Trustee, the Security Registrar, any paying or other agent under this Indenture or by the holders of Securities or by any other
Person pursuant to this Indenture to or on the Company may be given or served by being deposited in first class mail, postage prepaid,
addressed (until another address is filed in writing by the Company with the Trustee), as follows: . Any notice, election, request or
demand by the Company or any Securityholder or by any other Person pursuant to this Indenture to or upon the Trustee shall be deemed to
have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.05 Governing
Law; Jury Trial Waiver</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Indenture and each Security
shall be governed by, and construed in accordance with, the internal laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">EACH PARTY HERETO, AND EACH
HOLDER OF A SECURITY BY ACCEPTANCE THEREOF, HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY&nbsp;HAVE
TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS INDENTURE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.06 Treatment
of Securities as Debt</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">It is intended that the Securities
will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of this Indenture shall be interpreted
to further this intention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.07 Certificates
and Opinions as to Conditions Precedent</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)</B>&nbsp;Upon any application
or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to
the Trustee an Officer&rsquo;s Certificate stating that all conditions precedent provided for in this Indenture (other than the certificate
to be delivered pursuant to Section&nbsp;13.12) relating to the proposed action have been complied with and, if requested, an Opinion
of Counsel stating that in the opinion of such counsel all such conditions precedent have been complied with, except that in the case
of any such application or demand as to which the furnishing of such documents is specifically required by any provision of this Indenture
relating to such particular application or demand, no additional certificate or opinion need be furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)</B>&nbsp;Each certificate
or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this
Indenture (other than the certificate to be delivered pursuant to Section&nbsp;13.12 of this Indenture or Section&nbsp;314(a)(1)&nbsp;of
the Trust Indenture Act) shall include (i)&nbsp;a statement that the Person making such certificate or opinion has read such covenant
or condition; (ii)&nbsp;a brief statement as to the nature and scope of the examination or investigation upon which the statements or
opinions contained in such certificate or opinion are based; (iii)&nbsp;a statement that, in the opinion of such Person, he has made such
examination or investigation as is reasonably necessary to enable him to express an informed opinion as to whether or not such covenant
or condition has been complied with; and (iv)&nbsp;a statement as to whether or not, in the opinion of such Person, such condition or
covenant has been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.08 Payments
on Business Days</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as provided pursuant
to Section&nbsp;2.01 pursuant to a Board Resolution, and set forth in an Officer&rsquo;s Certificate, or established in one or more indentures
supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption
of any Security shall not be a Business Day, then payment of interest or principal (and premium, if any) may be made on the next succeeding
Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for
the period after such nominal date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.09 Conflict
with Trust Indenture Act</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If and to the extent that
any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Section&nbsp;318(c)&nbsp;of the Trust Indenture
Act, such imposed duties shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.10 Counterparts</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Indenture may be executed
in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same
instrument. The exchange of copies of this Indenture and of signature pages&nbsp;by facsimile or PDF transmission shall constitute effective
execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes.
Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.11 Separability</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In case any one or more of
the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Indenture or of such Securities,
but this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable provision had never been contained
herein or therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.12 Compliance
Certificates</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company shall deliver
to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series were outstanding, an officer&rsquo;s
certificate stating whether or not the signers know of any Event of Default that occurred during such fiscal year. Such certificate shall
contain a certification from the principal executive officer, principal financial officer or principal accounting officer of the Company
that a review has been conducted of the activities of the Company and the Company&rsquo;s performance under this Indenture and that the
Company has complied with all conditions and covenants under this Indenture. For purposes of this Section&nbsp;13.12, such compliance
shall be determined without regard to any period of grace or requirement of notice provided under this Indenture. If the officer of the
Company signing such certificate has knowledge of such an Event of Default, the certificate shall describe any such Event of Default and
its status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.13 U.S.A.
Patriot Act</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The parties hereto acknowledge
that in accordance with Section&nbsp;326 of the U.S.A. Patriot Act, the Trustee, like all financial institutions and in order to help
fight the funding of terrorism and money laundering, is required to obtain, verify, and record information that identifies each person
or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will
provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. Patriot
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.14 Force
Majeure</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In no event shall the Trustee,
the Security Registrar, any paying agent or any other agent under this Indenture be responsible or liable for any failure or delay in
the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including
without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes
or acts of God, and interruptions, loss or malfunctions or utilities, communications or computer (software and hardware) services; it
being understood that the Trustee, the Security Registrar, any paying agent or any other agent under this Indenture shall use reasonable
efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Section&nbsp;13.15 Table
of Contents; Headings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table of contents and
headings of the articles and sections of this Indenture have been inserted for convenience of reference only, are not intended to be considered
a part hereof, and will not modify or restrict any of the terms or provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page&nbsp;follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have caused this Indenture to be duly executed all as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt"><B>THERIVA BIOLOGICS,&nbsp;INC.</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt"><B>[TRUSTEE]</B>, as Trustee</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CROSS-REFERENCE TABLE<SUP>(1)</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 84%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;of Trust Indenture Act of 1939, as Amended</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;of <BR>
Indenture</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">310(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.09</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">310(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.08</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.10</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">310(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">311(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.13</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">311(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.13</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">311(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">312(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.01</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.02(a)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">312(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.02(c)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">312(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.02(c)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">313(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.04(a)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">313(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.04(b)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">313(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.04(a)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.04(b)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">313(d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.04(c)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">314(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">5.03</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">13.12</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">314(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">314(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">13.07(a)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">314(d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">314(e)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">13.07(b)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">314(f)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Inapplicable</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">315(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.01(a)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.01(b)</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">315(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.14</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">315(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.01</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">315(d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">7.01(b)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">315(e)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">6.07</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">316(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">6.06</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">8.04</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">316(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">6.04</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">316(c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">8.01</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">317(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">6.02</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">317(b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">4.03</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">318(a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">13.09</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 96%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Cross-Reference Table does not constitute
    part of the Indenture and shall not have any bearing on the interpretation of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">any of its terms or provisions.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1(A)
<SEQUENCE>3
<FILENAME>tm2413199d1_ex5-1a.htm
<DESCRIPTION>EXHIBIT 5.1(A)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;5.1(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2413199d1_ex5-1aimg006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="padding-left: 0.625in; text-align: justify">May 2, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9605 Medical Center Drive, Suite&nbsp;270&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Statement on Form&nbsp;S-3</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as special Nevada
counsel to Theriva Biologics,&nbsp;Inc., a Nevada corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with its filing
on the date hereof with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) of a registration statement
on Form&nbsp;S-3 (as amended, the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), including a base prospectus (the &ldquo;<B><I>Base
Prospectus</I></B>&rdquo;), which provides that it will be supplemented by one or more prospectus supplements (each such prospectus supplement,
together with the Base Prospectus, a &ldquo;<B><I>Prospectus</I></B>&nbsp;&rdquo;), under the Securities Act of 1933, as amended (the
&ldquo;<B><I>Act</I></B>&rdquo;), relating to the registration for issue and sale by the Company of up to $200,000,000 offering price
of (i)&nbsp;shares of common stock, par value $0.001 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;), including shares of Common
Stock as may from time to time be issued upon conversion or exchange of Debt Securities or Preferred Stock (each as defined below) or
the exercise of Warrants or Units (each as defined below); (ii)&nbsp;shares of preferred stock, par value $0.001 per share (&ldquo;<B><I>Preferred
Stock</I></B>&rdquo;), in one or more series; (iii)&nbsp;debt securities, in one or more series (the &ldquo;<B><I>Debt Securities</I></B>&rdquo;),
which may be issued pursuant to an indenture to be dated on or about the date of the first issuance of the Debt Securities thereunder,
by and between a trustee to be selected by the Company (the &ldquo;<B><I>Trustee</I></B>&rdquo;) and the Company, and one or more indentures
supplemental thereto with respect to any particular series of Debt Securities (the &ldquo;<B><I>Indenture</I></B>&rdquo;); (iv)&nbsp;warrants
for the purchase of Common Stock, Preferred Stock or Debt Securities (&ldquo;<B><I>Warrants</I></B>&rdquo;) pursuant to one or more warrant
agreements (each, a &ldquo;<B><I>Warrant Agreement</I></B>&rdquo;) proposed to be entered into between the Company and one or more warrant
agents to be named in the applicable Warrant Agreement (each, a &ldquo;<B><I>Warrant Agent</I></B>&rdquo;) in the forms to be filed as
Exhibits 4.5, 4.6 and 4.7 to the Registration Statement; and (v)&nbsp;units consisting of one or more of the Company&rsquo;s Common Stock,
Preferred Stock, Debt Securities or Warrants, or any combination of those securities (&ldquo;<B><I>Units</I></B>&rdquo;), pursuant to
one or more unit agreements (each, a &ldquo;<B><I>Unit Agreement</I></B>&rdquo;) proposed to be entered into between the Company and one
or more unit agents to be named in the applicable Unit Agreement (each, a &ldquo;<B><I>Unit Agent</I></B>&rdquo;). The Common Stock, Preferred
Stock, Debt Securities, Warrants and Units are collectively referred to herein as the &ldquo;<B><I>Securities</I></B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have acted as special
Nevada counsel to the Company in connection with the sale through A.G.P./Alliance Global Partners, as the sales agent (the &ldquo;<B><I>Sales
Agent</I></B>&rdquo;), from time to time by the Company of shares of Common Stock (the &ldquo;<B><I>Sales Agreement Shares</I></B>&rdquo;)
having a maximum aggregate offering price of up to $1,235,303 pursuant to the Registration Statement, the Base Prospectus and the related
prospectus for the sale of the Sales Agreement Shares included in the Registration Statement (the Base Prospectus and such prospectus,
collectively, the &ldquo;<B><I>Sales Agreement Prospectus</I></B>&rdquo;), and that certain Sales Agreement dated as of February&nbsp;9,
2021, as amended by Amendment No.&nbsp;1 thereto dated May&nbsp;3, 2021, and Amendment No.&nbsp;2 thereto dated May&nbsp;2, 2024, by and
between the Sales Agent and the Company (the &ldquo;<B><I>Sales Agreement</I></B>&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As such counsel, we have examined
such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied
upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified
such factual matters (&ldquo;<B><I>Reliance Documents</I></B>&rdquo;). We are opining herein as to the Nevada Revised Statutes (the &ldquo;<B><I>NRS</I></B>&rdquo;),
and we express no opinion with respect to the applicability thereto, or the effect thereon, of the federal securities laws, the laws of
any other jurisdiction or, in the case of Nevada, any other laws, or as to any matters of municipal law or the laws of any local agencies
within any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion
letter, we have examined and relied upon the representations and warranties as to factual matters contained in and made pursuant to the
Reliance Documents, Registration Statement, and upon such other documents as in our judgment are necessary or appropriate to enable us
to render the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our knowledge of the Company
and its legal and other affairs is limited by the scope of our engagement, which scope includes the delivery of this opinion letter. We
do not represent the Company with respect to all legal matters or issues. The Company may employ other independent counsel and, to our
knowledge, handles certain matters and issues without the assistance of independent counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our examination of the
foregoing, we have assumed, without independent investigation or verification: (i)&nbsp;the genuineness of all signatures on all agreements,
instruments and other documents submitted to us; (ii)&nbsp;the legal capacity and authority of all persons or entities executing all agreements,
instruments and other documents submitted to us; (iii)&nbsp;the authenticity and completeness of all agreements, instruments, corporate
records, certificates and other documents submitted to us as originals; (iv)&nbsp;that all agreements, instruments, corporate records,
certificate and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other copies conform to
authentic originals thereof, and that such originals are authentic and complete; (v)&nbsp;the due authorization, execution and delivery
of all instruments, agreements, and other documents by the parties thereto; (vi)&nbsp;that the statements contained in the certificates
and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for
the purposes of this letter are true and correct; and (vii)&nbsp;that the officers and directors of the Company have properly exercised
their fiduciary duties. We have assumed that the issuance and sale of the Securities by the Company will not, in each case, violate or
constitute a default or breach under (i)&nbsp;any agreement or instrument to which the Company is subject, (ii)&nbsp;any law, rule&nbsp;or
regulation to which the Company is subject, (iii)&nbsp;any judicial or regulatory order or decree of any governmental authority, or (iv)&nbsp;any
consent, approval, license, authorization or validation of, or filing, recording or registration with any governmental authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have further assumed that:
(i)&nbsp;the Registration Statement and any amendments thereto will have become effective under the Securities Act and comply with all
applicable laws at the time the Securities are offered or issued as contemplated by the Registration Statement; (ii)&nbsp;an appropriate
prospectus supplement, free writing prospectus or term sheet relating to the Securities offered thereby will be prepared and filed with
the Commission in compliance with the Act and will comply with all applicable laws at the time the Securities are offered or issued as
contemplated by the Registration Statement; (iii)&nbsp;all Securities will be issued and sold in compliance with the applicable provisions
of the Act and the Securities or Blue Sky Laws of various states and in the manner stated in the Registration Statement and the applicable
prospectus supplement; (iv)&nbsp;any purchase, underwriting, warrant, deposit, unit or similar agreement (collectively the &ldquo;<B><I>Securities
Agreements</I></B>&rdquo;) relating to the Securities being offered will be duly authorized, executed and delivered by the Company and
other parties thereto; (v)&nbsp;the terms of any Warrants and Units included in any Securities offered and issued as executed and delivered
are as described in the Registration Statement; and (vi)&nbsp;the number of shares of Common Stock offered pursuant to the Registration
Statement does not exceed, at the time of issuance, the authorized but unissued shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the foregoing and
the other matters set forth herein, it is our opinion that, as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When an issuance of Common Stock has been duly authorized by all necessary corporate action of the Company, upon issuance, delivery and payment therefor in an amount not less than the par value thereof in the manner contemplated by the applicable Prospectus and by such corporate action, such shares of Common Stock will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the NRS.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;4</P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to the shares of any series of Preferred Stock offered by the Company (the &ldquo;<B><I>Offered Preferred Stock</I></B>&rdquo;), when (i)&nbsp;a Certificate of Designations for the Offered Preferred Stock in accordance with the applicable provisions of Nevada corporate law (the &ldquo;<B><I>Certificate of Designations</I></B>&rdquo;) has been filed with, and accepted for record by, the Secretary of State of the State of Nevada, in the form to be filed as an exhibit to a post-effective amendment to the Registration Statement or as an exhibit to a Current Report on Form&nbsp;8-K or other applicable report under the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;), in the manner contemplated in the Registration Statement or any prospectus supplement relating thereto; (ii)&nbsp;the terms of the Offered Preferred Stock and of their issuance and sale have been duly established and are then in conformity with the Articles of Incorporation, including the Certificate of Designations relating to the Offered Preferred Stock, and the Bylaws so as not to violate any applicable law, the Articles of Incorporation or the Bylaws or result in a default under or breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or restriction imposed by any court or other governmental authority having jurisdiction over the Company; (iii)&nbsp;if the Offered Preferred Stock is to be certificated, certificates in the form required under Nevada corporate law representing the shares of Offered Preferred Stock have been duly executed and countersigned and (iv)&nbsp;the shares of Offered Preferred Stock are registered in the Company&rsquo;s share registry and delivered upon payment of the agreed-upon consideration therefor, the shares of Offered Preferred Stock, when issued and sold or otherwise distributed in accordance with the applicable underwriting agreement, if any, or any other duly authorized, executed and delivered valid and binding agreement, will be duly authorized, validly issued, fully paid and non-assessable, provided that the consideration therefor is not less than $0.001 per share of Preferred Stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When the Sales Agreement Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Sales Agreement, the issuance and sale of the Sales Agreement Shares will have been duly authorized by all necessary corporate action of the Company, and the Sales Agreement Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that (i)&nbsp;the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the NRS and (ii)&nbsp;upon the issuance of any of the Sales Agreement Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its articles of incorporation, as amended and restated as of the date hereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is given as of
the date hereof. &nbsp;We assume no obligation to advise you of changes in law or facts that may hereafter be brought to our attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter is for
your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant
to the applicable provisions of the Act. We consent to your filing this opinion letter as an exhibit to the Registration Statement and
to the reference to our firm contained in each of the Prospectus under the heading &ldquo;Legal Matters.&rdquo; We further consent to
the incorporation by reference of this letter and consent into any registration statement or post-effective amendment to the Registration
Statement filed pursuant to Rule&nbsp;462(b)&nbsp;under the Act with respect to the Securities. In giving such consent, we do not thereby
admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules&nbsp;and regulations
of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    PARSONS BEHLE&nbsp;&amp; LATIMER</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1(B)
<SEQUENCE>4
<FILENAME>tm2413199d1_ex5-1b.htm
<DESCRIPTION>EXHIBIT 5.1(B)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right; text-indent: -0.25in"><B>Exhibit&nbsp;5.1(b)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; color: Red"><IMG SRC="tm2413199d1_ex5-1bimg001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; color: Red"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">1271 Avenue of the Americas |New
York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">blankrome.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right; text-indent: 0.5in">May&nbsp;2, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9605 Medical Center Drive, Suite&nbsp;270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-size: 10pt"><B>Re:</B></TD>
    <TD STYLE="width: 94%; font-size: 10pt"><B>Theriva Biologics,&nbsp;Inc.</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel
to Theriva Biologics,&nbsp;Inc., a Nevada corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with its filing on the
date hereof with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) of a registration statement on Form&nbsp;S-3
(as amended, the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), including a base prospectus (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;),
which provides that it will be supplemented by one or more prospectus supplements (each such prospectus supplement, together with the
Base Prospectus, a &ldquo;<B><I>Prospectus</I></B>&rdquo;), under the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;). The Registration Statement relates to, among other things, the offer and sale from time to time, pursuant to Rule&nbsp;415
of the General Rules&nbsp;and Regulations promulgated under the Securities Act, of up to $200,000,000 of any combination of the following
securities of the Company (the &ldquo;<B><I>Registered Securities</I></B>&rdquo;): (i)&nbsp;shares of common stock, par value $0.001
per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;), including shares of Common Stock as may from time to time be issued upon conversion
or exchange of Preferred Stock or Debt Securities (each as defined below) or the exercise of Warrants or Units (each as defined below);
(ii)&nbsp;shares of preferred stock, par value $0.001 per share (&ldquo;<B><I>Preferred Stock</I></B>&rdquo;), in one or more series;
(iii)&nbsp;debt securities, in one or more series (the &ldquo;<B><I>Debt Securities</I></B>&rdquo;), which may be issued pursuant to
an indenture to be dated on or about the date of the first issuance of the Debt Securities thereunder, by and between a trustee to be
selected by the Company (the &ldquo;<B><I>Trustee</I></B>&rdquo;) and the Company, in the form filed as Exhibit&nbsp;4.3 to the Registration
Statement and one or more indentures supplemental thereto with respect to any particular series of Debt Securities (the &ldquo;<B><I>Indenture</I></B>&rdquo;);
(iv)&nbsp;warrants for the purchase of Common Stock, Preferred Stock or Debt Securities (&ldquo;<B><I>Warrants</I></B>&rdquo;) pursuant
to one or more warrant agreements (each, a &ldquo;<B><I>Warrant Agreement</I></B>&rdquo;) proposed to be entered into between the Company
and one or more warrant agents to be named in the applicable Warrant Agreement (each, a &ldquo;<B><I>Warrant Agent</I></B>&rdquo;) in
the forms to be filed as Exhibits 4.5, 4.6 and 4.7 to the Registration Statement; and (v)&nbsp;units consisting of one or more of the
Company&rsquo;s Common Stock, Preferred Stock, Debt Securities or Warrants, or any combination of those securities (&ldquo;<B><I>Units</I></B>&rdquo;),
pursuant to one or more unit agreements (each, a &ldquo;<B><I>Unit Agreement</I></B>&rdquo;) proposed to be entered into between the
Company and one or more unit agents to be named in the applicable Unit Agreement (each, a &ldquo;<B><I>Unit Agent</I></B>&rdquo;). The
Common Stock, Preferred Stock, Debt Securities, Warrants and Units are collectively referred to herein as the &ldquo;<B><I>Securities</I></B>.&rdquo;
This opinion is being furnished in accordance with the requirements of Item 601(b)(5)&nbsp;of Regulation S-K under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also acting as counsel
for the Company in connection with the Sales Agreement prospectus included in the Registration Statement (the &ldquo;<B><I>Sales Agreement
ATM Prospectus</I></B>&rdquo;) relating to the issuance and sale of shares of Common Stock having an aggregate offering price of up to
$1,235,303 (the &ldquo;<B><I>Sales Agreement Shares</I></B>&rdquo;) under that certain Sales Agreement dated as of February&nbsp;9, 2021,
as amended by Amendment No.&nbsp;1 thereto, dated May&nbsp;3, 2021, and Amendment No.&nbsp;2 thereto, dated May&nbsp;2, 2024, by and between
A.G.P./Alliance Global Partners, as the sales agent, and the Company (the &ldquo;<B><I>Sales Agreement</I></B>&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2413199d1_ex5-1bimg001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering this opinion,
we have assumed, without inquiry, (i)&nbsp;the authenticity of all documents submitted to us as originals; (ii)&nbsp;the conformity to
the original documents of all documents submitted to us as facsimile, electronic, certified or photostatic copies, and the authenticity
of the originals of such copies; (iii)&nbsp;the legal capacity of all natural persons and the genuineness of all signatures on the Registration
Statement and all documents submitted to us; and (iv)&nbsp;that the books and records of the Company are maintained in accordance with
proper corporate procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In making our examination
of executed documents or documents to be executed, we have assumed that the parties thereto had or will have the power, corporate or other,
to enter into and perform all obligations thereunder and we have also assumed the due authorization by all requisite action, corporate
or other, and execution and delivery by such parties of such documents and (except to the extent we have opined on such matters below)
the validity and binding effect on such parties. In addition, we have assumed that (i)&nbsp;a purchase, underwriting or similar agreement
with respect to any Registered Securities will have been duly authorized and validly executed and delivered by the Company and the other
parties thereto; (ii)&nbsp;the Registration Statement and any amendments thereto will have become effective and comply with all applicable
laws at the time the Registered Securities are offered or issued as contemplated by the Registration Statement and no stop order suspending
its effectiveness will have been issued and remain in effect; (iii)&nbsp;all Registered Securities will be issued and sold in compliance
with applicable federal and state securities laws and in the manner stated in the Registration Statement and the applicable prospectus
supplement; (iv)&nbsp;a prospectus supplement or term sheet will have been prepared and filed with the Commission describing the Registered
Securities offered thereby and will comply at all relevant times with all applicable laws; (v)&nbsp;the Company will have obtained any
legally required consents, approvals, authorizations and other orders of the Commission and any other regulatory authorities necessary
(x)&nbsp;to issue and sell the Registered Securities being offered, and (y)&nbsp;to execute and deliver the applicable purchase, underwriting
or similar agreement, or other applicable operative document; (vi)&nbsp;any securities issuable upon conversion, exchange, redemption
or exercise of any Registered Securities being offered will be duly authorized, created and, if appropriate, reserved for issuance upon
such conversion, exchange, redemption or exercise and, with respect to shares of Common Stock or Preferred Stock offered, there will be
sufficient shares of Common Stock or Preferred Stock, as applicable, authorized under the Company&rsquo;s Articles of Incorporation, as
amended (the &ldquo;<B><I>Articles of Incorporation</I></B>&rdquo;), and not otherwise reserved for issuance; (vii)&nbsp;at the time of
issuance of the Registered Securities, the Company validly exists and is duly qualified and in good standing under the laws of its jurisdiction
of incorporation, and has the necessary corporate power for such issuance; (viii)&nbsp;at the time of issuance of the Registered Securities,
the Articles of Incorporation and then-operative by-laws, including the current Amended and Restated By-Laws (the &ldquo;<B><I>By-Laws</I></B>&rdquo;)
of the Company are in full force and effect and have not been amended, restated, supplemented or otherwise altered, and there has been
no authorization of any such amendment, restatement, supplement or other alteration, in either case since the date hereof; and (ix)&nbsp;the
terms, execution and delivery of the Registered Securities (x)&nbsp;do not result in breaches of, or defaults under, agreements or instruments
to which the Company is bound or violations of applicable statutes, rules, regulations or court or governmental orders, and (y)&nbsp;comply
with any applicable requirement or restriction imposed by any court or governmental body having jurisdiction over the Company. As to any
facts material to the opinions expressed herein that we have not independently established or verified, we have relied upon, and assumed
the accuracy of, statements and representations of officers and other representatives of the Company and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2413199d1_ex5-1bimg001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page&nbsp;3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Sales
Agreement Shares, we have assumed (i)&nbsp;that each sale of Sales Agreement Shares will be duly authorized by the Board of Directors
of the Company, a duly authorized committee thereof or a person or body pursuant to an authorization granted in accordance with the Nevada
Revised Statutes, (ii)&nbsp;at the time of issuance of any Sales Agreement Shares, there shall be a sufficient number of duly authorized
and unissued shares of Common Stock to accommodate the issuance of the Sales Agreement Shares, and (iii)&nbsp;that the price at which
the Sales Agreement Shares are sold will equal or exceed the par value of the Common Stock. We express no opinion to the extent that future
issuances of securities of the Company, anti-dilution adjustments to outstanding securities of the Company and/or other matters cause
the number of shares of the Common Stock available for issuance under the Sales Agreement to exceed the number of shares of the Common
Stock available for issuance by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the foregoing and
subject to the limitations, qualifications, exceptions and assumptions stated herein, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. With respect to any series
of Debt Securities offered by the Company (the &ldquo;<B><I>Offered Debt Securities</I></B>&rdquo;), when (i)&nbsp;the Indenture has been
qualified under the Trust Indenture Act of 1939, as amended (the &ldquo;<B><I>TIA</I></B>&rdquo;); (ii)&nbsp;the terms of the Offered
Debt Securities and of their issuance and sale have been duly established in conformity with the Indenture and any supplemental indenture
relating to such Offered Debt Securities so as not to violate any applicable law, the Articles of Incorporation or the By-laws, or result
in a default under or breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or restriction
imposed by any court or other governmental authority having jurisdiction over the Company and (iii)&nbsp;the Offered Debt Securities,
in a form compliant with the Indenture and any supplemental indenture relating to such Offered Debt Securities and to be filed as an exhibit
to a post-effective amendment to the Registration Statement or as an exhibit to a Current Report on Form&nbsp;8-K or other applicable
report under the Exchange Act in the manner contemplated in the Registration Statement or any prospectus supplement relating thereto,
have been duly executed and authenticated in accordance with the provisions of the Indenture and any supplemental indenture relating to
such Offered Debt Securities and delivered to the purchasers thereof upon payment of the agreed-upon consideration therefor, the Offered
Debt Securities, when issued and sold or otherwise distributed in accordance with the Indenture and any supplemental indenture relating
to such Offered Debt Securities and the applicable underwriting agreement, if any, or any other duly authorized, executed and delivered
valid and binding agreement, will be valid and binding obligations of the Company, enforceable against the Company in accordance with
their respective terms under the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. With respect to any
series of Warrants offered by the Company (the &ldquo;<B><I>Offered Warrants</I></B>&rdquo;), when (i)&nbsp;a Warrant Agreement
relating to the Offered Warrants has been duly authorized, executed and delivered by the Company and the other parties thereto;
(ii)&nbsp;the terms of the Offered Warrants and their issuance and sale have been duly established and are then in conformity with
the applicable Warrant Agreement so as not to violate any applicable law, the Articles of Incorporation or the By-Laws or result in
a default under or breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or
restriction imposed by any court or governmental body having jurisdiction over the Company and (iii)&nbsp;the Offered Warrants have
been duly executed, delivered, countersigned, issued and sold in accordance with the provisions of the applicable Warrant Agreement
to be filed as an exhibit to a post-effective amendment to the Registration Statement or as an exhibit to a Current Report on
Form&nbsp;8-K or other applicable report under the Exchange Act in the manner contemplated in the Registration Statement or any
prospectus supplement relating thereto, the Offered Warrants, when issued and sold or otherwise distributed in accordance with the
applicable Warrant Agreement and the applicable underwriting agreement, if any, or any other duly authorized, executed and delivered
valid and binding purchase or agency agreement, will be valid and binding obligations of the Company, enforceable against the
Company in accordance with their respective terms under the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2413199d1_ex5-1bimg001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page&nbsp;4</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. With respect to any Units
offered by the Company (the &ldquo;<B><I>Offered Units</I></B>&rdquo;), when (i)&nbsp;a Unit Agreement relating to the Offered Units has
been duly authorized, executed and delivered by the Company and the other parties thereto; (ii)&nbsp;the terms of the Offered Units and
of their issuance and sale have been duly established and are then in conformity with the applicable Unit Agreement of which the Offered
Units are a component so as not to violate any applicable law, the Articles of Incorporation or the By-Laws, or result in a default under
or breach of any agreement or instrument binding upon the Company, and so as to comply with any requirement or restriction imposed by
any court or governmental body having jurisdiction over the Company and (iii)&nbsp;the Offered Units have been duly executed, delivered,
countersigned, issued and sold in accordance with the provisions of the applicable Unit Agreement to be filed as an exhibit to a post-effective
amendment to the Registration Statement or as an exhibit to a Current Report on Form&nbsp;8-K or other applicable report under the Exchange
Act in the manner contemplated in the Registration Statement or any prospectus supplement relating thereto, the Offered Units, when issued
and sold or otherwise distributed in accordance with the applicable Unit Agreement and the applicable underwriting agreement, if any,
or any other duly authorized, executed and delivered valid and binding agreement, will be duly authorized and validly issued and will
be valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms under the laws
of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the assumptions,
comments, qualifications, limitations and exceptions set forth above, the opinions set forth herein are further limited by, subject to
and based upon the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">Our opinions herein are expressed solely with respect to the applicable laws of the State of New York
that, in our experience, are normally applicable to transactions of the type contemplated by the Registration Statement. The opinion set
forth herein related to the Offered Units assumes that such Offered Units are governed by New York law. The opinions set forth herein
are made as of the date hereof and are subject to, and may be limited by, future changes in the factual matters set forth herein, and
we undertake no duty to advise you of the same that may occur after the Registration Statement becomes effective. The opinions expressed
herein are based upon the law in effect (and published or otherwise generally available) on the date hereof, which laws are subject to
change with possible retroactive effect, and we assume no obligation to revise or supplement these opinions should such law be changed by legislative
action, judicial decision or otherwise after the Registration Statement becomes effective. In rendering our opinions, we have not considered,
and hereby disclaim any opinion as to, the application or impact of any laws, cases, decisions, rules&nbsp;or regulations of any other
jurisdiction, court or administrative agency.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2413199d1_ex5-1bimg001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;2, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page&nbsp;5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">Our opinions set forth above are subject to and may be limited by (i)&nbsp;applicable bankruptcy, reorganization,
insolvency, conservatorship, moratorium, fraudulent conveyance, debtor and creditor, and similar laws which relate to or affect creditors&rsquo;
rights generally, and (ii)&nbsp;general principles of equity (including, without limitation, concepts of materiality, reasonableness,
impossibility of performance, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify">Our opinions are subject to the qualification that the availability of specific performance, an injunction
or other equitable remedies is subject to the discretion of the court before which the request is brought.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify">You have informed us that you intend to issue the Registered Securities from time to time on a delayed
or continuous basis, and this opinion is limited to the laws, including the rules&nbsp;and regulations, as in effect on the date hereof.
We understand that prior to issuing any Registered Securities you will afford us an opportunity to review the operative documents pursuant
to which such Registered Securities are to be issued (including the applicable prospectus supplement) and will file such supplement or
amendment to this opinion (if any) as we may reasonably consider necessary or appropriate by reason of the terms of such Registered Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the use of this
opinion as an exhibit to the Registration Statement. We also consent to any and all references to us in the prospectus which is part of
said Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent
is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations of the Commission promulgated thereunder. This
opinion is strictly limited to the matters stated herein and no other or more extensive opinion is intended, implied or to be inferred
beyond the matters expressly stated herein. This opinion letter is not a guaranty nor may one be inferred or implied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ BLANK ROME</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>BLANK ROME LLP</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>tm2413199d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the use in the Prospectus
constituting a part of this Registration Statement of our report dated March 25, 2024, relating to the consolidated financial statements
of Theriva Biologics, Inc. (the Company), which is contained in that Prospectus. Our report contains an explanatory paragraph regarding
the Company&rsquo;s ability to continue as a going concern.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to us under the
caption &ldquo;Experts&rdquo; in the Prospectus.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/BDO USA, P.C.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raleigh, North Carolina&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May 2, 2024&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>tm2413199d1_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Form&nbsp;Type)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white"><B>THERIVA
BIOLOGICS,&nbsp;INC</B></FONT><B><FONT STYLE="text-transform: uppercase">.&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of Registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table 1: Newly Registered and Carry Forward
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Security<BR> Type</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Security&nbsp;Class<BR> Title</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Fee<BR> Calculation<BR> or Carry<BR> Forward<BR> Rule</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Amount<BR> Registered</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR> Unit</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Maximum<BR> Aggregate<BR> Offering Price</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Fee Rate</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Amount of<BR> Registration<BR> Fee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Carry<BR> Forward<BR> Form<BR> Type</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Carry<BR> Forward<BR> File Number</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Carry<BR> Forward<BR> Initial<BR> Effective<BR> Date</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Filing Fee<BR> Previously<BR> Paid&nbsp;In Connection<BR> with Unsold<BR> Securities&nbsp;to<BR> be Carried<BR> Forward</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="35" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Newly Registered Securities</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; width: 6%"><FONT STYLE="font-size: 10pt">Fees to Be Paid</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 10%">Common Stock, par value $0.001 per share<SUP>(1)</SUP></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 6%"><FONT STYLE="font-size: 10pt">Rule&nbsp;457(o)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 5%"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 5%"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 5%"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">Preferred Stock, par value $0.001 per share<SUP>(1)</SUP></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Rule&nbsp;457(o)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Debt</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Debt Securities<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Rule&nbsp;457(o)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Warrants<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Rule&nbsp;457(o)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Units<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Rule&nbsp;457(o)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Unallocated (Universal) Shelf</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Rule&nbsp;457(o)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">0<SUP>(5)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">0.0001476</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">$ 0.00</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="35" STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carry Forward Securities</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; background-color: #CCEEFF">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carry Forward Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock, par value $0.001 per share</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 6%">Rule&nbsp;415(a)(6)</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Rule&nbsp;415(a)(6)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Rule&nbsp;415(a)(6)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Rule&nbsp;415(a)(6)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Rule&nbsp;415(a)(6)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unallocated (Universal) Shelf</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Rule&nbsp;415(a)(6)</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-255726</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/11/2021</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;32,730</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Offering Amounts</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)&nbsp;</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Fees Previously Paid</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,730</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Fee Offsets</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Fee Due</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Separate consideration may or may not be received for securities that are issuable upon the conversion
or exercise of, or in exchange for, other securities offered hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">There are being registered hereunder such indeterminate number of the securities of each identified class
being registered as may be sold by the registrant from time to time at indeterminate prices, with the maximum aggregate public offering
price not to exceed $200,000,000. Any securities registered hereunder may be sold separately or together with other securities registered
hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">The proposed maximum per security and aggregate offering prices per class of securities will be determined
from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not
specified as to each class of security pursuant to Instruction 2.A.iii.b of the Instructions to the Calculation of Filing Fee Tables and
related disclosure on Form&nbsp;S-3.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">Calculated pursuant to Rule&nbsp;457(o)&nbsp;under the Securities Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Pursuant to&nbsp;Rule&nbsp;415(a)(6)&nbsp;under the Securities Act,
the securities registered pursuant to this registration statement include $200,000,000 of unsold securities (the &ldquo;Unsold Securities&rdquo;)
previously registered pursuant to the Registration Statement on Form&nbsp;S-3&nbsp;(File&nbsp;No.&nbsp;333-255726),&nbsp;which initially
became effective upon filing on May&nbsp;11, 2021 (the &ldquo;Prior Registration Statement&rdquo;). In connection with the filing of the
Prior Registration Statement, the registrant paid a filing fee of $32,730 associated with the offering of the Unsold Securities (based
on the filing fee rate in effect at the time of the filing of the Prior Registration Statement). The filing fee associated with the offering
of the Unsold Securities is hereby carried forward to be applied to the Unsold Securities registered hereunder, and no additional filing
fee is due with respect to the Unsold Securities in connection with the filing of this Registration Statement. The registrant is not registering
new securities (&ldquo;New Securities&rdquo;) on this registration statement. Therefore, no filing fee with respect to the New Securities
is being paid in connection with the filing of this registration statement. To the extent that, after the filing date hereof and prior
to the effectiveness of this registration statement, the registrant sells any Unsold Securities pursuant to the Prior Registration Statement,
the registrant will identify in a&nbsp;pre-effective&nbsp;amendment to this registration statement the updated number of Unsold Securities
from the Prior Registration Statement to be included in this registration statement pursuant to Rule&nbsp;415(a)(6)&nbsp;and the updated
amount of New Securities, if any, to be registered on this registration statement. Pursuant to Rule&nbsp;415(a)(6), the offering of securities
under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2413199d1_ex5-1aimg006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413199d1_ex5-1aimg006.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "  ($# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]GO\ @HY_
MP62^/_[&7QY^*OPK\ >%O@GKVD^ [SP/#9R>-O"OQ#U7793XJ\ ^%_&-P+^;
M0?BEHELL<+>(%AM&2QM1(L;AHC)$['\W!_P<R_MB*SX^&G[*T2,0ZM_P@?QB
MW2,V2^X?\+I(ROR_]]>U>1_\%ZO^3T/VC/WFP?:?@[GW_P"+-^ _Y?IFOP+C
M^\_[S?PG_ >#^6?3M7WV"RG*ZF$P^(KT/;U73C)T;M<[E%)]5\*?-I;;8^&Q
M6/S"CB:U.G6]AA^9WJV3Y$FW'_P)VCMU/Z4O^(F;]L3M\.?V5S]/ 7QA_P#G
MTTO_ !$R?MBMU^&O[*S8]? /QAXSZ?\ %ZAUK^;'_@>S\,Y_7M_6CYS]RXQZ
M\8^G?ZUU?V9DW_0G_P#)I?\ R1S3S+'<K]GG"Y]+>ZN^O3M<_I._XB8?VQOX
M?AG^RK[_ /% _&+\.GQJ^M'_ !$P_MD_]$S_ &5?_"!^,?\ \^JOYL"TZ=+@
M'/K[?C[T>=<?\]Q_G\:/[,R;_H3_ /DTO_DC#^TLW_Z&_P#Y+'_Y$_I/_P"(
MF']LG_HF?[*O_A _&/\ ^?51_P 1,/[9/_1,_P!E7_P@?C'_ //JK^;#SKC_
M )[C_/XT>=<?\]Q_G\:/[,R;_H3_ /DTO_D@_M+-_P#H;_\ DL?_ )$_I/\
M^(F']LG_ *)G^RK_ .$#\8__ )]5'_$3#^V3_P!$S_95_P#"!^,?_P ^JOYL
M/.N/^>X_S^-'G7'_ #W'^?QH_LS)O^A/_P"32_\ D@_M+-_^AO\ ^2Q_^1/Z
M3_\ B)A_;)_Z)G^RK_X0/QC_ /GU4?\ $3#^V3_T3/\ 95_\('XQ_P#SZJ_F
MP\ZX_P">X_S^-'G7'_/<?Y_&C^S,F_Z$_P#Y-+_Y(/[2S?\ Z&__ )+'_P"1
M/Z3_ /B)A_;(R,_#']E@CN4\ _&/CZ_\7K[\XSZ&@?\ !S)^UXFYF^&?[+P*
MJQ/_ !07QBZ_C\:B.2.O/X<U_-AYUQ_SW'^?QIRS29.]]_RG&.WK^?'<=*/[
M,R;_ *$__DTO_D@_M'-_^AO_ .2Q_P#D3^E&V_X.8OVO+B+?_P *S_9=&?,;
M'_" _&'^#'7/QJ)[^N!7ZF?\$E_^"N7QU_X* _M ^+/A7\3O"OP@\.:+X=^#
M7B7XBV%S\.O#GC31]3EU?1_'/PW\+PQ7W_"5>-_%T=QIXM/&%XTGV-=/DBE\
ML323+/&UO_#39SR"#]WVDY_\>Q]<<^@]^E?T9?\ !L\[O^VG\3M_;]EOX@X_
M\/'\ L_G@5PYC@<LHX*O5P^6^PK1C%PJW;Y&YPB]&VM8MQVZG9@<;F5;%T:=
M?,?;TI2?/2LESVC)K5)/224M^A_;=Y^D?\]=)_.W_P#BJ*T**^/OZGUI_!I_
MP7K_ .3T?VB_^OGX/?\ JFO =?@>G4_1?Y5^^/\ P7H_Y/6_:'_Z^/A#_P"J
M;\ 5^!T:;EE;^ZO\\_X?_7]?T'#RY,OP,NU"E^,$OU/B<=_OE?\ QO\ ,?15
M:1C+:11QY\U6F<>T:;#)[=-O;GUZX6VE6Z0R1_ZJ/"J/]L9\SCIP0IZ_A7H0
MK\])Q[V_!IG'/X7\OS+%%21Q_:,IY?F;,=NF<^_MZ=NOJV::"V0K+'L:,$1\
MYSN^\?7LO0\9J#.$>>2CWO\ @K^?8;15:)\XD\S:)CPO]\)_ANJVZ.D?FK'L
M4#YI/7/ /MCF@TEAI\K]FK3Z:>>O1=+C:* Z!%:.\WS2YQ%V!7J/QW?I]*CD
M/E8+1;)'R9&QP^,;<<CIN/KUJ*GPOUC_ .E(PG0Q,(N51^XK7WZM)?BT2457
M\['SL^R-/O\ !RV>G<],'\\U)&_F9=7WQMC9UR,9S^?'Y9KHHQYX..]TOPY7
MY]C#FY/>VM^NGEW)*<O\7^Z?Z5"[QHZ;Y-F=V%_OXVY_+(_.EBEC,S".WE.5
M.YH\_-P<9Z\^GU)QUISH<D7*VUNG=V[+N5"OSR4;[WZ]E?N^Q;L?]7;_ /7X
MG_HJXK^C#_@V<_Y/0^(__9J?C[_U=/P)K^<VT3;SLE3<)?\ 6=\;>GTSS]17
M]&__  ;1?\GJ_$S_ +-6\>_^KC^ E>1F_P#R+L5_AA_Z=IGJY9_OV'_Q2_\
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CII\G-&45MK[S:C\S]\Z*-MQ_>C_-Z*^/MYK[_P#@'UI__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2413199d1_ex5-1bimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413199d1_ex5-1bimg001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  F 0<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^UG]J3]JK
MX3_LB_#[1_B9\9]0FT;POJGB[3_!]G=P-HR[=<U32==UN.-FUW7O#4* :'H&
MMR$B8RH\8(AE"R ?$/\ P^Y_8._Z'K6?^_?A'_YJ*^<_^#D?_DQ#X??]G,^&
MO_5+_'FOTO\ V7OA5\,M1_9J^"]Q/\._!-S-=?#;PO>7ER?!^B8OC_8P&?NY
MR2<8+$<@;1DD 'A?A;_@L?\ L'>*=9@T/_A;EGX>N+D#9=>++WPCI.G@^C3?
M\)/(Q&,\A/ZX_2#PKXN\+^-]%L?$?@_6].\2:!JMJ;NQU?2;Q;_3[U&^7*LI
M8D< KG:<=0, 5XU\0OV7?V;OB=X3U?PKXY^#WPOUSPQJEHUG>V=WX/T0J5]-
MWECH.0!@GN37X[_\$.?[;T'4?VQ/A7X<U?5-9_9X^''QCU31?@[JMU>_VCIE
MGIA5@4T36_XA@EB!TV[A]VN<VLK=5;^OZ_SL?L!\,_VKOA%\6_BM\5O@SX&U
M.?4_'7P:OEL/'NG[M(V:;J#%5V(T>MR2. =O6-.,EF0*2?INOY_?^"<W_*4#
M_@IQT_Y&9?\ CWZ?\AQ?_'O3WQ7[]P_ZD?0_RKH,2>BBO _VB?C5X7_9[^"?
MQ(^,_BZ\M;71O 7A34?$;+=[/]*U.-'.AZ6&RK$SZYY,/RDO%O!P0KT >2ZE
M^W;^SAIG[1VG_LFWWCJT@^+VJ+Y5GHS7VC!3J/\ 8_\ ;?\ 8I4>(!KPU_[-
MP8%LMOF9'F_\M#]G>?[?I_\ 7K^.;7OV0/BUKW[$FL?\%,[BRU'_ (:Q/QKT
MS]JJRN;NT']J'P%H&M@'1@,Y(7PXR^)R>@_L$9.2!7]1O[+'QR\._M+_  $^
M''QA\+7"W&G>,_#>F7MVO7[%JF(_[<TEL@$&-P1A200RL2",+SFS45TN<=^T
M1^VQ\ _V6-;^'/AKXU>))_#<_P 3[MK#PW<W+:/%IH;!&W6)]9U^W>(;AAG5
M)6(R!@@@_5MGJMCJ=C!JMC<)=6%U:B^M+JV^=;NQVA@R%@#CY@<9!.<C&2*_
MFU_X+@?"O0_C9^T__P $[_A'XBFN+71_B+XP\=^%KN\L^-1LAKJK\R $X7^$
M?0X]_5_^"=W[1OC[]F;XR:O_ ,$T_P!K?5+BW\8>%<']GGX@ZN R_$GP*"K)
MI']M8P61E#*>H/0C/ %M%W_JY_0#-=PP0^?*<0D=<9_,>G^'O7S;\ _VJOA'
M^TM!XV?X5:Q<:A_PKOQ%_P (OXGBN6T<R6&JX)"!-'UV[4QD9RSNIR0 OS8/
MT(<^5<>1G\,=??VS_GI7X/?\$,/^09^VO_V<[JG_ +GZ 44OZ_K6W4_5[X._
MM6_";XY^,?BKX ^'NIW.I>)?@UK&EZ'X\L[C^R0=.U+5T:2*,+%KDY*'# @E
M0"0B"1F5#](S7D,/WCGKT^F:_GY_X)%^1#^U?_P4W!_Z+!X7_P"7/M_Q/_\
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MZ\_Y_(?B:_FM_P""W/[1?@?6?B)\ /V+O%/C&U\)?#CQ3XQ\+_$']H75]IU
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M;7R?P[9IW_!2[]E7XB_";XDZ'_P4F_9)A_LWXO\ PI4-\7/"=LC1Z;\3/ +
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M,N'/$!X/B+*)3X2X-LJB6E)Q:4I<EXM3;33G%JHK\MN91[?D]^V/9_#W7/\
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MKHW#C"+J--.VCIMNSZVTO'2'X-_M3^%OB1^R'X7_ &DOMUM_8UWX"/B?6KG
M"V>J:*0-</?)CU]&SV.0<9P1^8__  3H^'NJ_'34/VKOV^O'\7GZO\8[[Q+X
M;^%QN\9T'X7:#H_R)V^\XZ@YPI&.:_-KXCGXP_ _QC\9O^"67A6RU(:-\;_B
M_IGBCP%JNDG6,:#\+]> .NZ,6]@, J=N-!.<\8_J3\$_"[P_\'/V>K;X4^&X
M+6UTGP5\.VT.$"V%A@G2EAU7@9V[U5R5P,$'=D].?"5WF]_K:^!7=EHKMKTW
M;^;5MCS^)LKRC@#)9/ K_A8\0>,5+A&7-91X)7*TVUK^\FXPU:NDUUL_R\_X
M(BY_X9__ &C/W_VG_C)+XHY]<>7H6,X]\9^O;-?"G["?P3_:#^,'Q0_;'N/@
MC^T?KGP.T_2OVA?'EGJUG9^&=$U33;YO[9;)7<< XR,Y&,^E?<__  1)0C]G
M7]H=-V)V_:-^*$87'\6="<'N.@(Z@]/:ODS_ ()S?MB_L]?LO?$K]M#2?C3\
M0-$\$7'BC]H7Q1>Z/:ZJ2#?Z6.1C@_CVQQR#BN;_ &-?V-UTZ76][JZUT>FG
M=GW&*^NX?%>/4>&HK/K2X/C%N,:BE%2BXU.25T[N]HR3LXI[I'W\?V)?^"@T
MHR/^"@_B*V&>H\&Z)[?]2U^/Y>O/UQ^RU\!OVD?A7>>);SXZ?M+:Y\=+;4QI
MP\/6NI^'-(TPZ$%!$B@H"<G[IVC).<<@UY.O_!73]@R+B/X\>&4''2/GW.2Q
MQD@=/2O1OA'_ ,%'?V1?CG\1=!^%/PY^+VA>)O&WB5M3_L;2K:*,?;3HFCZY
MKNKX=I$"^7HVA:K,6.?]5M*\U[&&^J73CG"J2NN57=V[Z*SBUOHM=_1'XOGM
M3Q'Q643CGN0SI4%%NI6EP=1HPC!:RDZL>%:<J:22;G>/+:_-'=?H+1117K'Y
MD>=^.?AOX.^)NDVVA^,M$36](L]336K>S?4=2TQ1J*I,8Y9'TJ>VE8*E_..9
M#EB20Q.ZO,O^&1OV>O\ H0#_ .%7XV_^:2BB@#;\+_LW?!KP;?0ZGX7\(-I6
MIV9Q;WG_  DGB^[>/OG;=>('5OH17M_V>/SO.Q\V,>W^<\T44 >!:U^RW\#/
M$>L7OB#6_!)O]9U.Z%U=WTGB7Q>LLT@'5A'X@2,$@$G8BJ&/"@#%8T/[(?[.
M<48V_#O@\_\ (U^-B>3ZCQ(.I]N*** -K2OV:/@?H*Z_;:3X*>SA\2>&AX?U
MQ(_$OBYAJ&@9(_LN4OK[%8#@D^64?.,/USZGX6\(:!X'T'3_  WX;L&TK2+!
M%M=.M!J&H:HEFISM\MM5FN),9&3ECU.!CBBB@#L*XCQ=X&\.^//#][X9\1Z=
M_:7A_5?L4M[8?VAJ&FK,L.IKJH5VTR:WD!6=5<%)59V!21]K%J** .,'P7^%
MO_%!?\4P/^*$S_P@O_$TU_\ XD1V'F3_ (G?_$P^<AL7GG9''U]JHHH J36<
M4\5Q#(,K<9WX^F!^7^?6N \"?"[P/\+K#4[7P;H(T.SU&Y;4]1@CU;5]4%S>
M $M(W]KW-T<XZ$%>3T'6BB@!?"OPQ\&^!=4U_7O#NB#3=6\57:W7B&[.K:MJ
MLNH2@?><ZK<3J,D D(L8'.TXP!Z-Y:?W1110!Q'CCX>^%?B-X=F\+>+]*&M:
M#>#_ $JR?4-1TU9 1P2VDSVCDC)X\Q0.>N37%M\%/A@9/!EROAK$O@NU^R^#
M6.IZX3H46%X@']K8?C _>;VQD%C\I4HIIM:Z?-)G1A:U7#Z4:DZ2_N2:Z/JO
MN]+KJ>T>1%_=JA?:58ZC%<6]]")X;E!;LK?W",G!['WYZ=.U%%(YS@_ GPL\
M%_#>SN;+PEHPTB"\N6U"Y4:GJNI;KTD9D#:K<W38 X# K_N X(TO%OP]\+^-
MM,GTCQ#IWV^QNQBYA-Y?6ZR<Y/\ Q[SH>?0%>Q'3%%%<_P!6H7?[M?UY6M;Y
M&RS3,/KGU[ZYB/KB=_K'M9^UO_CYG+\3X1A_X)2?L$2^((?%(^!UPNOV^I_V
MW'J)^)_Q<,HU$@#[1M'CL1E@3G:4,>?X,<5]Y>&O /AKP=IMOI'A[3$T^RM1
MBWA^VW]TJ#G_ )[S9ZXZEA113AAZ-/X*<8^B2ZVULE?^M#:7%W%/$&&Y<ZXA
MSG,HIZ+%YCBJZ7FO:5)V>KLUJ.\:^"?#?Q!\.W?AOQ1IHU/0=33;>V/V[4-.
M$JYX#/ID]M,<$Y&)AR<G)Y.AH>A:5H&EZ=INEV@M]/L;9=.L;999 MM:%2!&
MN2Q.%0#!)/ P]%%=7V5MJ^W3F6GH8+$5G@/9^TER:/EOI=Q=W;:[6FEM-[G'
M7OPC\#WWC'3O'=[HPN?%&EV;6=AJKZEJ@^RQGDB.P%T+,C)Y9EW$<=26KOY;
M&QDA^SO;AHFC\G:3_!SQP !117 XIMW2=Y-N_5V3N^[U>ISXO,\?6Y54Q56:
M@E""E)OEBDDHQN]$EI9=$ET1P_A+X6^"_ >G7VG>'M&.F6&H:D^LWEO_ &GJ
M>JK)J,@7?,IU:>=@&V#*AE4D [,@$>:ZK^R7\#-7N)[Z\\&O<7$UR=2DDE\3
M^+]QO0O,H"Z]M!)YX4#T4=***KV-);0B[*+2<8R6M[Z.+1Z.&X@SK#8N<Z&9
M8RC.5N:=*O4A.5FDKRC.+=DDE<@'[(?[/Q!9O   '&%\5>,O_9M>/L>OJ/2M
M3P]^S9\(/ FMZ?XA\-^$([+6K/[0;*]N?$7BW5FMUETO^S94":IK=S$0UF G
M,>=PW JY+T45"P]!235*":=U9-6:>C33335KIWT>IV8_C/C/&99.CBN,>*J]
G*=.49TJN?YG4ISC)<LHRA4Q$X2C*+:E%Q::=FFM#Z0HHHKM/%/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2413199d1_s3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413199d1_s3img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Q *$# 2(  A$! Q$!_\0
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M%?\ @JA^PIXR\20^%-#_ &C/AS>ZI<S16MI'%K*^?<SRLRPPQQ[<NS,I7 (
MSG'-??VEZK8ZI:17UG,EQ97445S:7$0(AGAF4LDT3<!UD7# CH,9ZUMBL%B,
MNE2CBL%*A*JK\S22C[K>_P#Y+NMQPQ-&HU",KR=[;ZVU?ELC7V+Z?J?\:*A\
MV'U_4_XT5S^UAW_+_,V/PS_X*,_\$T/%'[67QX^!7[0/@?QE!8:M\(+S1TU7
MPAK9_P")3JVEZ9J[:S-,>H^T6PO'%N,G+3L>M>$?M&:&^J?\%-O FJW$/FQ#
MQC\-K-X[E?.0QVFF:1:RK%:\>?;YE)C/6,9/\5?T.Q0$F<'D;UEV]VVV\ZC;
M]/,Y/&>!7X&?MCZM<?#/]M71?'FIV.I?V3H<WAO7UDCM_.:5K.TMP;2%QGR?
M/$K>9G[WE+GE17['X8YQFV<8ZC@JOUN>,P_!V+PN7?4;1Q-.E4PE95W"RNE3
MHSE.LTF_8JH[-[_S9](?#++,)P[FD:3J93#BGA.IFU);/V<*$,//UCB%2G;^
M[H>M?M!Z/(/VCHOBE_PT)HG@?P)\)Y-*M?$OAZ/Q.UG<Z1%H]E:7,-NFAG$
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>_P!*CHHH DC[_A_6KD'\?_ ?_9J** +%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2413199d1_s3img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413199d1_s3img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %$ L4# 2(  A$! Q$!_\0
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ME"S1_&GX6[CDG_BC=87DD-C;YLVWDGY1--C&/,DQN,J_#[_@H$5 3XP_"6)
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MW4;*^9,"[AM=0L)].>>W!S@JLC%?4^X(KX$_X5Y^WYW^-'PDSW_XH[5^O?\
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MA_K_ )Q_T;?C#[H'Z/?:(O[W_CB_XT?:(O[W_CB_XU^</_"N/V_/^BT_"?\
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MLK03Q[DF7#)Q(''-_M>?MM_"[]C?0- \4?%#3/$4^F:_>2:?:C0+72[V0-$
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M/@VS5H[[IW?VGT/[,/\ A_7^QY_T+?Q:_P#!)X4_^:6C_A_7^QY_T+?Q:_\
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M_1NJ7_@V'_R0?\2DXO\ Z',?Q_\ D3_.!^Q7!Y^Q7///_'GZT?8;C_GRN?\
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M>P^Y_P"9_1,8B23YQY.>W^--BCVA_P!\3EVZ8&.3^O\ D&OYV_\ B(=^"?\
MT1KXD?\ @5HW_P 71'_P<,_!(L3_ ,*:^((Y/6[T;//<_-USPWH>II_\2Z>-
M_P#T0N)7G:A_\TC_ .(U^&__ $/(^MG^5S^BD*0 /-/ QVHVG_GJ?S%?SKM_
MP<.?!,$C_A37Q'X)'%UHV.#V^?IZ>U)_Q$._!/\ Z(U\2/\ P*T;_P"+I?\
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M3[Y_/IFK8Y /K52109..N6Z_3T]/\^HKFJT_:1=]H^\_-=3:/)S+GM?7DO\
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MVED_=?<_\P^K>7X?_:G(45U__"!^-_\ H3?$?_@HUJC_ (0/QO\ ]";XC_\
M!1K5']I9/W7W/_,/JWE^'_VIR%%=?_P@?C?_ *$WQ'_X*-:H_P"$#\;_ /0F
M^(__  4:U2_M;)Z<Z;OO)K;LKA]2]II:UM=OEV1R'_?C_@77\??U]Z?ODC2&
MX#"/R#<12Q#I-!,2 R]L,AROU%=9_P ('XW_ .A-\1_^"C6JAE^'_C5XIBW@
M_P 21LMNT3P_V/K/[Z2XNP+(_P# LJ?Q]17,N(\DPV,Q%6M_NBPM;ZU_U[]G
M.W_DU_Z8Y93BJE&HL)\2GAW/?X7627_DQ_0-_P $6/C'K.L>!?B'\%+Z"ZNM
M(\%3V6N^&[Z;_4VD&IE9#IZ9_@MXV6%#V5?>OW>4*))P@ 03R!0.@4.VT#V
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M0^)O!%ZVL>)Q9^#=(LQXDR+&Z\)#3/$M]K3 F2.[\PD9"T =#X;_ &%O&O\
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M]_Z)WX/_ /"9TC_XFNE%K-@8DDQCC,Z9Q[_,.?P%'V6;^^__ '_C_P#BJ?\
M:.9_]#.I_P"#N*/_ )>']GY9_P ^J?\ XC='_P"4G-?\*[^'O_1._!__ (3.
MD?\ Q-'_  KOX>_]$[\'_P#A,Z1_\372_99O[[_]_P"/_P"*H^RS?WW_ ._\
M?_Q5']HYG_T,ZG_@[BC_ .7A_9^6?\^J?_B-T?\ Y0<U_P *[^'O_1._!_\
MX3.D?_$T?\*[^'O_ $3OP?\ ^$SI'_Q-=+]EF_OO_P!_X_\ XJC[+-_??_O_
M !__ !5']HYG_P!#.I_X.XH_^7A_9^6?\^J?_B-T?_E!S7_"N_A[_P!$[\'_
M /A,Z1_\33?^%=_#?O\ #[P:#W'_  C6E]>_2(CKZ$UT_P!EF_OO_P!_X_\
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M5I("-*T=BJ;CL7.T[\+@$D@D]J;#\/K2-BT\C7>222=/TE Q.26VX&,GG /
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M ?#O_A8G_P"9NOYLZ*:^A]X&?\O.#YI=/?GOUWJ/H'_$??%+_HKH_P#@,/\
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MC#_6/&=E]_\ P#Z&_P"%UV__ #X?J?\ XJC_ (77;_\ /A^I_P#BJ^>:*/\
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M>1U[]J/LD/H?S'^%6:* *WV2'T/YC_"J[6<.X_OIQR> 6P.>@PN,#H,5HT4
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M]2.*N'[0+BFFVY^'=.2:LO\ C-.,='>_V92Z>@U]%7*5\7%DXKI;)*>5W?\
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MR>%=(U]?">F>&O%ATCQ#;1>)M-0Q0F\L-"AN9-)LM(,$82V,4/E($"CX]?\
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MWM D93C[K*A VDUJ>.>SBT@(!'VC!&1C.,'ICY>E'V2'_IX_7_XFO*=3^/\
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MWI_@KXN^'/'7C/QSX*TJWUE=:\ 7NGZ5X@ENK/%C*FJ0M<0R6IYQ;N03"?\
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M3^'='T/7XO"VAZ-'(!(NA:,?$>MVVFQN-X@@1)7/#5VGPE_90^%OPH\0^/\
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M^;Q9)K5[XE_:QL_&,HOG8>$_$FGZUX(M?AW\\G[QEUGP=IW@X[I/G82;FY)
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M?_ +_P"QK+_B)GAO3U_UOX-5]/\ DLN#>FO_ $62,O\ 5+C'_HD'_P"(8O\
M,^,**^S_ /AWC^V5_P!$"\:_^ 7_ -C1_P .\?VRO^B!>-?_  "_^QH_XBCX
M<?\ 18<&_P#B9<&__1F'^J7&/_1(/_Q#%_F?&%%?9_\ P[Q_;*_Z(%XU_P#
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M_P :_"99WD_M'_PKV]U;/S[I+\C]G_LW&?TSAZ*[C_A7GB/_ )\5_,_XT?\
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MUKT^A^)?B%JTWB?^U-1\1Z]IVD:E"SZ7IFIZE%MM;>*]@>*"41[8=[D1X3%
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M5Z/H^A$_JEEKU\NQ3N+&*[@D@FCMYUE,4GEYXQ$5;G)Y(V]1TR>N:N)Y.PX
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M]_N]>]'U;R_#_P"U#]U_R]VZ>O7?R*NS_IE#_P!]_P#UJ=C_ *86_P#WU_\
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M3[2]M].U:)+*2]MI-6#VO]HZ=<0I('&U=Y)(&]17KOE 7-H?2&3(^JC],_\
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M@(  -N  !TZ"G_2J_E0^GZ'_  H\J'T_0_X4 *WE9.>N3G[O7/-)^Z_Z8?\
M MN?Q]_7WH\J'T_0_P"%'E0^GZ'_  H JS8W<8QVQTQ@8Q[>GM14[6\  XQD
ML>W.2#W(]:* )D4-''Z[%_\ 010<]-H..,@<\>N#D5CSWL=M#&Y:)0(Y9 9O
ME6&.U#?;)B1EMHPQXQD'T.*\^L/C'\,M1TJ\\0V/BK2;C1=-UB;P_>ZK#<@6
MMMJ\>H:3IEQ93,=NR6*^U?389>"5:4=A@Z0ISJ7]FN9K5KE;LKV35FNIQ5L;
MA:$U#$XB.'YFXTVW;GFDFXW\HM2^9Z8X&YLQ@\GG )Z_0FN9\12:@NEZF-&$
M46K-8W\-GOME>WGO5L9;FRBN">=I;",W<LX P=M,T;Q?H.O6DM]X<U>PU/3;
M>9[66[L9!(BW$3E&MD( #;67:"ORXQ@D?,=5KIGWNZXBEC",K=5)7!SZ%>0>
M>Q-8XJ+H*C/$X5XJG[:"4;.]-WB^9J5GK'W=->_1.J\:E6@W0S5*,TU!IIZ\
MMTM%ITMZ'XSR?MY?%6[T,W5CI'AV]\0?#;POXJG^,^GI;M<1VWCW4?&NC_#_
M ,#:?=P1E?*TYK+4CXA91AFBT'8Y/.>O^*/QY_:H^"GP<G\53>*_A?\ %KQ3
M=>,/ %CX6LO#VA:M8"ZTOQA?!/%4&I2Q>(8HFBL$6X72'CAA5HXXB(HQB-/N
M$?!3X!^&-1\=7UWX4\/VEU\=-9CL/'=Q.I,OC/6H5D;3+>?D9EAMV8MTP^>N
M.<'2?V5?V=_!>D7=AH_@*W@TY-9T+QE<13Z_XCG*ZMX7OYKSPJ1;SZZDEMI.
ME7<UP+6S"P^'H;152UMH[-(TC_2J>=<,QKX"%3A[VO)3I\T.2$W5=E[2\JDK
MTKU9."E%<S@H15HJ/+^?XW).(Y3K5(\1?5J7+?FU5US?#YVBN;K]]SP/]G7]
MM[3?BA-X]U/Q1K&BZ%HS_$.P\$_#ZWN[O54O+W5I=/D?4?#]TF^4+=6VJH;.
M95FD42*X+R !JY^+]J']I1_A9^U;XEN/#/PV?Q]\&_%>I:5IGAJZOM971].\
M.6&FVE\=0UXC!;5!9OYMLJG#2(P8%,@_17PZ@_9.\,/XVO/A]_PKC=>^-H==
M\9W%E=Q:I:0^/=5F?1++5X=*N7ETFVU'571Y3J&GM]C:=Y);=Y;=X9*]+NO
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M &X48E/B'I)0DE2G@WP<8]I/ 3S?#\T@7&-N^:5\8W2R-ES W_!:']N3<?\
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MUJVH76OK>Z)%%K&ZVU*WTMXS%!=6T@MKF,&<*XDC9?T!=_)C09!VJHR%50<
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MD<EO!)OB3ZM_;M\=^+K[X6_L1:Q\8--U.;QMKWP\^+%EXA#VNE6TD6C66O\
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MZMHUSJ.G^,9O#NJ6MV^GPMX)L[$>(Q-%X@O(Y3=OJ!D\EW+'RRC!1VOQ%O\
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M/B')\.M-.I^-KKPUJMMX8M$P&&M7E@FFZ5->@_,;(7C7,CG[IB((QA@/QT\
M_LE_M*_##P3XO^&EYX2T*^\-^-]5^"OC:%_!)&D6.G>*/"_Q=\.ZCXYTS4X3
M_P A*X\0VMROB">Y./M#:/+)_&*_?QU\N-<\_(#CZ ?3_/>JZEU.XR *W(7+
M=#V(Z< XKZ3A[C+$\.8)Y?A,'E.+ESTJM59ISI)T7'V4J37VTX\LTVU*F^5Q
MLVSY3-^&,#GU>I6QV(EAHQC^ZDK:SE>,EY^YKZGX6^"O@A^UEX9'Q"T7P?:>
M+O!PO=,^)EY?/=:L)?#VM7FMW7AX^%H?!-J3ML]7EEM[H:A"<""1GB+5T'B#
MPQ^VC\0KF_NXE^*_A+1KO4HHK'38O$HTJXD2+X._$/RKF0#!C>3QVOA1Y$_A
M<@'.T9_;$\DE=N23D_7T_P#KT@W*K(=N7R<GD@GDX./0\=/SKWWXJYJZL*DL
MDX,;C/FNX1YTU%17O2A*6EM-?=7NQLCRJ?AS@_JLJ<,WG[.=XQMLM;]U;3==
M=S\7M-^%_P"V'I]SH=I+=^+M7AT?QA::Y'?:_?C5M9@DD^#OQ0TJ]^Q:N#^Y
M \3:WX/".1C@GU%>L?!CX6?M%Z1?>)M'\=WOBO7M!\5?L_7L.KVOB7Q"+Z6+
MXC7&L2KIVF6=_P FRANM(EUJ%5'$*N@)&%K]1X\J2/E...3Z9'T/UR/I4@$1
M63,0R2=W'4@G)^C'I7!FOB!FF/J1K?V+DD(RE%O^R::C*\)4JD?::<O(I4HN
M"25IW?F;X/@["8.A]56<-\K?57U3CK=K35_UJ?SX^#OV5/CE;^%/'7A;1OA;
M?^#?"=WJGPI-G!J$/@FS\:Z5K/A/XL^%M4?_ (1_7/#GAC1=?U/0K;2&UP:=
MJ>K:Q?ZG>6:175[?W-U++._T!JGPO_:[TZ,6GAZ]\37R>'I/C+'X3N/$5Y)?
M7:Z5<Z+X7B\,_P!IZG</)-:[IO[=72UEEDE!V*\CN"3^Q_E PDA1 I7(;U&,
MYQD\XZ\>M,3A5'VC.% SCK@#GKWZUO+Q2SBC]5F\HRAJE6<_^%3*7FL+^RC"
MU.GS-4JEE[\THJ=-1@XMQYGB^ <ME)SK9PTI:+;>]WWZ/S]>WX::?\$OVQ-7
MTWX>ZQKTNKZAXP\.:K\2M2\.:GK]]Y.K>"I[WX:W?A.W%S>?\O,>L:YJ-X-(
MN?\ ELCQ2?Q5T_@C]G?X\Z[I?[4L?]B>,_#'B/XC?#;X1VVBZCXZUN76M7U[
MQ;X"U/Q)=^)=*L;O53]AT[0]7.M75I:QPG[/;VOB)%CQ&@K]IL_]-_T_^O1^
MZ[G)[GY>3W/XU.8^)^<9@X5/['R--SC)/*<C_LNHG"<*B=:>GMJ:</<I77).
M4JF[&N!<FI:_VQ>]UTVL^_K^!^&-O^R[\0OBIJ6HZWI?P+MO@5IGACX(:IX1
M>UMCHSZO\3/B98>)O 'B7P1X@&E0KY%UI?@O6O EP]KKA91J$/BD746Y6.W[
MO_8<^%_CGP=\-M>\=_&C1[73/C!\3/$K^*?&,1,(;3+72=-\.^'+&R=@3;XT
M@>&SJF% 3==Y1L%"/MV,)&Y;<!"263IGSR<GC_>SSTJ_#-%QOQOXW<\;CUYY
MZ'./T[UY6;<7YGF^"C@ZV#^JPYW*G9R<I-Q:E"4I3G*2O+GLWI:,4E&,3ORW
MA?+,OQ*Q-'&K%."7,M+05[J5EM?X?O>MV4+S2[>^22&XMH+[SG;SHKC)1868
M_(O'15X4'.<#CKG+;PUI<;6)@TC2&_LU'CTQY;8-/:Q.-LJ6S$YV+'Q'V*A?
M7)Z59H0[8FP=QR,XP<GC//'4?X4IGAR<R'J?XA7RE.6+H4U!XKZM[S?,G\=U
M\/Q1V3OZ,^DJO"3G[1VNTH=%MKL^AS<_AO2;F&*UN-+L;NUB97CM[RV^UJDP
M_P"7DP,1Y;,?F*Y&TG:,< :1T>":..&[L=,N8XT6.W*V(1+>)0%CB5 3Y:QH
MJJJ G:H"Y(Q6EYL/KGWSU]^M'FP^OZG_ !K58FM>]7&_65KRQT7(V[N6DOM;
M/36VK%#V%W[+>WO>E]/Q,:S\.Z9I[H+2QTVVC,MU-=*MF,W$UX[O+)R<?.[%
MN?7OW8WAC1VC^RG3;![=I?,CMIK-2B3P$_OU&[H2 RYP"",$YKH!)'@888P,
M4PRPY.3SDY_SFJ^L_P![\?\ [8U=+VFFCMKIK:^G8Q9?#VEW$066PM)HS*UR
M(FM0;<73L7>YCP3A&8EUP2-I')Z5F:YX*TSQ1IL.G:W9VEY#;WL-[9NJA5A>
MW<-&% SM"!=H4$@#CJ*ZSSQV'';CMV[T>?[?I_\ 7H^L^?X__;"^K>7X?_:F
M5+HMDSPD6%J\UJUP=/E/6$W#-]I .>,988YZ #!JCX8\(:#X4345T>Q6V?5;
MZ[U._G3'[^[O)WN)Y0=W1Y9'<#U;.<5U0EAP,GG S]<<]Z/,@]3^9_D3C]*3
MQ7V;OWM-'VU[LJ-*G3NZB235E?NM>ROH-3:6)R2,\-UXYYR,CGCZ]JM#H,=,
M#%5C)!C_ %@!]R1C\AR:430X'[[L.Y_J,_G0J?*W/7WM-4[=]'L_ET-5[/\
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M/^^F_P :,M_SW3_OIO\ &M/^*B?T@/\ GSP/_P"(E5_^B4/^)5N /^?O%_\
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MPK;5/^>X_P"^!7T!OM_0?Y_&C?;^@_S^-'^M>;=E]T?_ )$R_P!2<G\OO?\
MF?/_ /PK;5/^>X_[X%'_  K;5/\ GN/^^!7T!OM_0?Y_&C?;^@_S^-'^M>;=
ME]T?_D0_U)R?R^]_YGS_ /\ "MM4_P">X_[X%*_PVU0*/WW8'H/IQUQ[=,^F
M:]_WV_H/\_C0\T(4 ^@V].G;U_(U<.*<VGS1:BDXZWBGIY62:]2Z?!N3TYQE
M]JZY;-[_ 'GG/@_0+G08Y8;J/?)*24?LP).">PSGZBE\=^!]&^('AC6_"GB3
M38]4T?6]-ETJ_L#-BX?S)DGMYX6RH1K-OWT?.Y3&20R+M;M9Y@+B#'W0J]^,
M8&,\\_ICWJ8'+N<\%F(&>!DDC';@=_QKYG,Z>'SF%:CC<,L2I*\HM+W7*\6U
M=I*ZNCZG"4IY/+#RP][2FHPUL_<M-6MMK;Y7\SX[7]D^QNT\.Z5XE\=>)_%/
M@SPQ?17VF^$M8.CRZ)>&T(_LN+6-^@RS2V^E(D4>F!YW<QQH7D=LN>7^)WPE
M_; O_%OB"Z^%'QG^'/A;PIJ\&FZ?I>B^)?AY::G?Z)#:Z9K$4TL6KZ6L4VH^
M?&T:M9Z\BZ4S,%9=IVU]VL\6,%N>A!Z9'7WZU824*H &1@?R'O7EY5D&3Y+[
M7^S<%'"5JT8QKR2?-.$9N<8N3;7+&;<DEU=SV,QS;,LQ="EC6W2H.4Z.R7-.
M,83?*DH\SC&-Y:R>S=C\T]#^!/[;T%MIVB:O\;O@])X>TXZSJ"75M\)=*TW5
M+34;C38FT.2/1['/A/3SI.O?:]<-_HH6[5[O,)&%PW4/A3_P4<G-W9:9^T'\
M(M(TB6[4V,K_  ]N;R_L+"WT"V-NUS=W.O0W%Y=7WB9;J2YN)H8YI69YYXXR
MY _2XRQD]0#W!]>_K4RR)@?,.@_E7L',V^2*L[7O?Y6[GY]:+\)OVW)?&/A[
M6_%?[07AI?#FG:3X47Q!X8T3P1I5BGB#48&UU/%\R2O+<.BW<(T*2+S)I' R
MIE=D+'Z.^+'P5^&7QN\*W_@/XI>"=#\8>&+TK>W&E:Y9(VG)/:78DLY55!L2
M^4@.YC*J) VP[& KW.26(#D@]/Y_Y_\ UU5)C/((&<G/R].HZ_KG/K45*5*O
M'V5574[I+SM=Z--/0='$8["5J6(P.)^JU*4U*<TVFXK6*3335I:^EU9IM/\
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M_>..>YY.:?;V/D Q@C8&DNI2/XKRX+23N./NM(S.!VW =:TO,3^\*/,3^\*
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M_4Y6M$0*DUM%QSD98=,AOE."._;.3UIXD@P/GMGP -P3[V!][\>OKS7\CO\
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M\!7^1_7KNM_^G;_OW1NM_P#IV_[]U_(5_P -]_M4?]%,NO\ PF_!O_S.4?\
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M?]^Z-UO_ -.W_?NOY"O^&^_VJ/\ HIEU_P"$WX-_^9RC_AOO]JC_ **9=?\
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M\GILVSDJ\85\'5A7I>%<\*XS<I327-.]KK2"5T]>UNS;M^P(AMBHB5+0! '
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M5XO_ /1M_P 6'_$JOTA/^C;\8_\ DO\ F?F!17Z?_P##JC]H7_GWT[_P,_\
MK5 G_!*[]H59&'D::,,?^7SL#@_G].V1VH_X@5XO_P#1M_Q8?\2J_2$_Z-OQ
MC_Y+_F?F/17Z?_\ #JG]H4\_9].YY_X_/7\*/^'5'[0O_/OIW_@9_P#6H_X@
M5XO_ /1M_P 6'_$JOTA/^C;\8_\ DO\ F?F!17Z?_P##JC]H7_GWT[_P,_\
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MUVECI.J>(9-870/$#^)KQK,^&'DR\EK=6/RWDDI#2(?F^=\-^E%D MM$ L:
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M0_:M.%/[:M/RC_P[-?WK3A2^VK3_ ,*U_,S?/@ER//QR>GUR21^&.O'\U$L
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MCW_7_P"M6?M/9Z]]/NU-2O\ :X?^?C^?_P 31]KA_P"?C^?_ ,35CR/?]?\
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MEB/])U+H>G_+'Z'H!GH*_'>BC_B8#Q[_ .BP_!?_ "(?\3>?20_Z.-Q=_P"
M4O\ Y4?L?_P^#^*HX/@;PMD<'_2M0Z]_^7;UH_X?"?%3_H1O"W_@5J'_ ,C5
M^.%%'_$P'CW_ -%A^"_^1#_B;WZ2'_1QN+?_  71_P#E)^Q__#X3XJ?]"-X6
M_P# K4/_ )&H_P"'PGQ4_P"A&\+?^!6H?_(U?CA11_Q,!X]_]%A^"_\ D0_X
MF]^DA_T<;BW_ ,%T?_E)^Q__  ^$^*G_ $(WA;_P*U#_ .1J/^'PGQ4_Z$;P
MM_X%:A_\C5^.%%'_ !,!X]_]%A^"_P#D0_XF]^DA_P!'&XM_\%T?_E)^Q_\
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MI=WFHR:;X>7Q1/'9V>=VF%Q MXI.3LEB82+GC:P^E9TW[0GPUM+B*WU*ZO\
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M=VA7OCM_$?B/Q/K'A_Q7\2]"M_"FC^#->^P:]'I#7?BKR(K/5^OA:TTC0/\
MA$H=3/\ S%!!(>"U=]_PK/\ ;<O=:72]2\=^,-/^TZ=I^FS^)])\;:2VD_\
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M7XBNO$L[7.DP:\UEH['3;&_T*VT:=0FP@F[%H'1@Q*NP(4$ U\[^'_CO\0?
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M_%4>1!_SQM/_ ![_ .*H_P")*O#_ /Z'O%__ (,A_P#)!_Q37\-_^BQXP_\
M E_\D?QF?\,K_M#?]$J\:?\ @GUFC_AE?]H;_HE7C3_P3ZS7]F?D0?\ /&T_
M\>_^*H\B#_GC:?\ CW_Q5'_$E7A__P!#WB__ ,&0_P#D@_XIK^&__18\8?\
M@2_^2/XQ6_97_:&R?^+5>-.I_P"8/K/K2?\ #*_[0W_1*O&G_@GUFO[._(@_
MYXVG_CW_ ,521V]N-V(;4Y8D_F?J?SH_XDJ\/O\ H>\7_P#@R'_R0?\ %-;P
MW_Z+'C#_ ,"_X)_&8O[*_P"T-@?\6J\:=!_S!]9]*7_AE?\ :&_Z)5XT_P#!
M/K-?V9^1!_SQM/\ Q[_XJCR(/^>-I_X]_P#%4?\ $E7A_P#]#WB__P &0_\
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M+]HG>;LG=/:_?6_D8"Z+HQ B6SM J (H%F, * H (3IP,?A[4S^P-%(0G3[
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M/LMO_P \!^?_ -E0 OG^WZ?_ %Z//]OT_P#KTGV6W_YX#\__ +*C[+;_ //
M?G_]E0 OG^WZ?_7H\_V_3_Z])]EM_P#G@/S_ /LJ/LMO_P \!^?_ -E0 YI?
MW9/?!_SS^7ZYJI:3#,G3[[>W<_YY_J*L_9;?_G@/S_\ LJ/LMO\ \\!^?_V5
M "^?[?I_]>CS_;]/_KTGV6W_ .> _/\ ^RH^RV__ #P'Y_\ V5 "^?[?I_\
M7H\_V_3_ .O2?9;?_G@/S_\ LJ/LMO\ \\!^?_V5 "^?[?I_]>CS_;]/_KTG
MV6W_ .> _/\ ^RH^RV__ #P'Y_\ V5 "^?[?I_\ 7H\_V_3_ .O2?9;?_G@/
MS_\ LJ/LMO\ \\!^?_V5 "^?[?I_]>CS_;]/_KTGV6W_ .> _/\ ^RH^RV__
M #P'Y_\ V5 %:]EB^S2%NNZ+=]25(_3(_P :M"6 @'/7_/K2?9;?_G@/S_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2413199d1_s3img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413199d1_s3img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V )\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WTD>M5+C4
MK2U=$GN(T=SA0S8)-<%XV^(%SI.IMHVEVOF7I &YAD<CC KD5\(ZSK3&\UW5
M#;7,G^J1V^8'^E=%/"W7--V,)UDM#W174J&5@0>A%0)>V\EPT*S(TB]5!Y%>
M/6/BCQ%X-E%CK4+W5GC:DIZX]0U61I\>HN=7\+ZB[RYW/"SY=?\ 'Z4WA5%^
M\].@W51[""#R*,^]<5X*\576M>?:WD8$]NN68=ZR;_Q[X@M;VXBC\/M)%&Y
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&HHH&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2413199d1_s3img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413199d1_s3img004.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Z L@# 2(  A$! Q$!_\0
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M9XK#K#5+74&]6OYGMWLMTUL]';HA7I5TY4M5%V>CW>JW\B9/NC\?YFG4Q6&
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M%;^ +B\U/6Y/"1\.)J<R^)[SQ(MJ^M:I;6ITF*,RE,^M?\+Z_;(/_-K.F?\
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M'\*8Z_E_GUK\ZO\ A?'[:?\ T:OI?_ATS_\ ,W3?^%[?MI?]&KZ7_P"'2_\
MP:KYC&</9WC:OM:F9\')JZ27%V'M%.3FTKO^:4Y7T=YR[Z^MAO$_)\)0IX?^
MQ^,N6FK1_P",/DM/^W?1;]D?HY&"!U?GT13W/H0*?D^K_P#?L?\ Q5?G!_PO
M;]M+_HU?2_\ PZ7_ .#5)_PO?]M'_HUC2C[?\+3'/M_R+8Z_45Q/A+,O^7F:
M\()O:W%N%>GSDGOZF[\5\F?_ #)^,_\ Q$:J_!-'Z0=>,L?8QC!]C\W3UI-H
M_N+_ -\+_P#%5^<'_"^/VT_^C4],_P##IK_\SI_D?H:3_A?7[:?_ $:EIO\
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M^*/"'C'0O%\L>MZKK"'Q3'X8U46(MX]'TAA9+J$LR?*IC5_TM_90_9H3X)?
M/_A6?B_1_"=]JVM:IK_B3Q?;6AO]1\*S:YXFU/\ M"[DATW6\36L'V6^*2J&
M5D'?(6N'_P"%[_MI=_V5]-QWS\5./Q_XIFC_ (7O^VC_ -&K:7@?]53/\_\
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M/>$IM6UN"*8>&PUU=KXLLM.*Z==V<C+Y4-M<AK66)S#<#8[J=G_A>W[:??\
M99TTCN/^%ICG_P MFC_A>W[:>?\ DUC2_P#PZ7/Y_P#"->G%>GEF19_EM3$?
M4<WX2A4JX:;E*/%^'4THM*ZES^ZK))N+<K7M&_+*.-?Q*R#&)1J\(\8RY4U'
MFX.J-V;N[N2=]>^FWS^=/$W_  39\7WGQ2O_ (C^&O'7A'0=6?\ :#\2_%72
M?$'_  B,.LZOHWA[7?A=\1_ UAHMM!(VV:WTKQ!XGTZ46S K+# 0_P C GQC
MPU_P2U^-$>D_%"3QEJ?PP\2^(/%]O\)8[!A/KMJT^K_"S7FU,ZQ!/8;++1M9
M%NJR6$,BO:Q7JQ^=F%)2OWE_PO;]M(<_\,L:7[[OBF,8]#CPP./7.:/^%]_M
MH#I^RMHH_P!WXI)G\/\ BF.OI[U]+@LYX_P>#H4EF_"$H-2<&LVI9HN6-1)I
M56^:E=K6#2YK\\4[:^1+BSA-*;J\.<8X5R=U%\'27.NLOA>S]U:^NY\':W_P
M2I^,.N7'P=OO%GQ,\)?%&\T7PA#X(^)">+=-O=#T^VTF+Q9X5\3V&M>!9?!Y
MM]3N=22U\/#36U'4YX")46X=T1'=?J[]LG]F?]I/XT:I\+=#^%^N?#J'X+>"
MS::MXX^&?C"UU6T?XB:KIMY81Z3I9UVTUN6[LM"\.+;KJ-YHNJ1W-EX@A$NG
MWHD69XSZ&?CY^VB 3_PROIHQSD_%)<#'K_Q2DW_HJ7_KF_W2P_M ?MI8)'[+
M6F=,\_%/"].,X^''3U([9KCQ>*XQQV/PV8XO,^$ISPE"MAZ:=2E\%>M[9ZWC
M\,M(^ZVENV[MSA^-N%:5*M1I9/QBHSJPG+_C#I:.,.5?9[>G?;0^]O#%I<:;
MH6B:9=6MGI]Q8:9I]E<6>GQ[=/M9K:Q@B-MI@91_H2;=L8(4J@ (KJ8P0.K\
M^B*>Y]"!7YLG]H']M+J?V6-#^H^*>6_#/P\ARW''[Z+H/WL?W@Y?CU^VE(0W
M_#*^F  Y_P"2HKZ],?\ "-'KC_\ 57R<N$L\G7Q.(J9IPBOK-7VL%//:.7R2
MM*ZY9RE*O9SLJC^!6IGO1\5LAA3ITJ>3\96I1Y)6X0JK7II[J3LE?E5GN]3]
M)\GU?_OV/_BJ,GU?_OV/_BJ_-[_A?7[:/_1J^E_^'07_ .9JE_X7Y^VE_P!&
ML:9_X=%?_F:H?"69+^)FW""?2W%N%VZ]5U!^*V3?]"?C/_Q$JWZ,_1\G@\MT
M/6,8Z=_FZ>M5I2A4*5&"0"?+&0"<$X[XSQ^N.M?G0WQ[_;2VM_QBQIG0_P#-
M45]/^Q:JN/CU^V@.O[+&F8_[*B@X[_\ ,J3'\HI?^N;_ '2O]4L=_P!#7A5_
MX,YH9@O1SA*U/R@]9?'LBEXJ9#*$O:91QDM;:\(UGI;71MK[T?<WQ'\':7\0
MO 7C3P)J,DUIIWC#PEXC\*ZC=VY:&>VL?$.CWFD7<\4JRQ&*6&"\DDCD$L>Q
MU#!T(W+^4>@_L-?M7:Q\-;_]GKXB_&WP=%\#M!^$/B[X7^'+;PCX&DTGQ-XH
MO=2N=-'A76O$=XGB3=:6WAZ33H);RV@S)KL2M'A1<[J]W_X7Y^V9_P!&M:9_
MX=$?_.WH'Q\_;,!!'[+6F9!R/^+I#KG/_1-^/TKU<LRO/,NC/#X/,>$W*K4A
M7]ZI0FXSIQ=-24IO1\K<;ZV3TL_>7FUO$CA3%*4:N4<8WUBO^,.GJG=]KM7Z
M7_#?Y"\._P#!,GXRS6FE:WX@\6_"S2?%(^)'P6OK_2/ _A'5]%\#MX#^$'AG
MXCZ9H\L>G/KTXD\8ZI)X[_TC56MYDCNRUQY4J)M;DO$?_!+/X^WUAX"\.6_Q
M-\!:KX8\/WOA[49;67PW]@U+2QI/Q=NOB;)/::DN6N+OQ)'>+X;A8J%#Z7%(
MQ"$L/O(?M _MH_\ 1K.EL.__ !=(?S_X5Q_/-+_PT!^V?_T:OI?_ (=(?_.W
MKZRCG/'E.'LEF_!RC2=HJ3R%V3459/,KS:]W_ETY0U?.W/EY?+?&7"%)O_A&
MXR]_WM.#GTTV<59Z['P;IG_!)+XP:WXCUO2/''Q*^'VD>"O[1^,7B'1_$W@3
MPI/8?$/5=4^)]CX>TVUL/$U\'@DOM%M)-&1-0C2:%[BV#PK+&SJZ]+X?_P""
M6WQ3U+^S=;^(WBCX8V^OV_C[X%C5/#/@GP?J.E>!]2\!?!30OB1Y5TFD7FOS
MVMSXP\3:WXZL]3O=0NX9;:.[\.K)-#+%N6OLT_M ?MGX/_&*^ECW_P"%I+Q_
MYC>F?\- ?MH?]&M:5_X=%/\ YV]16S;CN;BUF_"&CO[LLF2OS.33_LUJ%IZ<
MRJWFU%<G+"Z>U/CCA"S_ .$;C%>O!\OTCT6B];ZGR=XW_P"":7QH\<?'G5OB
M!X@\>>#)O#44_P 9;/PP;'2[CP[?0>&/BAX&T7P[IWA>71](>&RNY/#=YI"Z
MHE]//"C-'O+JH9EY71_^"7'QU== T[5/&_P>CT[Q1X3^$_A3XGZG8_#YH]<\
M,)\$O&.N>)O#VH_!.<^(]GAP^+X=632?%;2C_B8-+)*ZJK9K[;_X:!_;/[_L
MM:5CO_Q=)!Q]?^%;\?6C_AH+]LS_ *-9TK_PZH_^=Q7-/->.$H1GG&3P45&R
MRZK1C3?(X\LJUIZU$XQ<7MRIZ-:%_P"N_"&_]C<9/?;@Z77_ +</EG4/^"87
MB+2_@9KO@;2-0\ ZW\0[OX^>(OC1I'C&;1-7TBZTJU\1:.^B17<CV>O3:;JN
MMV05;J"UOH9;&ZFC2.YBE@:13^F_[-?P[\7?"7X,?#[X>>.O%$OC+Q3X8T8:
M7K.OO:Z=9P7^I-.UX1;0P)Y@-G:#$8 )98RP(&=GS=_PT#^V:>!^RSI63P,?
M%49R>G_-.*:?CU^V>>6_99TL@>OQ47'YGX<Y_6O&S6CQ!G='V&89KDM6:FYT
MY9AB*4JBC)WG&GS3D_92FE*48N$542LE=WZL'X@\+X*NL32P?&.%48N+@^#I
MKGOJI7C"^B]U[?C<_1>-V5<8=A_>9 <<GU]O4CD<]ZL&3(&!@DC)VQ?I@?GC
MI[BOS@'QZ_;/'3]EG2R#U'_"TTP?;/\ PKC/MP<TI^/7[9F#_P 8JZ5T/_-5
M1_\ .YKY^7"N-BHQEF651:35L!B*7L]_MQ]Y1ETBEHXZZL]1^+'#CE*2P/&.
M)YFGS1X0K6A96Y?LWO\ %K?0_1.Y)\J7EAB.3I%YQ'R'GR8E>67_ *YQQL\G
MW45F(!_+']M[]C/XQ?M&>)_#FO>!]?\ AE+HUIH'_"+FU\7^'M?/BWP-?17,
MMQ#\0?A[X^\(^+]"U"WN\A(9- U+3[NTN9X(UD@GA>2*NU_X7W^V=V_96TO/
M;_BZH//T_P"%<\_2G+\>_P!M($?\8L:8 #GCXIKQ_P"8XKULFRK.\HQ4<;@<
MSR1SINULRJTI2NTK*DFXKDLE>ROSVUU:>.*\4>&L9A*N"J91QC[.LU*7_&'5
M+Z+ETNFGH^NJ_+Y \1_\$V/VA;'5_%EQX+^*'@G4X_%WP^^">@>*]4\3>&M3
MN?%'BG5?A7%X@T#6=)751KLFCV&G^)=.U(7\^H75M/K-B4\P1/<Q>6<+1?\
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MYM_-@_\ Q)<-_P#)A_Q%CA[_ *$_&7_B)5S]'"Z@$[AQS]U.WXFF?:(O5?\
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M_7()+C3=4TTY@N;=%+@'_8=1@D@$CDXY%?YISRSLCJN;J0HPFME.TW%F01-
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M%TTLUPS>8>&/RGGH?8X.>!D<5]!KU'U'\Z^$S7#?4\7+#7O[&\/ND?98&O\
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MD!]&!_$<]>Y_0?E15NX_X]HOP_E17;?2*_E5@+*_ZJ+ZQ_S%3U O^JB^L?\
M,5/2 **** "BBB@ HHHH **** $8 @@]""#],52F'#+&%+%2%\P'RR2,#>!R
M4)'S <X)[U=;@$GI@_RJD>6)4$]2H4KN)QD!2Y"YSTW$+G[V!FIG"-2#C/X+
MIR%'V?M(\UN?E?)?UU^YGSC\>OCUHGP.TW1KR^T'Q'XPO==U2[@TGPYX8L_/
MUJZCL+1_$=YJ<8.-UEI<5I(THVC=&K EN0?F1?\ @I)\"6\26WAU-(\8212Z
M+;ZW<ZE8:*C)875SHMUKNG:)>B26&/\ M%])L[J$"2:.,R$*\B*2Z^P_M??
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M2^.!J%QI=CX*NM-OM4TO3- TO1-=UZ?76CD#:/;Z/I^L:;)=V:[I4CC<+D@
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M^?-3_P !7_R0EF&$7VOO39U&^3T/_CW^-&^3T/\ X]_C7+_\)KH'_/R/R/\
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M./\ /_ZO2IZACX0#W4Y^I'%35\M3O9_RW]WT_P"'/I8?#'^:RYO6R&O]Q_\
M=;^1K^=#_@X:&?@M\&A^]Y\:ZV./N\Z?HWWO;^][;J_HO?[C?[K?R-?SI?\
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MW3R&IXJ\55LLPZP].&83A6BFG%UXW4[-/[+C*,E=N,^=.S32_P!$O##^TO\
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M$='@\9?#73M?\3:QKEA<V4UC/K.FK-X+O-?U73+F[E5@3'XW217EU(1E5&F
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MK&K>);'1-1D@-AI?Q!\8>%8=6T30M5:.\U"ST.#28M4BNH729X]4C\ME;80
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MHB^TU-+ED81F%?$EJ2MT@!^K%Y_J4^H_E14!0):P =88@/\ O\NWG\_Z^Y*
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MINL>'-4TO55US5?AW\0M$\1W-M;Z;HEE-X!BU* && :[;N?/3CH8'/,;B*V
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M_@JG_P#*SX7_ .';/[#_ /T;MX4_[[U3_P"7-'_#MG]A_P#Z-V\*?]]ZI_\
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M_OXW_P 51Y;>MM_W\;_XJG_Q$GQ'_P"BRXT_\3'%_P#S4'^H' O_ $2/"/\
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MO^?0?D/_ (FC_A&]*_Y]!^0_^)K1Q>_\]5_(?X48O?\ GJOY#_"K^L8ON_\
MP)FOU7"^7W/_ ",[_A&]*_Y]!^0_^)H_X1O2O^?0?D/_ (FM'%[_ ,]5_(?X
M48O?^>J_D/\ "CZQB^[_ / F'U7"^7W/_(SO^$;TK_GT'Y#_ .)H_P"$;TK_
M )]!^0_^)K1Q>_\ /5?R'^%&+W_GJOY#_"CZQB^[_P# F'U7"^7W/_(SO^$;
MTK_GT'Y#_P")H_X1O2O^?0?D/_B:T<7O_/5?R'^%&+W_ )ZK^0_PH^L8ON__
M  )A]5POE]S_ ,C/'AS2@0?L@.#G&!SCM]VG'0-*P?\ 0 >#QQS[=*O8O?\
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MOQ(L-.NBL,GB?4;WQ='X*U+PC;3G+0:]HGC273O#4$I9XQ>>)H7$:$<0Z_\
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M1_T-^#/P_P S^R[_ (?\?LD_]"M\2/\ P3__ &5'_#_C]DG_ *%;XD?^"?\
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M-_\ /_?%6OH->"W_ "]EQM?I^\EMU_$/^)HO$C_H;\&?A_F?V7?\/^/V2?\
MH5OB1_X)_P#[*C_A_P ?LD_]"M\2/_!/_P#95_&CYW_3?_/_ 'Q1YW_3?_/_
M 'Q3_P")&O!+^;C;_P &2#_B:+Q(_P"AOP9^'^9_9=_P_P"/V2?^A6^)'_@G
M_P#LJ1O^"_'[).#_ ,4M\2.A_P"8/[?[U?QI>=_TW_S_ -\4>=GCSLYXQZY[
M?<'7ZBD_H->#'_+J7&UNO[R6_3\ _P")HO$C_H;\&?A_F?V2M_P7X_9*"L1X
M6^(^0"1G1@1D#C(W<CU]J:O_  7V_9'$4D[>'O'UOY4;R/G1PIPJEFYSM4D
MC.  "3ZU_&ZO4?4?SJ,J[^:D6?-9&6/;][>R,$Q[[B,>]88OZ#/A"L,Y89\:
M/%U:BPU&\F_C@Y];Z<R6FUQ0^E%XBNNHUL3E&+H2I24Y92DZ=-N:7+6T?[QQ
MO*'_ $[N?Z.?PX_:.^'OQ5\!>&/'V@7UU)HOBJTAU2PWVI2Z@RJRI!=C)"*2
M CMR%3)R,D5Z2OQ/\.^4I$XSU[XX'3G'^>WI_,/_ ,$5_CQ<^*? 7C_X(7\U
MQ='P+>V_B70;QNB>'M7(MEMF]0;LLA] 3@XXK]QYO]<G_7/^E?YX<<>$N#X/
MX\S[A9?VDJ>3XN=&E+,;QJNA5O6I.%U=6AI5M>/M4G%J,K+^MN#_ !%Q.><(
MY9C\4OWU6GS3T2]Z34I;>>WW:'UB/BGX<)&Z?N,\#C]<^OX5+_PM/PQ_S\_H
M?\*^2:*^=EP7EL)R56=1.ZY;2W5M6[Q=W?\  ^GEQ/7J0HNBE90:E?NY)K\#
MZV_X6GX8_P"?G]#_ (4?\+3\,?\ /S^A_P *^2:*/]3LH_Y^U?\ P)?_ ")G
M_K'C.T?O/K;_ (6GX8_Y^?T/^%'_  M/PQ_S\_H?\*^2:*/]3LH_Y^U?_ E_
M\B'^L>,[1^\^MO\ A:?AC_GY_0_X4?\ "T_#'_/S^A_PKY)HH_U.RC_G[5_\
M"7_R(?ZQXSM'[SZU/Q3\,8/^D]CV-0-\4?"S#_CX(/H!G\,G^M?*-*O4?4?S
MIK@K*:O-"$ZCJ*+E'F::T_[=74'Q)6:Y*MDY27+;ML_Q/M'0?$NGZ_<?Z#-E
M$BW8QUQVZ]_Q_I798R@&.>H_/_ U\]?!4_+<CU=A^>:^B<<8P,8QCM]/I7YI
MF>!^H9E/#]*49I?X>?K]Q]QEN(^L86$_3\8W,*2>2)91(RHF\J[L2%1"?F=F
MX 4#DG/09KS/5/C3\-M'U^T\,WWC70[/6-0FB@L]/DN5:XN[IY%BBM8$SS-<
M2M'"BG[SNH.<FM7QYJR66B7B7<NH117XFTU;VQD2%M*^UQO;_;TFE_=Q/9^8
M+A))/D0QAF^45^.5U\!-'\$>,?!.E_M'_M6V>K> ?A[XRM?'/@7P.UMH_A/7
M;C6([O7YM+U#QMKL+_:-9ATRY\00RV\,2J9UCP"2W/RF9Y_A\%57M<?DF"=[
M1CFLW"<U=1<Z-O\ EW%^[)ZM3>B9]WPUD669O1S.KCL;+#5L/0E&A3C!SE53
MI3J.22ZJ:45=Q2W<UHG^X6E74>HVZ3I(LT+3+)&RCNK@@^GOCG&*WZ^!?VG_
M -M#P%^R=X(^%'C37;._\7Z#\4OC%X>^$EI=Z'?I?0:?<:UX6\2^*I=;N+B1
M)XQ:6.F^%+J>5?*D!17?   ?X[N?^"QME9>!;GXS7/[,WQ-C^ OB+QA#\,_@
MK\4M2UO2;5_C7\2;SQ;J'ACP[H6B^'1H<<NFV&J7.EZ[<C6#-(MK#H%Q(^X,
M&C]G"XFEBZ$*]+%9=BXU%=SRZ?/2B[+2>K<7)>]"]G*"<K6/D_94Z%Z%+$?6
M8T93AS/>/OMJ+^6JU=[;G[?45^?G[&?[<6C_ +4WB+XO?##Q!\+/%_P.^-OP
M$UKPMI_Q(^&7CN==5O;6Q\9:++K'AO6-)U^)8X=?MK^;1]9@\Z.-6T_^R")"
MX  _0.N@ HHHH **** *D^ 22"0 <@=2,#@>]>8^*/C'\-_!/B#1O"7C#Q?H
M?A[Q)K\;2:;HUVY%W>INV1^1MX,LC%5B&&S(0,>OIMP&+*%8*Q8!6(#!6( #
M%3PP!P<'@]*_/GXZ? 3XI^+OCYX>^*G@RW%SHJ>"] \,75J?%TV@>5<Z==>)
M=4%X;:VEAN6\DZSOVP3PSOLQ%)'(590#[N_M,LSHMU991(9)KEP!$\5R,VI;
M& $(<;B2,+D>I&1>>,_#=CK%IH5[K5A9:UJ2"2VTNZ)74[K:R[)+9!PUDQ &
M2#\K-C:37YV0_L>?%6QC<6WQ1\76\=[I&M7^J6TGQ&\<R/J'C>ZU9)+8L+;Q
M7:SMHUBAB^T+#=VTK6ZL(KB%V65>4M_V/OCA=1:/JM_XM@TJ\THW,5AIK^,_
M%NJWGA?3)F=;^]A\<:OK>OWVJ2ZU$LUW%!#J-K/H[Z_F*ZA>$2( ?K$VI0;5
M_P!)MER1\V<[<L#NQTX'/X<U#=ZW::?'YM[<VUO"P)6X9]J-@9W$_P (ZDGG
M:,G'%?DUXU_8O^/C>"=5TWX8?&/Q98ZOJ<^Z6*]\=^+;NQO='D1C:VT%Q/XD
M\B,S7>Y/,E!CC4EY!L5JGU']BCXQ:UH 7Q-\1]=\4ZW]I\,1WUMJ?CCQS9:1
MKND:5X3\"P1VCZ'HWB":SO$AU31-:B>ZGCD5T9F:*10RD _2?Q!\5/!7AC7;
M'PSKOC#P[IOB'68T;1]'DN2;F\\YA';&%#G=++(R+$.CEEQD&NNBO&>W26&2
MW00@ P?W_/P!<=<_*6WC QP<GFOB7QG\$OB--\3]?\3>%_#WP]\0Z7\0[7PO
M'JGBWQQ87OB#Q%\/)=)L8-,FD\.V>M3PW-Z8Q%+J%I:++!+<S:KY2N@82#PR
MP_9+^/M^GB#3M<\<WVB6$E_+>7;>'OBGX^U"+QEK0<L/&:SR^(_[;\)/-9A=
M/'A^R/\ 9,6!$X$()(!^J\NIQ6UI)<W=W:QI;PR3R2-]V-(D9V=NF BJ2<=@
M:RX=?LGTRWU4ZCIXTV>*TACD!YFN9+H1HB\C_6%M@'S?,_3J:_*K6/V8/CY;
M^/-#T+P]XH\17OABP\,64G_"2:M\5/B->P^%M6FD636X+MKO7Y8?&L,_B1M0
M>>QNH)8K2+=#-"Z;D/-S_L._M%W?B+Q9;:K\5[K5/A\_A30](\->$'U_7M/T
MR&/P[H>F:=9Z1$MO^_\ +TS4],&JCR/WI48B_>!: /V4L[UKJ;*RP- 8\H$S
MN)..F3S_ /6XK5K\^_V.O@C\=_@[KOQ6O/B]\0;SQIIOB#7W.AV4^IZC?VEH
MUKJ>J"?7K=]9Q<G[=HW]B:<NP;_DZ=:^\_M>/F<93@Q^Y ^4>Y)Q^- &C2-T
M/T/\JSO[0]8F'OZ>_6M!2& ;'+*#^8S0!7N_]5^=%1WOW1^'\Z* )U_U47UC
M_F*F;H?H?Y5"O^JB^L?\Q4] %8\@CU!J"6S\QHFS]UD8_@0?Y?7 S6A10!5^
MS*/_ -9_PI6MPRE6/RL"IY[$8/;T-6:* ,\6IC(6+A"<'Z'@]/;^O:A+3$C'
M./?^6/3 Z=/RK0HH J&U# JSLRD$,"."#P0>>A'%0-:M$"(;CRE_N<8;VY(Y
M(../6M*B@"LL4NP RD],Y'4>F<=Q[<>M#1!59F(PH).6VC &3DXX&.I[=:L'
M@$^@-5V.70G^\/YBI<%*2EUBG]U[@>6>//A?H?Q$G\'2Z]),I\#^.!XPTZ%+
MC,,M[;Z?KVG6JS1$8DB;^WP)8WP711%D!N/+9/V4_AM/XUU+QO=?VKJ%]J^L
M>-M5U+3;R_EN=)EN?'>A>!_#VK0&S"XM+>71O NC0YCVO&K.VX92OJ2W("R9
M.,N1G\*EX_OG\C_C710S/&8?FCA<6\.K^\E;5]'OI976EGKOH<]?"T<0XNK%
MMQ32L[:-IO\ $_/;3O\ @GO\,-!\*Z+X-\,>,/BEX<\-:=8ZWH&K:/:>-M1O
MM*\3:#K/BA/%4EAJ^G^)8M3LK*."\5[6SGTRS=K:.57C24QE6Z\?L8> ;#5U
MCT7QA\1?#?P\N#X8O-:^%FD>+_$*^$M?O_"=E+9V5QJ5RUS+KVD"2U.AVMYH
M^F:Y::/K-OHZV\^BS1SRQC[;&,CYR>>F#S[4_ ]!^0K=YKF-5WK8IUY+12?+
M>*>MM;]=F]8K2+6ELHX+"TTTHVN[ZOMIV9\4>'/V._"?A;QAINM:5XX^(S^$
MM \5ZEXQT;X:S^*+Y_"VC^*M9MW>]O+8VWEWTD-S_;&JO+'JCR0XG"7 :$[G
MUK3]FVPD^)6M^(=7OH+SPW%\2M/^,WA:PMX5M7MO';>'I/!.OG4[L\ZA:+H>
MDZ0)X&P)H_-C_B85]@E1@\#\ ,_A598@&8D<8YQUP1WR<=,],UG/,<7IKS:-
M=.KWT2UU>N]GOU+6%PKW5OZ]/^ ?$LG[(^@>$?!'Q:\,> +W4$O/C)XJM]9\
M2:CXBE.K2Z2DDH6^L= 3 _LN#47EUV2"YX^R/X@\WGRLCW.[^!O@#5-*^'>E
M:WH.C:Z?AE-I#^%;C5K!+R6&ZT/1WT[3I?,8$*4T^68%B'"L00&.5;VCRXAR
M%.1R.G7M3AU'U'\ZS>88JI^Z?VKU&_-)0?;2VEDK;.UU<?U7"GRC\=OV4/!O
MQYO[34M8\2>*?#>JP:)/X8U&X\*:I]@&N>%Y]6MM<MM*UZ)8PTL%O=6KK:\D
MYD8Y(^5/-]'_ &!_A5I/B9M=7Q)\0+J"PG2;PUH-[XE>30_"5G-XBU'Q&;?0
M8!%^[BU;5=1U+[>'D+3)=.FQ $:3[Z8D8 ./4_\ U^W3M3<'^^/^^C710SW,
M\+%TJ&,EAXQ?PIJTFU\2ZZ)N.][-K9V,:F786LU*4'HK*S6U[]NY\#>*_P!@
M+X.>)M7^*FO#5?$FFZI\6?$7@_Q;JUW;:G'.^BW7@G1SHUI#I,-S%+;OI5Z&
M!U>UND:">)G@D;RW)KF+/_@G!\*=.L8K;1/%?C[P[J\%[J=W#K>FZE9V.LVT
M&N^(=3U[4K(+I,,5LVG:E/JVM12)(H4QS,I4A7%?I!@_WQ_WT:,'^^/^^C6Z
MXESE*RS6IIWE?9):MN[V77>[W;OG_9.#_D?X?Y'POX>_83^$_AC2['1M,U'Q
M/'!IUGXBMK>:XU8M?6O_  E/A?P3X1O;MGQA_M5I\/-(;!"[I!(O\+D>8M_P
M3,^# EU<P^(?'&EZ?)8SVNF6EMKXC71I+[3M(L[V[GU:-%UGQ,TL>BZ40/%L
MUU_9FS=I;0*(\?IM@_WQ_P!]&D''1@/S']*TCQ+GWLYPAFE3V<G>HEJFVFFV
MUHFT^NKWN0\GR[VD)RA^\CI!M]+W>B7<\'^#'P2T'X,Z)J^C:=J^N^)KWQ'K
MFJ^)?$_BGQ3=+>^(-7OKD)96L6H7)'SVUCI\4-E8E=H2'3(CN?<:_$C_ (."
MXYY/@U\&[.&VN9YF\;:R8FMEWHL*:;HRDR <.NT D#@J" >:_HND#&-U+ @J
MP(!YP00>>OY<^E>;>-/ O@OQL+>U\9>%?#/BZU@(^SVOB70-!UF"V=B,-"FK
M03R@AN2J12?-SL9B ?4X(\0)^'W&N1\>XBEFN:RX:Q<<TE0RZ45.JXM4>5N\
MKU+3ZQ;C1<FEJSS.+^%WQ9PWC>'H8MX1XE+D>ZTBX7?;5I7M;I?4_P TY='U
M7>_^@7)X/'V(<\'CWS[9X]!Q2_V/JW_0+N![_8NGOT[5_HZI^SM\!MRF/X-_
M"?,3HTJGX>>$2-BD,QP=!4$!<Y4YSCK@\V4_9[^ ;,VWX+_"0D\#/PY\'+_L
MYS_8@*]>N>.H-?Z!Q_:)Y?"=2A2\,>+8\GLZ]6I2XDR/ 1JU,;36)E*2S'"R
ME5E&SC)TK1I.]*HO::G\F1^B/CXXKZU5XJAA/9.<:<)9)_:CG"<_:<_.W^X5
M]%!)J?\ $Z6/\X#^QM5_Y\KG_P  C1_8VJ_\^5S_ . 1K_2#_P"&=O@1D9^"
M_P (PO?'P_\ !V2,\X/]CD_D"<^M/_X9V^ ?_1%_A-_X0'A#_P"4E7_Q44RW
M_E[X:\8M]+<9\)O3KMA.YG+Z)N-J5:M1<89'+GDG?,^#DZBLK?N?>C:G_-_?
ML?YO/]C:K_SY7/\ X!&C^QM5_P"?*Y_\ C7^D-_PSM\ _P#HB_PF_P#" \(?
M_*2C_AG;X!_]$7^$W_A >$/_ )24?\5$\H_Z-IQE_P")EPG_ /,@?\2E8W_H
MKN$/_$,7_P L/\WG^QM5_P"?*Y_\ C1_8VJ_\^5S_P" 1K_2&_X9V^ ?_1%_
MA-_X0'A#_P"4E'_#.WP#_P"B+_";_P (#PA_\I*/^*B>4?\ 1M.,O_$RX3_^
M9 _XE*QO_17<(?\ B&+_ .6'^;S_ &-JO_/E<_\ @$:/[&U7_GRN?_ (U_I#
M?\,[? /M\%_A-GM_Q0'A _I_8G-+_P ,[? ;_HBWPE_\-[X0_P#E)2?[17+E
M_#\->,DNO_&9<)[]/^83L'_$I6-_Z*[@_P#\0V/_ ,L/\WC^QM5_Y\KG_P
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M^4E _9W^ 61_Q9;X3'V/P_\ "# ^V/[$YSZ=^E'_ !43RC_HVG&7_B9<)_\
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M4X[E@5'5N,UGS>%_#MWJ-OJMYH6CW.IV<7V>/5KC3].FN4CD(!BCN%59X7Y
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M2J@[U7)V\4ND_MC?LXZ[K"Z#HGQ;\(W6LW\VH/IUL+L?*+"T8W! (P<%&P,
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M^A5+20.I$XR&4CG'((/6IH8YPDN+A?OGG(&.>O3. .?I^=?SR?\ $0A\'/\
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MC^VL%_,_P_S/4O*F_P">Q_7_ !H\J;_GL?U_QKRW_A:^B?WHO^^A_P#$T?\
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M)O[0=Q<?$35]%M_#MGX7BAM[?Q-]HN9I'D\2P1PP;9I7D6./YR"?(OB)\'/
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MILM]90Q&>2ZMDBQNCD:[7;*<9"G/!#'@_>SGIVK(UKQ3X<T"WGN]7U>PM+>
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M\/\ [4R**U_[ U7_ )\+G]:/[ U7_GPN?UH^MX/O^*_S#ZMY?A_]J9%%:_\
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MOJO\S13[C_CVB_#^5% %I(\*OJ,'!]CGM^?Z5-5$KYJQG./F4YZXY'/X=?\
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M !-=EY/_ $\?I1Y/_3Q^E1]:QG_0W7W?_;A_9V#[+^OF<;_P@G@S_H3-!_\
M!3H__P 31_P@G@S_ *$S0?\ P4Z/_P#$UV7D_P#3Q^E'D_\ 3?/MCK[=.]'U
MK&?]#=?=_P#;A_9V#[+^OF<;_P ()X+[^#-!_P#!3H__ ,33O^$$\$_]"9H?
M_@IT;_XFNP\CW_7_ .M1Y!['GMSW[=J'C<5'1YNM?)_I(TIY=@[/U_3U./\
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MGS_'_P"V#ZLNWX?_ &I!_9T/_/C;?I_A1_9T/_/C;?I_A4_DS?\ /?\ 4?\
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MO"=I!'IMM'#=+"L-Y<0_Z^]F)"M/='DG)RS#  !).0,5T9LB01Y]SR".W?\
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M_=4JSIPN]H^\]/+3IH?T@_\ $0UX]_Z(IX2_\'&L_P"-'_$0UX]_Z(IX2_\
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MHT>@0>';#POX?ATE[KQKKNES1>*+6Z\0>$9["47:1$?MO^PO\>-4_:2_9+^
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MU=I-N5KVOT1M1PF!A=/"QPU1M.*NKR25N;331Z=]ARH RD$\,#S]1]*M56#
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M_H:R^[_[8^:/^$3UP\?9^O';O^%'_"':[_SP7]:^F!Y>1R.H[+_B:EPOJ/\
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MQ"=3UO2]6UBX\0W.NOI^U]DEOHFC:%I>FXP09/%"!_G5"-C]KK]B?X,?MF^
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M9Z;>IX:GU:/5UMYK:;6+&_M/#.DV][9>:DEW%I,D"RH\G[O]&I(XE9!(^W#
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MQHROH/\ QW_&OYJO^'M_QH_Z$_P[_P"!6M?X4?\ #V_XT?\ 0G^'?_ K6O\
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M]]);:W\:_#6JQ^#X4%ZPL]/T#P^VH7MA<'_56!6*0JPZ*A/8 ^)FV8933RG
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M-N/-!7(^\-PQD>XSP?7I4R_8G=XQ N4'&<8! _B]OZ>M*T5N%),,( !)(Z@
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M0]A]:EC?S45NX()'^?;/2LTP61! MSD@@<GJ>G>K26D 1<P#L>P/UX/^1U-
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M;_\ / ?G_P#94 0+&L1"I]F\QB!(,<[2?F]QP>G'TYJ8QC!^6#H?6E^RV_\
MSP'Y_P#V5'V6W_YX#\__ +*@")8<,I_T<8(Y4G<.>J^_I[T^6'<>9B"3C!Z\
MCI^/Z4[[+;_\\!^?_P!E1]EM_P#G@/S_ /LJ (/LF.?-W8_A_O>W7OTI#&4Y
M$XC(Y$1QM<CD(Q)^Z>A ['OWL?9;?_G@/S_^RH^RV_\ SP'Y_P#V5 $-O#-&
MYD808<Y.W<#@XZ<8S_7ZU?JM]EM_^> _/_[*C[+;_P#/ ?G_ /94 62< D]!
MR:C,D>#EP!@Y/I[U%]EM_P#G@/S_ /LJ0VMN01Y(Y!'7_P"R/\C0 RYEB,9
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M);W$CQDL(E8@;MM>H_"'P?\ M*V7PL^*.B3^'M(\/^*/$OCWXER7EWJVJ:K
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M('']I&\AO&OM,NPKB=FA!*[LGL-#^#'C]/BW\/ETKPIXQEC%[X.U>Q\8ZM"
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M*^ZOTU/74"^7M.>G'ZBJ4F'E9=K$"(_*OWCA20%R0-QQ@9/7&34\7W&^A_\
M9JK@#SB#R"#D9QU'(R,$?4'(]:^MJKDJTJFTO;04O5_J[GW.(G6IU:+I_;J1
MYM.NEU\TWKW1\/?MDZYXQTCPM\.K/PG<^*+.]U[XCZ7HMW-X5<+JT]E+X?\
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M2PN =6,,A69Q526&NVIQ451<M6Z>\W>HS_&BO]/[Z0LL3.3SC@[G]A@HR?\
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MHVMX&CD\Y7C6>)B,$PS?.A^FUC@]Z@ZU)32:O_7]?AT%N_\ 5?G4D! B!/
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MM.UW4P-(_M72](:T-O<:<3)'J*>(Y(L,BD@'ZQ"6,D .I). ,]2:<2%!8G
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MJOA[_P!"3H/_ (!:;_\ &Z3^@_2_Y=<722ZZ/?IMY$_\4SL=_P!'>J?^ /\
MS/XF/[&U7_GRN?\ P"-']C:K_P ^5S_X!&O[9_\ A57P]_Z$G0?_  "TW_XW
M1_PJKX>_]"3H/_@%IO\ \;I?\20?]5?+[G_D'_%,[&_]'>J_^"W_ )G\3']C
M:K_SY7/_ (!&C^QM5_Y\KG_P"-?VS_\ "JOA[_T).@_^ 6F__&Z/^%5?#W_H
M2=!_\ M-_P#C='_$D'_57R^Y_P"0?\4SL;_T=ZK_ ."W_F?Q,?V-JO\ SY7/
M_@$:/[&U7_GRN?\ P"-?VS_\*J^'O_0DZ#_X!:;_ /&Z/^%5?#W_ *$G0?\
MP"TW_P"-T?\ $D'_ %5\ON?^0?\ %,[&_P#1WJO_ (+?^9_$N='U4 G[#<\
MG_CR/:HAIFJ$@?8+KD@?\>9[FO[;?^%5?#W_ *$K01[_ &'3SCWPB!SCT7YC
M_#SBEC^%7P\&_'@[P_G!X_LU%SP<@&1-@/8;OE&>1BG_ ,20?]5?+[I?I%_U
MY!_Q3.QO_1WZG_@M_I<_B7_L;5?^?*Y_\ C1_8VJ_P#/E<_^ 1K^V?\ X55\
M/?\ H2=!_P# +3?_ (W1_P *J^'O_0DZ#_X!:;_\;I?\20?]5?+[G_D'_%,[
M&_\ 1WJO_@M_YG\3']C:K_SY7/\ X!&C^QM5_P"?*Y_\ C7]L_\ PJKX>_\
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M%1+W9SWBGJXKI9O77]$<V*R7*JCISQ6$CB)R@W&4K>ZKZQM;6[U_ST/*;O\
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3CF:$%W(,L8(+'!&\<'FB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2413199d1_s3img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413199d1_s3img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ +<# 2(  A$! Q$!_\0
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M&R/H17>Z/K5]JG@\WR1@W94A0.YK*I22LX;,N-2YU6X49KQ^7Q%\0(('E>Q
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MZ]J]O\6 ?\(IJ?'_ "[O_(UPWP956T[4"1R91S3HS<:$["G!2EJ<UK>C^(O
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AY(QDGM3/[+M_/$NTDYS^-:.!Z447#D0T=,44ZBD6?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
